nct_id,brief_title,page_rank_score_brief_title,page_rank_score_brief_title_summary_combined
NCT01762813,Assessment of Clinically Related Outcomes and Biomarker Analysis for Translational Integration in Colorectal Cancer,0.00045097313579095684,0.0005717591431732476
NCT01762293,A Study of Famitinib in Patients With Advanced Colorectal Cancer,0.0008050158751740554,0.0006668192046438758
NCT01766479,Non-cathartic Computed Tomographic Colonography to Screen Subjects With a Family History of Colorectal Cancer,0.0004613316639643199,0.00036162096518444034
NCT01703910,Study of Individualized Therapies Selection for Patients With Metastatic Colorectal Carcinoma According to the Therapeutic,0.0009521599643045036,0.0008171590573461657
NCT01703390,Biomarker Directed Treatment in Metastatic Colorectal Cancer,0.0006689730096770518,0.0007688029116656507
NCT01723969,Screening Platform for Clinical Trials in Advanced Colorectal Cancer,0.0005940811710387032,0.0005478584044794759
NCT01759238,Chemoradiotherapy for Patients With Oligometastatic Colorectal Cancer,0.0009393504733814732,0.0008042866659220836
NCT01767857,A Phase III Study of Xilonix in Patients With Advanced Colorectal Cancer,0.0008052555535999648,0.0007350076405264538
NCT01776307,A Study of BBI608 in Adult Patients With Advanced Colorectal Cancer,0.0009270662154524993,0.0008071933799877282
NCT01791309,Vemurafenib and Panitumumab Combination Therapy in Patients With BRAF V600E Mutated Metastatic Colorectal Cancer,0.000758867983855034,0.0007662278764833311
NCT01736904,wXELIRI Versus FOLFIRI Regimen in the Treatment of Advanced Colorectal Cancer Patients,0.0007503800613034048,0.0009864731618901032
NCT01736813,CCR5-blockade in Metastatic Colorectal Cancer,0.0012584573285393242,0.0005542478395506639
NCT01740947,Does Administration of Antibiotics in Patients Undergoing Surgery for Colorectal Cancer Result in Less Complications and Better Prognosis?,0.0005954817200434865,0.00046771102769752076
NCT01741038,AlloStimÂ® In-Situ Vaccine in Pre-Treated Metastatic Colorectal Cancer,0.0007020376394880365,0.0004557977234765805
NCT01700283,Developing Objective Fatigue Indicators in Colorectal Cancer Survivors.,0.0005185005051985901,0.00047040715086469573
NCT01732783,Observational Study of Vectibix With Chemotherapy for Metastatic Colorectal Cancer Patients,0.0008402156504618738,0.0006642232966744522
NCT01729923,A Trial of Maintenance ADAPT Therapy With Capecitabine and Celecoxib in Patients With Metastatic Colorectal Cancer,0.0008070535457723951,0.000895179722575428
NCT01701310,IVICA: Intravenous Iron in Colorectal Cancer Associated Anaemia,0.0005199787063842287,0.00039681685586303054
NCT01765582,A Study of Sequential and Concurrent FOLFOXIRI/Avastin (Bevacizumab) Regimens Versus FOLFOX/Avastin in First-Line in Participants With Metastatic Colorectal Cancer (STEAM),0.0006939420721128582,0.0008264456840703062
NCT01721954,FOLFOX6m Plus SIR-Spheres Microspheres vs FOLFOX6m Alone in Patients With Liver Mets From Primary Colorectal Cancer,0.0006240886354541426,0.0006863314581117825
NCT01792934,Chemotherapy and Maximal Tumor Debulking of Multi-organ Colorectal Cancer Metastases,0.00046306397727273967,0.0006434755451477607
NCT01719380,"Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in BRAF Mutant Metastatic Colorectal Cancer",0.0008595013957043586,0.0013138872603925573
NCT01722162,Levocetirizine + Capecitabine + Bevacizumab for Patients With Refractory Colorectal Cancer,0.0007165966896477066,0.0007792650229276899
NCT01715441,Sorafenib in Combination With Irinotecan in Metastatic Colorectal Cancer Patients With KRAS Mutated Tumors,0.0007784443663375501,0.000827520137039191
NCT01715363,Feasibility of an Immediate Preoperative Chemotherapy Before Resection fo Colorectal Cancer,0.0005260141123906237,0.0006338274992402034
NCT01754636,Inclusion of Elderly Patients With Colorectal Cancer in Clinical Trials,0.0009458976213857788,0.0006690229614387086
NCT01763450,Bevacizumab Therapy Untreated Unresectable Liver Metastases From Colorectal Cancer,0.0005433122180272442,0.0008430870938121412
NCT01793207,Peripheral Blood DNA Methylation Markers for the Early Detection of Colorectal Carcinoma in the Egyptian Population,0.000530744394009965,0.0004785615836717967
NCT01775644,An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer (Koralle),0.0008528678296440198,0.0008146932983111665
NCT01733628,Evaluation of Hypertension as a Predictor of Efficacy Bevacizumab in Metastatic Breast Cancer and Metastatic Colorectal Cancer,0.0006191040512283447,0.0006880416727527276
NCT01726296,Adherence to Survivorship Care Guidelines in Health Care Providers for Non-Small Cell Lung Cancer and Colorectal Cancer Survivor Care,0.0005200307631622833,0.0005338391297513767
NCT01718873,Optimization of Bevacizumab Scheduling With Chemotherapy for Metastatic Colorectal Cancer,0.0006950471681991462,0.0007888585179352222
NCT01750918,BRAF/MEK/EGFR Inhibitor Combination Study in Colorectal Cancer (CRC),0.0006697485614075626,0.0007080584136738431
NCT01712347,An Observational Study of First-Line Bevacizumab (Avastin) With Fluoropyrimidine-Based Chemotherapy in Participants With Metastatic Colorectal Cancer,0.0007095914392618726,0.0007514370458638899
NCT02866344,Resection Versus Microwave Ablation for Resectable Colorectal Cancer Liver Metastases,0.0005505892010203211,0.0005434090366264176
NCT02877056,Molecular Determinants of Response to Preoperative Therapy in Patients With Locally Advanced Colorectal Cancer,0.0006628882918453188,0.0006701303627490085
NCT02817178,Study for Validation of Immunological Biomarkers in Patients With Metastatic Colorectal Cancer,0.0008447816721648033,0.0008578741091804331
NCT02863107,Young-Onset Microsatellite-Stable Colorectal Cancer,0.0008998547854466865,0.0008285769067267436
NCT02863172,Molecular Basis for Variations in Hereditary Colorectal Cancer Syndromes,0.0005192416172065125,0.00038647168155696244
NCT02891538,Chemopreventive Effects of Epigallocatechin Gallate (EGCG) in Colorectal Cancer (CRC) Patients,0.000747589024215815,0.0005962289266871355
NCT02859155,Prognostic Factors Affecting Outcomes in Multivisceral en Bloc Resection for Colorectal Cancer,0.0006494631354884901,0.0005499003287484085
NCT02864485,Living Donor Liver Transplantation for Unresectable Colorectal Cancer Liver Metastases,0.00046208936476249636,0.0006324395394318655
NCT02869269,A Study of Circulating Immune Cell Activity Changes in Blood of Colorectal Cancer Patients,0.0006693001178783518,0.0006050082475668017
NCT02869503,Institut Paoli Calmettes Colorectal Cancer Database,0.0008998547854466865,0.0009059482859953498
NCT02848443,Study of S 95005 in Combination With Oxaliplatin in Metastatic Colorectal Cancer,0.0007658995151007173,0.0008657949319967049
NCT02830139,Radical Gastrectomy and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Locally Advanced Colorectal Cancer,0.0005791303790625497,0.0004371075402224797
NCT02820389,CT Colonography as the Initial Diagnostic Imaging Tool for Patients With Suspected Colorectal Cancer,0.0007488368348782676,0.0006020563611523645
NCT02831842,A Real World Study to Evaluate Effectiveness of Avastin (Bevacizumab) for First Line Treatment of Patients With Metastatic Colorectal Cancer and Known KRAS Status,0.0008462995191054636,0.0008020595288144786
NCT02827565,"Technical Optimization of Detection of KRAS, BRAF and NRAS Mutations on Tumor DNA Circulating in Metastatic Colorectal Cancer",0.0007171106031734126,0.000682180546957018
NCT02861300,CB-839 + Capecitabine in Solid Tumors and Fluoropyrimidine Resistant PIK3CA Mutant Colorectal Cancer,0.0004959942095857696,0.0007115087705471116
NCT02829385,Clinical Study of Apatinib and XELOX Combination Regimen to Treat Colorectal Cancer Patients,0.0006994624794529224,0.0008290646330023956
NCT02821559,Biweekly Versus Triweekly Raltitrexed With Oxaliplatin (With or Without Bevacizumab) in First-line Metastatic Colorectal Cancer,0.0006829931703809179,0.0006748480944875583
NCT02845973,Study of Fecal Bacteria in Early Diagnosis of Colorectal Cancer,0.0005622025603311948,0.0006381166344562003
NCT02826837,LEAC-102 for Advanced Colorectal Cancer,0.0010206250789822578,0.0010008669591990895
NCT02809716,High Definition Single Cell Analysis in Colorectal Cancer,0.0005204371754449614,0.0005402070256414001
NCT02885753,Systemic Oxaliplatin or Intra-arterial Chemotherapy Combined With LV5FU2 and an Target Therapy in First Line Treatment of Metastatic Colorectal Cancer Restricted to the Liver,0.0006480777811462917,0.0007143698502201748
NCT02813278,Simo Decoction and Acupuncture on POI in Colorectal Cancer,0.0005182113062595099,0.0002926190615850263
NCT02873455,Effects of Video Information on Preoperative Anxiety in Patients With Colorectal Cancer,0.0006550371531094869,0.0005539156348509614
NCT02873195,Capecitabine and Bevacizumab With or Without Atezolizumab in Treating Patients With Refractory Metastatic Colorectal Cancer,0.000802645880805999,0.000948409037491622
NCT02870582,Donafenib for Previously Treated Metastatic Colorectal Cancer,0.000877483160805472,0.0006960446872145844
NCT02870153,SOX Versus XELOX for Patients With Peritoneal Metastasis of Colorectal Cancer,0.0007602729178314356,0.0009038398182179654
NCT02872779,Correlation Between Circulating Tumour Markers Early Variations and Clinical Response in First Line Treatment of Metastatic Colorectal Cancer,0.0006012367535277553,0.0008290682032916253
NCT02849106,Predictive Response to Chemotherapy (FOLFOX or FOLFIRI) by ex Vivo Culture 3D Technique in Metastatic Colorectal Cancer,0.0006581787230574572,0.0006651140518399869
NCT02837263,PI Pembro in Combination With Stereotactic Body Radiotherapy for Liver Metastatic Colorectal Cancer,0.0006542874416959177,0.0006628617511909916
NCT02837159,A Mobile Aplication for the Promotion of Healthy Lifestyle Habits in Patients With Colorectal Cancer,0.0007465545508412451,0.0007678239415692356
NCT02842294,Cohort Study to Assess Impact of Chemotherapy Plus Bevacizumab on Health Related Quality of Life in First Line Metastatic Colorectal Cancer,0.0006981272026672799,0.0006375828935596358
NCT02842580,De-escalation Chemotherapies Versus Escalation in Non Pre-treated Unresectable Patients With Metastatic Colorectal Cancer,0.0007961411627874997,0.0007967889369904625
NCT01588990,A Translational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer (ASCENT),0.000849148412892523,0.0008115711159009949
NCT01557101,Comparison Colon Capsule Endoscopy vs Optical Colonoscopy for Colorectal Cancer Screening in Familiar-Risk Population,0.0004482211123486365,0.0005040651336419837
NCT01574677,Assessment of Septin9 Biomarker for Detection of Colorectal Cancer in Patients With Positive Fecal Immunochemical Test,0.0006024355459041428,0.0006384137496885585
NCT01545141,Chemokine-Modulatory Regimen for Recurrent Resectable Colorectal Cancer,0.0006434863490793336,0.0005929962219883799
NCT01519895,Effectiveness of Telephone Intervention for Colorectal Cancer Caregivers,0.0005229100309363303,0.000821755657122787
NCT01549067,The Real Clinical Background of Advanced Colorectal Cancer Treatment Situation Survey,0.0005610391772064456,0.0007448484577303028
NCT01549327,The Effect of a Virtual Navigator on Colorectal Cancer Patient Empowerment,0.0013521402111330778,0.000565782054759008
NCT01550055,Study of Cetuximab to Treat KRAS Wild Type Metastatic Colorectal Cancer,0.0007539597977347233,0.0007727782723978458
NCT01596634,Bovine Lactoferrin in Reducing Taste Disturbances in Patients With Colorectal Cancer Receiving Oxaliplatin-Based Chemotherapy,0.0006618248017382558,0.0006442380541985633
NCT01596790,COLOSPOT Study : Assessment by EPISPOT of Circulating Tumor Cells in Patients With Metastatic Colorectal Cancer,0.0008411540906993066,0.0007903514704796484
NCT01571284,Safety and Quality of Life Study of Aflibercept in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen,0.0008185934914508128,0.0007525191384614587
NCT01575340,Study to Assess the Effect of Consumption of Fish Oil Encapsulated on Inflammatory Markers in Colorectal Cancer,0.0005137985277188239,0.0005906017009565436
NCT01506167,An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer (ACORN),0.0008528678296440198,0.0008343506906474909
NCT01566942,FOLFIRI or mFOLFOX6 in Adjuvant Chemotherapy in Advanced Colorectal Cancer,0.0007215276797914571,0.0008335609579673411
NCT01567917,Incidence of Venous Thromboembolism Following Surgery in Patients With Colorectal Cancer,0.0007720611308391247,0.0005560755618191667
NCT01507545,Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO),0.000653722041776665,0.0012070763685668037
NCT01564810,Cetuximab in Combination With Chemotherapy for the Treatment of Metastatic Colorectal Cancer,0.0006981633225287696,0.0009095464225252715
NCT01529164,Efficacy and Safety Study of Recombinant Endostatin Combined With Chemotherapy to Treat Advanced Colorectal Cancer,0.0006502573617596354,0.0006974493570670006
NCT01531595,Study of Bevacizumab in Combination With Alternating Xeliri and Xelox in Metastatic Colorectal Cancer,0.0007836536375412994,0.0008473104344938932
NCT01531777,Dose Finding and Pharmacokinetics/Pharmacodynamics Study of Apatinib in the Treatment of Advanced Colorectal Cancer,0.000590249136368496,0.0005814540732230523
NCT01531621,A Population-based Prospective Study of Metastatic Colorectal Cancer (CRC) Patients in Finland,0.0010487611687361596,0.0009100457312436586
NCT01565811,Prospective Phase II Trial on Prophylactic Perihepatic Lymphadenectomy in Patients With Colorectal Cancer With Liver Metastasis,0.0006744977979360623,0.0005397168568774352
NCT01523431,Individual Dosage Selection of Irinotecan (CPT-11) Based on UGT1A1 Genotype in Metastatic Colorectal Cancer Patients,0.0007753291274544024,0.0008447291947753933
NCT01591590,Correlating the Tumoral Metabolic Progression Index to Patient's Outcome in Advanced Colorectal Cancer,0.0006570700349131656,0.0006098103679866874
NCT01591109,A Reversal in the Vascularity of Metastatic Liver Tumors From Colorectal Cancer After the Cessation of Anti-VEGF Therapy,0.0006444603651945408,0.0006947075137210668
NCT01591421,P13Kinase Inhibitor BKM120 in Combination With Panitumumab in Patients With Metastatic or Advanced RAS-Wild Type Colorectal Cancer.,0.0007904913075769195,0.000770289661313326
NCT01526200,Contrast-Enhanced Intraoperative Ultrasound During Liver Surgery for Colorectal Cancer Liver Metastases,0.00048205467730492925,0.0006151180882920684
NCT01526239,Reminding Patients of the Important of Colorectal Cancer Screening Results in Patient-Initiated Promoting Colorectal Cancer Screening Via Colonoscopy,0.0005981325384325519,0.0005879433155445121
NCT01533740,Circulating Regulatory Lymphocytes and Outcome of Metastatic Colorectal Cancer Patients,0.0008082093934387406,0.0008414181036317023
NCT01584830,Asian Subjects With Metastatic Colorectal Cancer Treated With Regorafenib or Placebo After Failure of Standard Therapy,0.0006257931933177426,0.0007795725613764781
NCT01505166,Randomized Phase II Adjuvant Chemotherapy Â± FANGâ¢ in Colorectal Carcinoma With Liver Metastases,0.00048780419406614016,0.0007366452254103397
NCT01595256,Exploration the Effect of Walking Program in Patients With Colorectal Cancer,0.0006561433139566094,0.0005607845651436828
NCT01589900,Identification the Expression of Sox2 in Colorectal Cancer Tissues,0.0005204400585992871,0.0004197246443428459
NCT01589146,ONE WEEK VERSUS FOUR WEEK HEPARIN PROPHYLAXIS AFTER LAPAROSCOPIC SURGERY FOR COLORECTAL CANCER.,0.00046422261791679453,0.0005021159116890617
NCT01539824,A Study of IMM-101 in Combination With Radiation Induced Tumour Necrosis in Colorectal Cancer,0.0005568494738929497,0.0006980114024223317
NCT01504477,Panitumumab and Bortezomib for Patients With Advanced Colorectal Cancer,0.0007181848906537882,0.0008092400490819664
NCT01516216,Study of Vitamin D in Untreated Metastatic Colorectal Cancer,0.0007219301490502568,0.000785102146097606
NCT01538680,Regorafenib in Subjects With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy,0.0006714834001673039,0.0006995858040928313
NCT01532804,2nd-line Treatment of Metastatic Colorectal Cancer,0.0009483571664645194,0.0008050391134811271
NCT02202096,A Pilot Randomized Trial of a Comprehensive Transitional Care Program for Colorectal Cancer Patients,0.000659974448472764,0.000461312658439666
NCT02202928,Adoptive Cell Therapy Plus Chemotherapy and Radiation After Surgery in Treating Patients With Colorectal Cancer,0.0006613137854416057,0.0007855007202360284
NCT02223078,Two Center Study to Determine Effect of G17DT on Plasma Gastrin Levels in Patients With Colorectal Cancer.,0.0006721685566829538,0.0005311176136408918
NCT02274753,Personalizing Colorectal Cancer Medicine (ImmuCol2),0.0009035662590326675,0.0007639526687401985
NCT02291198,Measurement of NK Cell Activity in Whole Blood in Subjects Being Screened for Colorectal Cancer Using Colonoscopy,0.0004399142846738328,0.00041878893517801637
NCT02291289,A Multi-Center Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer,0.0006745635641442842,0.0007411088933893491
NCT02251977,Effect of GM1 in Prevention of Oxaliplatin Induced Neurotoxicity in Stage II/III Colorectal Cancer,0.000490725942303406,0.0005900262912246126
NCT02271464,Maintenance Bevacizumab Only or Bevacizumab Plus Metronomic Chemotherapy in Advanced Colorectal Cancer,0.0006305835018058219,0.0006855249844425996
NCT02215642,Nutrition and Lifestyle Study Cohort of Colorectal Cancer in China,0.0007924692137420521,0.0004295748367634405
NCT02286492,Expanded Access Study of TAS-102 in Patients With Metastatic Colorectal Cancer,0.0010487611687361596,0.0010120610809739067
NCT02204332,Phase II-b Randomized Clinical Trial of Cabazitaxel in Metastatic Colorectal Cancer Resistant to Standard Treatment,0.0005745536792153006,0.000717639559961917
NCT02226289,Bevacizumab-containing Regimen for Metastatic Colorectal Cancer Failed to Cytotoxic Treatment,0.0006521579016116042,0.0006208943404702826
NCT02238821,Role of the MET Oncogene in Human Colorectal Cancer - A Translational Study,0.000638656329006306,0.0005289897545129471
NCT02210364,"Study of Lurbinectedin (PM01183) in Combination With Capecitabine in Patients With Metastatic Breast Cancer (MBC), Pancreatic Cancer (PC) or Metastatic Colorectal Cancer (CRC).",0.0008232510207015979,0.0006735543071657703
NCT02278133,Study of WNT974 in Combination With LGX818 and Cetuximab in Patients With BRAF-mutant Metastatic Colorectal Cancer (mCRC) and Wnt Pathway Mutations,0.0008889818380081334,0.000747644637313834
NCT02244632,ModufolinÂ® in Combination With 5-Fluorouracil Alone or Together With Oxaliplatin or Irinotecan in Colorectal Cancer,0.0005055680815529882,0.0005203806290866718
NCT02228785,A Study of the Safety and Tolerance of Three Doses of G17DT in Metastatic Colorectal Cancer,0.0008197456747384137,0.0011165550789126223
NCT02232152,CPI-613 and Fluorouracil in Treating Patients With Metastatic Colorectal Cancer That Cannot Be Removed by Surgery,0.0007854950965949065,0.0008340225381492996
NCT02227667,Evaluate the Efficacy of MEDI4736 in Immunological Subsets of Advanced Colorectal Cancer,0.0005917887582898468,0.0006005382371471571
NCT02211443,"Safety, Tolerability and Pharmacokinetics of Recombinant Anti-epidermal Growth Factor Receptor(EGFR) Monoclonal Antibody in Patients With Metastatic Colorectal Cancer",0.000715462452368332,0.0008913673784856248
NCT02260440,A Phase 2 Study of Pembrolizumab (MK-3475) in Combination With Azacitidine in Subjects With Chemo-refractory Metastatic Colorectal Cancer,0.0006620384663761542,0.0008283466162180828
NCT02277093,Pacritinib to Inhibit JAK/STAT Signaling in Refractory Colorectal Cancer,0.0008998547854466865,0.0007808860654021702
NCT02248038,A Multicenter Clinical Trial on Laparoscopic Colorectal Cancer Surgery Compared With Open Surgery,0.0004867749571214809,0.0006103803877902704
NCT02248805,Phase 1 Study of MGD007 in Relapsed/Refractory Metastatic Colorectal Carcinoma,0.0008200352542475787,0.0006447044660821006
NCT02292758,Irinotecan and Cetuximab With or Without Bevacizumab in Treating Patients With RAS Wild-Type Locally Advanced or Metastatic Colorectal Cancer That Cannot Be Removed by Surgery,0.0008570966055003439,0.0008292487838430848
NCT02284529,Safety of OrectalipÂ® (Oxaliplatin) as Adjuvant Treatment for High-risk Stage-â¡ Colorectal Cancer,0.0006037423821261819,0.0005372433872293694
NCT02298946,"AMP-224, a PD-1 Inhibitor, in Combination With Stereotactic Body Radiation Therapy in People With Metastatic Colorectal Cancer",0.000642772623699636,0.0007724168387524083
NCT02256800,Prospective Analysis of UGT1A1 Promoter Polymorphism for Irinotecan Dose Escalation in Metastatic Colorectal Cancer Patients Treated With Bevacizumab Combined With FOLFIRI as the First-line Setting,0.000810952912697338,0.0008470164414930261
NCT02287025,A Phase 4 Study of Regorafenib in Metastatic Colorectal Cancer - Does Educating Physicians Change Patient Out Comes?,0.000811969397281053,0.0007555797962229992
NCT02287597,An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer: Continued Avastin Plus Chemotherapy After First Progression in Clinical Practice,0.0008641355569918981,0.0008292711953219766
NCT02295930,Induction Chemoterapy With Folfoxiri Plus Cetuxumab in Unresectable Colorectal Cancer Patient,0.0007605395465814462,0.0008182032474105039
NCT02217865,Patient-Centered Risk Adjusted Surveillance After Curative Resection of Colorectal Cancer,0.0007574252576191116,0.0006509168436749482
NCT02254941,Observational Study to Evaluate the Use of Targeted Therapies in Metastatic Colorectal Cancer,0.0007156661253974945,0.0007242399479591846
NCT02246725,"Observational Study of Early Contact With Palliative Care Unit for Patients Receiving First Line Palliative Chemotherapy With Cancer in Upper Gastrointestinal Canal, or Second Line Palliative Chemotherapy in Patients With Colorectal Cancer - an Open, Randomised Investigator Initiated Trial.",0.000699590890391484,0.0006178913208850958
NCT02246634,Screening for Synchronous Metastases in Colorectal Cancer With DW-MRI (SERENADE),0.0004823117949973236,0.0005514098546398545
NCT00532909,"Phase I Vandetanib Plus Capecitabine, Oxaliplatin and Bevacizumab for Metastatic Colorectal Cancer",0.000649104687024181,0.0007411584582779833
NCT00541125,G-CSF in Preventing Neutropenia During First-Line Treatment With Chemotherapy and Bevacizumab in Patients With Metastatic Colorectal Cancer,0.0007950221686268045,0.0009131836025865269
NCT00531245,A Phase I/II Trial of TS-1 and Oxaliplatin in Patients With Advanced Colorectal Cancer,0.000837617445404935,0.0007717978460426196
NCT00516230,Establishing Effective Screening Methods for Diagnosing Hereditary Nonpolypoisis Colorectal Cancer,0.0005315560260172867,0.00038798532341696983
NCT00561470,Aflibercept Versus Placebo in Combination With Irinotecan and 5-FU in the Treatment of Patients With Metastatic Colorectal Cancer After Failure of an Oxaliplatin Based Regimen,0.0008230743841003078,0.0008959745467571905
NCT00501410,"FOLFOX Chemotherapy Regimen (5-FU, Leucovorin, Oxaliplatin) in Metastatic Colorectal Cancer",0.0006181448220352608,0.0007811610250416421
NCT00557102,Cetuximab and Combination Chemotherapy as First-Line Therapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver and/or Lung,0.0006521833839356223,0.000698974944636471
NCT00577109,A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Previously Untreated Metastatic Colorectal Cancer.,0.0008826892673419834,0.0007929921952873936
NCT00598975,"A Phase 2a/2b Multicenter, Open-Label Study to Evaluate NKTR 102 in Combination With Cetuximab Versus Irinotecan in Combination With Cetuximab in Second Line Colorectal Cancer Patients",0.00074490238855148,0.000782362987322468
NCT00540943,"Study of Pazopanib, Irinotecan and Cetuximab in Combination to Treat 2nd Line Metastatic Colorectal Cancer",0.0007088029409833552,0.0006773444366064036
NCT00545545,Safety/Efficacy Study of Imprime PGG With Cetuximab in Patients With Recurrent/Progressive Colorectal Carcinoma,0.0007866840332915424,0.0006929726842242016
NCT00593060,"Temsirolimus (CCI-770, Torisel) Combined With Cetuximab in Cetuximab-Refractory Colorectal Cancer",0.0005576159857589913,0.0006679068306447031
NCT00500292,A Phase II Study of 2 Doses of ZD6474 (Vandetanib) in Combination With FOLFOX vs FOLFOX Alone for the Treatment of Colorectal Cancer,0.000568641642496687,0.0006988521226816432
NCT00537823,Pre- and Post-operative FOLFOX Based Therapy for Patients With Colorectal Cancer With Liver Involvement,0.0008143505922524833,0.0008407635365113331
NCT00559741,Cetuximab and Combination Chemotherapy in Treating Patients With Advanced or Metastatic Colorectal Cancer,0.0008415035571544881,0.0008295700644894657
NCT00559676,Study of Biomarkers in Patients Undergoing Chemotherapy for Metastatic Colorectal Cancer,0.0008778090385866493,0.0009384082901538612
NCT00559858,Pyridoxine in Preventing Hand-Foot Syndrome in Patients Who Are Receiving Capecitabine for Advanced Colorectal Cancer or Breast Cancer,0.0006503495447688855,0.0006110143524700208
NCT00582335,Identification of New Colorectal Cancer Genes,0.0009017614516959714,0.0007061716358084342
NCT00582452,Attitudes Towards Prophylactic Colectomy in Hereditary Non-polyposis Colorectal Cancer (HNPCC) Patients,0.0005885646477636999,0.0005762960342687132
NCT00582829,Colorectal Cancer Screening Intervention for Family Members of Colorectal Cancer Patients,0.0007474795666599244,0.0005428015678461941
NCT00508404,Panitumumab Plus FOLFIRI in First-line Treatment of Metastatic Colorectal Cancer,0.0007692060579447628,0.0007468053827503011
NCT00556413,Cetuximab and Combination Chemotherapy as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer,0.0008039451362314497,0.000769249649501492
NCT00522665,Phase I/Randomized Phase II Study of Second Line Therapy With Irinotecan + Cetuximab +/- RAD001 for Colorectal Cancer,0.0005841339305479062,0.0006994996389130939
NCT00578721,Trial of Aspirin and Arginine Restriction in Colorectal Cancer,0.000640765215705884,0.0006382365681888613
NCT00551421,Pertuzumab and Cetuximab in Treating Patients With Previously Treated Locally Advanced or Metastatic Colorectal Cancer,0.0008241210424625884,0.0007064303427935209
NCT00513266,Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Advanced Colorectal Cancer With Liver Metastases or Lung Metastases That Are Potentially Removable by Surgery,0.0006759836641839218,0.0007743975361529715
NCT00550563,DNA Changes That Affect Vitamin D Metabolism in Patients With Colorectal Cancer Receiving Vitamin D Supplements,0.000589800397893715,0.00044508128713895194
NCT00588900,"Irinotecan and Cediranib in Treating Patients With Metastatic Colorectal Cancer That Did Not Respond to Previous Oxaliplatin, Fluoropyrimidine, and Bevacizumab",0.0007867086470388705,0.0007876317345701163
NCT00524706,Phase I/II Study of SOL for Untreated Metastatic Colorectal Cancer,0.0007221793493961075,0.0007841224416492938
NCT00544011,Bevacizumab and Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer,0.000868894579922469,0.0008228676696451304
NCT00544700,Bevacizumab in Treating Patients Who Have Undergone First-Line Therapy for Metastatic Colorectal Cancer,0.0008614019485822744,0.0006778709350718524
NCT00535353,AZD2281 and Irinotecan in Treating Patients With Locally Advanced or Metastatic Colorectal Cancer,0.0008906102983179601,0.0008442057978195904
NCT00575562,Phase I Study of KRN330 Monoclonal Antibody in Patients With Colorectal Cancer,0.0007572461808025507,0.0008435292318818376
NCT00558051,Alpha-type-1 Dendritic Cell-based Vaccines in Patients With Metastatic Colorectal Cancer,0.0007502619949704458,0.0007871714571785065
NCT00597506,Expanded Cohort for Metastatic Colorectal Cancer (MCRC) Using Bevacizumab + Everolimus,0.0007530573886825154,0.0007602031076825426
NCT00506571,"Phase II Study of Irinotecan,Oxaliplatin Plus TS-1 in Untreated Metastatic Colorectal Cancer",0.0007156117439922351,0.0008675486894052961
NCT00506168,Study of Irinotecan & Capecitabine in Metastatic Colorectal Cancer,0.0007663541325673378,0.0009303734496569385
NCT00579891,Tissue and Serum Collection From Colorectal Cancer Patients,0.0006560701643022317,0.0006170325991640182
NCT00507598,Metabolomics-Based Detection of Colorectal Cancer,0.0009060029992823164,0.0006247573840788743
NCT00536809,Phase I/II Study of Lapatinib in Combination With Oxaliplatin and Capecitabine in Subjects With Advanced Colorectal Cancer,0.0006087268915344167,0.0007016327733775844
NCT00504153,Dasatinib in Treating Patients With Previously Treated Metastatic Colorectal Cancer,0.0009301110276507275,0.0007981448391035795
NCT00564694,Studying a Quality of Life Questionnaire in Patients With Colorectal Cancer,0.0007486726729082114,0.0006031854092747572
NCT00503685,Study Using IMC-A12 (Cixutumumab) With or Without Cetuximab in Patients With Metastatic Colorectal Cancer Who Have Failed a Treatment Regimen That Consisted of a Prior Anti-EGFr Therapy,0.0008723600800835236,0.000834695128126001
NCT00503737,Pilot Study of the National Colorectal Cancer Roundtable Toolbox (NCCRT) to Increase Colorectal Cancer Screening Rates,0.0008044000850629891,0.00042451396031568516
NCT00514761,Phase II Efficacy Study of AZD6244 in Colorectal Cancer,0.0011299834464365364,0.0013018126745034683
NCT00538291,Cetuximab and Capecitabine in Treating Patients With Metastatic Colorectal Cancer That Failed Irinotecan Treatment,0.0008272642913830729,0.0008496222216645076
NCT02706301,Pain Coping Skills for Colorectal Cancer Survivors,0.0008998547854466865,0.0003026886482446062
NCT02786329,Anesthesia and Postoperative Outcome in Colorectal Cancer Patients,0.0009393504733814732,0.0005038071337300488
NCT02728804,S1417 CD Financial Impact Assessment Tool in Patients With Metastatic Colorectal Cancer,0.0008123114664249112,0.0007897506456527639
NCT02715882,Clinical Study of Safety and Tolerability of CBLB502 as a Neo-adjuvant Treatment in Patients With Colorectal Cancer,0.0007395805333392976,0.0007262285630699792
NCT02723578,Pemetrexed and Erlotinib for Metastatic Colorectal Cancer,0.0007052951145776147,0.0006331363867333169
NCT02717923,"A Single Arm, Open-label Clinical Trial to Evaluate the Efficacy and Safety of Maintenance Treatment With Capecitabine Plus Cetuximab in Metastatic Colorectal Cancer",0.0006344491735627843,0.0006337079861996943
NCT02743221,A Study Evaluating S 95005 Plus Bevacizumab and Capecitabine Plus Bevacizumab in Patients With Previously Untreated Colorectal Cancer Who Are Non-eligible for Intensive Therapy,0.0007644182900694293,0.0009434585291590084
NCT02713373,Cetuximab and Pembrolizumab in Treating Patients With Colorectal Cancer That is Metastatic or Cannot Be Removed by Surgery,0.0007711355731428401,0.0007413197142595693
NCT02754856,Tremelimumab (Anti-CTLA-4) Plus MEDI4736 (Anti-PD-L1) in Resectable Colorectal Cancer Liver Metastases,0.0006706514547182231,0.0006647031419468046
NCT02748772,Application of Two Anti-angiogenesis Drugs Combined With Chemotherapy in Advanced Colorectal Cancer Under the Background of Precision Medical,0.000500409068686198,0.0006184757805692056
NCT02785068,Evaluation of MM-151 + Nal-IRI + 5-FU + Leucovorin in RAS/RAF Wild-type Metastatic Colorectal Cancer,0.0006063565428876017,0.0007935025449480395
NCT02746432,Insulin Therapy Reduce Post-Operative Inflammatory Response After Curative Colorectal Cancer Resection: Randomization Controlled Trial,0.0004661252567742372,0.0007041938215802857
NCT02781337,Epidemiological and Molecular Colorectal Cancer Registry,0.0006397533227495333,0.00047821206488266857
NCT02726334,"A Phase I, Dose Escalation Study of BNC101 in Patients With Metastatic Colorectal Cancer.",0.0010487611687361596,0.0007929219576476482
NCT02726243,Intestinal Microbiota and Colorectal Cancer in Inflammatory Bowel Disease,0.0006387227682585966,0.0004036042226134283
NCT02776683,"Open-label, Single Arm Trial of BI 695502 in Patients With Previously Untreated Metastatic Colorectal Cancer",0.0007284190004446659,0.0006510596538699449
NCT02705300,Side Effects to FOLFOXIRI + Tocotrienol/Placebo as First Line Treatment of Metastatic Colorectal Cancer,0.0005672441789532235,0.0006784541693071823
NCT02780700,Nintedanib Alone or in Combination With Capecitabine in Refractory Metastatic Colorectal Cancer [LUME-Colon 2],0.0005993532023272343,0.0007121267531734141
NCT02777814,Prophylactic or Preemptive Entecavir in Patients With Colorectal Cancer Who Are Inactive Hepatitis B Carriers,0.0005878795913371131,0.0004681623501935774
NCT02727894,Colorectal Cancer Study: Screening v.s. Other Diagnostics,0.0005739345166956616,0.0006187817057138059
NCT02751892,The Feasibility of an Active Lifestyle Programme in Patients Recovering From Colorectal Cancer,0.0007491996907518594,0.0006451810389572302
NCT02751177,"Detection of KRAS, NRAS et BRAF Mutations in Plasma Circulating DNA From Patients With Metastatic Colorectal Cancer",0.0008118566513724502,0.0007654435613128737
NCT02718430,VXM01 Phase I Study in Patients With Metastatic Colorectal Cancer With Liver Metastasis,0.0009282679113205113,0.00098904640721655
NCT02753127,A Study of Napabucasin (BBI-608) in Combination With FOLFIRI in Adult Patients With Previously Treated Metastatic Colorectal Cancer,0.0008597036362419359,0.0007865494345403153
NCT02796820,Huaier Granule As Adjuvant Therapy for Colorectal Cancer After Radical Surgery,0.0005430778304719857,0.000701854972427513
NCT02700555,Surveillance of Metabolic Parameters in Patients With Colorectal Cancer,0.0006557957437823052,0.0008198644759322679
NCT02738606,Trial of Liver Resection Versus No Surgery in Patients With Liver and Unresectable Pulmonary Metastases From Colorectal Cancer (Liver Resection With Unresectable Lung Nodules From Colorectal Adenocarcinoma - LUNA),0.0006266039926234365,0.0006135006449631904
NCT03008499,High-activity Natural Killer Immunotherapy for Small Metastases of Colorectal Cancer,0.0004774062121654965,0.0007305129834997591
NCT03084133,Impact of EDUcation Strategy on Patients With COLorectal CANCER or Advanced Adenoma in the Detection of Colorectal Cancer of Their First-degree Relatives,0.0006315735382108155,0.0004741679943601039
NCT03005002,Durvalumab and Tremelimumab in Treating Patients With Microsatellite Stable Metastatic Colorectal Cancer to the Liver,0.0007315773531120799,0.0007360780762924684
NCT03096951,Prehabilitation in Colorectal Cancer,0.0009010934323974563,0.0004783459902799418
NCT03096899,"A Study to Estimate Overall Survival in Patients Receiving Best Supportive Care for Treatment-Resistant, Metastatic Colorectal Carcinoma",0.0008058647083499767,0.0006871279267357955
NCT03097276,Management of Patients With High C-reactive Protein After Scheduled Resection of Colorectal Cancer: Pilot Study,0.0006709511383730923,0.0005681754133084275
NCT03053167,Irinotecan Plus Raltitrexed as Second-line Treatment in Advanced Colorectal Cancer Patients,0.000722935505535174,0.0007877892548737659
NCT03007667,The Impact of Colorectal Cancer Surgery on Localization of Ureters; Prospective Clinical Trail,0.0004858408678699165,0.0005005076494186449
NCT03007407,Study of Durvalumab and Tremelimumab After Radiation for Microsatellite Stable Metastatic Colorectal Cancer Progressing on Chemotherapy,0.0006619635247602847,0.0006553907618838639
NCT03088163,The Value of Diffusion-weighted Imaging in Evaluating the Early Efficacy of Liver Metastasis in Colorectal Cancer,0.0004841525527191472,0.0006658871976739781
NCT03050814,Standard of Care Alone or in Combination With Ad-CEA Vaccine and Avelumab in People With Previously Untreated Metastatic Colorectal Cancer QUILT-2.004,0.000577943036936536,0.0007697395109735418
NCT03081494,Phase Ib Study of PDR001 in Combination With Regorafenib in Adult Patients With Previously Treated Metastatic Colorectal Cancer,0.000865566318783841,0.0007307497946785002
NCT03017807,Safety and Pharmacokinetics of Recombinant Anti-EGFr Antibody in Patients With Metastatic Colorectal Cancer,0.0007518501857124573,0.0006242725542386836
NCT03031691,A Study of Brontictuzumab With Chemotherapy for Subjects With Previously Treated Metastatic Colorectal Cancer,0.000752747379424323,0.001016800682539895
NCT03093129,Safety and Effectiveness Study of Pre-operative Artesunate in Stage II/III Colorectal Cancer (NeoART-V),0.0005652311352696762,0.0005365196853237105
NCT03086538,Pemetrexed Plus Tarceva as Salvage Treatment in EGFR Overexpressed Metastatic Colorectal Cancer Patients Who Were Failed After Standard Chemotherapy: A Phase II Single Arm Prospective Study,0.0008221161624746839,0.0006891524010146465
NCT03055026,Rivaroxaban or Placebo for Extended Antithrombotic Prophylaxis After Laparoscopic Surgery for Colorectal Cancer.,0.00043989102346924183,0.0003996825797554734
NCT03043313,Tucatinib (ONT-380) and Trastuzumab for Patients With HER2-positive Metastatic Colorectal Cancer (MOUNTAINEER),0.0008084454510074208,0.0007230357226708594
NCT03047837,"A Randomized, 2x2 Factorial Design Biomarker Prevention Trial of Low-dose Aspirin and Metformin in Stage I-III Colorectal Cancer Patients.",0.0005972255550713399,0.0007784025107981373
NCT03047226,Diagnosis of Lynch Syndrome Based on Next-generation Sequencing in Colorectal Cancer,0.0004644925601063363,0.0004447105486089446
NCT03069950,Study of Chemotherapy With or Without Hepatic Arterial Infusion for Patients With Unresectable Metastatic Colorectal Cancer to the Liver,0.000841486604727009,0.0007200017107462311
NCT03038217,"Investigation of the Value of ctDNA in Diagnosis, Treatment, and Surveillance of Surgically Resectable Colorectal Cancer",0.0004909429398206119,0.0006655225611648165
NCT03013972,A Longitudinal Study of Cancer-related Fatigue Among Colorectal Cancer Patients During Adjuvant Chemotherapy,0.0006800528115992049,0.000744991111466307
NCT03013868,CTCs and Novel Target Bio-marker Analysis for Prediction and Monitoring of Metastasis/Recurrence in Post-surgery Colorectal Cancer Patients Using MiSelect R Rare Cell System,0.0006172930240231745,0.0004748654093701694
NCT03035253,A Study of OMP-305B83 in Subjects With Metastatic Colorectal Cancer,0.0010320524428695296,0.000649882190821197
NCT00284817,Phase I Study of MEDI522 in Patients With Irinotecan-Refractory Advanced Colorectal Cancer,0.0008354102509621232,0.0008101052418696837
NCT00284258,Phase II/III Trial of CPT-11/5-FU/l-LV Versus CPT-11/TS-1 as Second Line Chemotherapy of Unresectable Colorectal Cancer,0.0005199426688225103,0.0006948245839354379
NCT00203411,Bevacizumab Plus Capecitabine (Xeloda) in Patients With Untreated Metastatic Colorectal Cancer,0.0007813088177413176,0.0008744145937784755
NCT00296062,Dose Dense Therapy and Bevacizumab in Solid Tumors and Colorectal Cancer,0.0006352964653705398,0.0007735278167532727
NCT00220116,Phase II Trial Assessing Efficacy and Toxicity of Capecitabine and Oxaliplatin in the Treatment of Colorectal Cancer,0.0005516515057169932,0.0005631245206932451
NCT00220142,Molecular Markers of Prognosis in Colorectal Cancer Patients,0.0007584379479648489,0.0007757290529736833
NCT00220155,Phase II Fixed Dose Rate Gemcitabine for Advanced or Metastatic Colorectal Cancer,0.0006695313214174046,0.0006794961611322559
NCT00220246,Clinical and Molecular Characterization of Familial Microsatellite Stable Colorectal Cancer,0.0005242126066227087,0.0005523139732130418
NCT00291785,Phase I/II CT 2106 and 5-FU/FA in Colorectal Cancer,0.0009419892954911031,0.0006807589477028224
NCT00291486,Capecitabine and 131I-huA33 in Patients With Metastatic Colorectal Cancer,0.0009559479279799281,0.0007877910469148022
NCT00228189,Carcinoembryonic Antigen-loaded Dendritic Cells in Advanced Colorectal Cancer Patients,0.0007108491453527006,0.000802983127563804
NCT00250029,Gene Expression Analysis of Patients With Metastatic Colorectal Cancer Receiving Oxaliplatin Based Chemotherapy Regimen,0.0007689378797526036,0.0009116382913533979
NCT00233623,"Irinotecan, 5-Fluorouracil and Leucovorin With or Without Iressa in the Treatment of Metastatic Colorectal Cancer",0.0006389040775484717,0.0008214900350048149
NCT00235898,Clinical Trial in Patients With Metastatic Colorectal Cancer,0.0009325695037008227,0.0008640357959292666
NCT00225641,Assessment of Frequency of Surveillance After Curative Resection in Patients With Stage II and III Colorectal Cancer,0.0006018815271149346,0.0005680511025039901
NCT00212615,XELOX III. Xeloda in Combination With Eloxatin for Patients With Advanced or Metastatic Colorectal Cancer,0.0007929605813630983,0.0006639253680998164
NCT00251485,A Phase II Trial of Modified FOLFOX 6 and Cetuximab in First Line Treatment of Metastatic Colorectal Cancer,0.0007544291408430997,0.0007402531794738698
NCT00251186,First-Line Capecitabine and Cetuximab for Metastatic Colorectal Ca in Elderly Patients,0.0008039723138904992,0.0008156419082617471
NCT00252564,"Cetuximab, Bevacizumab & 5FU/Leucovorin vs. Oxaliplatin, Bevacizumab & 5FU/Leucovorin in Metastatic Colorectal Cancer",0.0006597190383788539,0.0008043870995660523
NCT00242788,IRESSAâ¢ In Combo With Xelodaâ¢ in Advanced Colorectal Cancer Patients After 1st-Line Chemo Failure,0.0006464799119422885,0.0007542906926175049
NCT00242086,"Comparison of Triphasic CT, PET and MR Tumour With Pathological Findings in Colorectal Cancer Liver Metastases",0.000453622344145845,0.0005739321721201501
NCT00208546,"Cetuximab, Capecitabine, Oxaliplatin and Bevacizumab in Advanced Colorectal Cancer",0.0005860534181004115,0.0006589856503913433
NCT00265850,Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer,0.0008304518041888504,0.0008618843747132756
NCT00265824,Optimized Chemotherapy Followed by Maintenance With Bevacizumab With or Without Erlotinib in Treating Patients With Metastatic Colorectal Cancer That Cannot be Removed by Surgery (DREAM),0.0007902361129708959,0.0006485804746744177
NCT00264979,Evaluation of 2 Resection Strategies of Synchronous Colorectal Cancer Metastases,0.0004622411451631967,0.0005957511449766555
NCT00264446,"A Study of ADH300004 in Surgically Resected Primary or Metastatic Colorectal Cancer and Liver Biopsy, or Planned Hepatic Resection",0.0006575807388495004,0.0005773230203177548
NCT00207155,An Exploratory Pharmacogenomic Study of Monotherapy Erbitux in Subjects With Metastic Colorectal Cancer,0.000640275947796516,0.0007245402594311812
NCT00205322,"Oxaliplatin, 5-FU and Leucovorin in Combination With Oral Capecitabine for Metastatic Colorectal Cancer",0.0006341071227400414,0.0005234263565019186
NCT00230646,Promoting Physical Activity After Colorectal Cancer,0.0006473726454008632,0.0004949662158342094
NCT00230399,Combination Chemotherapy Treatments in Patients With Metastatic Colorectal Cancer,0.0008714750323709348,0.0008674945277345579
NCT00294359,"The MAX Study: Mitomycin C, Avastin and Xeloda in Patients With Untreated Metastatic Colorectal Cancer",0.0008106344245098225,0.0008785604829753372
NCT00274872,Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer That Cannot Be Removed By Surgery,0.0007877107842016388,0.0008192467642271844
NCT00209625,Phase I / II Study of Irinotecan (CPT-11) Combined With l-Leucovorin (l-LV) and 5-FU in Patients With Advanced Colorectal Cancer,0.00075152065453148,0.0008366440590825044
NCT00209651,Phase II Study of Oral S-1 Plus Irinotecan (IRIS) in Patients With Advanced Colorectal Cancer,0.0007713385696002789,0.0009015447894968258
NCT00209703,Feasibility Study of mFOLFOX6 in Patients With Advanced Colorectal Cancer,0.0008084343660189663,0.0009280161748662609
NCT00215982,Study of Capecitabine With Irinotecan and Oxaliplatin (Eloxatin) in Advanced Colorectal Cancer,0.0006134316040482352,0.000654556769529244
NCT00215722,XELOX Plus Cetuximab as First-Line Therapy in Patients With Metastatic Colorectal Cancer,0.0008527491610515533,0.0008798850039014592
NCT00277303,Study of XL999 in Patients With Metastatic Colorectal Cancer,0.0010487611687361596,0.0007556872818873836
NCT00259844,Effect of TroVax in Patients Having Colorectal Cancer With Liver Metastases Removed,0.0006787916147883357,0.0006249961829250842
NCT00268398,Combination Chemotherapy in Treating Patients With Colorectal Cancer and Resectable Metastases,0.0007818829174713837,0.0007664343912306205
NCT00268463,Oxaliplatin and Capecitabine With or Without an Hepatic Arterial Infusion With Floxuridine in Treating Patients Who Are Undergoing Surgery and/or Ablation for Liver Metastases Due to Colorectal Cancer,0.0006490791353828797,0.0006715608546314525
NCT00268333,Combination Chemotherapy and Radiation Therapy in Treating Patients With Recurrent Metastatic Colorectal Cancer,0.0008285702635415849,0.0007865076914768628
NCT00227734,Capecitabine and Oxaliplatin With or Without Cetuximab in Treating Patients With Metastatic Colorectal Cancer That Cannot Be Removed By Surgery,0.000792906217021901,0.0008065762522608102
NCT00217711,"Oxaliplatin, Irinotecan, and Capecitabine in Treating Patients With Advanced or Metastatic Colorectal Cancer That Cannot Be Removed By Surgery",0.0008297890401081267,0.0008417134229191913
NCT00202787,Safety and Efficacy Study of Combination Therapy With Cetuximab and FOLFOX4 in Patients With Colorectal Cancer,0.0007864290697398725,0.0007222145565303477
NCT00202774,Safety and Efficacy Study of XELOX vs. Oxaliplatin+5-FU CI as First Line Treatment in Metastatic Colorectal Cancer,0.0008333228080328218,0.0008182161383032892
NCT00200200,Hepatic Arterial Infusion With Floxuridine and Dexamethasone Combination With Chemotherapy With/Without Bevacizumab for Hepatic Metastases From Colorectal Cancer,0.0005125466506803732,0.0006047142760398848
NCT00234429,A Phase 2 Study of Tomudex & Iressa as Second Line Chemotherapy in Subjects With Colorectal Carcinoma,0.0005649207680345331,0.0006425046472358993
NCT00258232,"Celecoxib, Capecitabine, and Irinotecan in Treating Patients With Recurrent or Metastatic Colorectal Cancer",0.0007944731282261254,0.0008235305084906836
NCT00254137,Cap/Iri Plus Cetuximab Compared to Cap/ox Plus Cetuximab in Patients With Metastatic Colorectal Cancer.,0.000841389525744331,0.0009783400943232817
NCT00286000,High Dose Simplified Folfiri in Advanced Colorectal Cancer: a Multicentre Phase II Study,0.0007009167684968903,0.0010770276755671072
NCT00286130,Safety and Efficacy of Folfox6 + Cetuximab Versus Folfiri +Cetuximab in Patients With Metastatic Colorectal Cancer,0.000969867501546438,0.001160390849265788
NCT02328365,Screening and Systematic Follow-up for Cardiopulmonary Comorbidity in Patients Having Surgery for Colorectal Cancer,0.000635336465478853,0.0005374670116766585
NCT02328677,ColoCare Study - Colorectal Cancer Cohort,0.0011299834464365364,0.0011271626701777197
NCT02321813,Direct Improvement of Quality of Life Using a Tailored Pathway With Quality of Life Diagnosis and Therapy: Randomised Trial in Colorectal Cancer Patients,0.0006508984423070665,0.0008337107620112854
NCT02321969,Green Tea Extracts for the Prevention of Colorectal Adenomas and Colorectal Cancer,0.0004654064601332173,0.0004982862924629273
NCT02380443,Increased Frequency of AlloStimÂ® Immunotherapy Dosing in Combination With Cryoablation in Metastatic Colorectal Cancer,0.0005698203419907769,0.0005672331771561658
NCT02305615,An Observational Study of Continued Avastin Plus Chemotherapy Until First Progression in Patients With Metastatic Colorectal Cancer,0.0008369421096040019,0.0008217988437683548
NCT02305758,Study Comparing Veliparib Plus FOLFIRI Versus Placebo Plus FOLFIRI With or Without Bevacizumab in Previously Untreated Metastatic Colorectal Cancer,0.000680856274937997,0.000732438244719371
NCT02310477,Regorafenib in Metastatic Colorectal Cancer : a Cohort Study in the Real-life Setting,0.000721685699478446,0.0008656020814317667
NCT02324114,Clinical Trial of Quantitative Detection Kit for Hsp90Î± in Colorectal Cancer,0.000523479217679413,0.0004746377866960822
NCT02347852,Assessment of Physical Activity During Therapy With Regorafenib for Metastatic Colorectal Cancer,0.0006237053157430707,0.000651518792078493
NCT02350530,FOLFOXIRI With or Without Bevacizumab as First-line Treatment for Unresectable Liver-only Metastatic Colorectal Cancer Patients With RAS Mutation-type,0.0008099616914896996,0.0010993208651426838
NCT02300922,Pretargeted Radioimmunotherapy in Metastatic Colorectal Cancer,0.0008775048352719344,0.0009340698249660815
NCT02375672,Study of Pembrolizumab in Combination With Chemotherapy for Patients With Advanced Colorectal Cancer,0.0007705303300867884,0.00061858698501846
NCT02386826,"INC280 Combined With Bevacizumab to Evaluate Glioblastoma Multiforme, Metastatic Colorectal Cancer, and Metastatic Renal Cell Carcinoma Patients",0.000763237377031305,0.0008964792639389932
NCT02388256,Acupuncture for Enhanced Recovery After Surgery in Patients Undergoing Laparoscopic Colorectal Cancer Resection,0.0006149458669951553,0.000635666090141527
NCT02365480,Berberine Chloride in Preventing Colorectal Cancer in Patients With Ulcerative Colitis in Remission,0.0006534916970090185,0.0006144561830256547
NCT02368236,Facilitating Risk-Appropriate Colorectal Cancer Testing - Testing the Cancer Risk Intake System (CRIS),0.0009120512848019579,0.0006215254897791449
NCT02368886,Lower or Standard Dose Regorafenib in Treating Patients With Refractory Metastatic Colorectal Cancer,0.0007578966511698229,0.000749148147043053
NCT02383810,Dose Finding Study in Colorectal Cancer Patients Receiving 5-FU-based Chemotherapy to Assess the Efficacy of Elsiglutide in the Prevention of Chemotherapy Induced Diarrhea (CID),0.0007032758921248784,0.0006752818495060013
NCT02384850,Phase 1 Trial To Evaluate mFOLFOX6 With Selinexor In Patients With Metastatic Colorectal Cancer,0.0008187596228925071,0.0009022072614022521
NCT02323464,Prevalence of Sleep Apnea in Patients Undergoing Surgery for Colorectal Cancer,0.0007720611308391247,0.0004697508811277396
NCT02395224,A Longitudinal Study of Colorectal Cancer Patients With Metastatic Disease in Middle-Norway,0.0008654964145816015,0.0007615302783065805
NCT02304978,Prognostic Value of Tissue Factor (TF) in Blood t in Colorectal Cancer in Adults,0.0004650502178598103,0.0005925576338706787
NCT02364024,Validation Study of Linear Quantification of CD3+ Cells in Localized Colorectal Carcinomas,0.0007991901725427049,0.0007092981482150766
NCT02364154,Colorectal Cancer Detected by 1H-NMR Spectroscopy,0.0006370993815903944,0.0004262311027403244
NCT02394769,ASPirin Intervention for the REDuction of Colorectal Cancer Risk,0.0009048539901597865,0.000924656900881012
NCT02376452,Phase II Study of 2-weekly RAILIRI Versus FOLFIRI as Second-line Treatment in Advanced Colorectal Cancer Patients,0.0008494296314454072,0.0009740232484484642
NCT02331927,PERMAD: Personalized Marker-driven Early Switch to Aflibercept in Patients With Metastatic Colorectal Cancer,0.0007599892494336392,0.0008607101743268933
NCT02355353,Evaluation of Diffusion Weighted Imaging -MRI in Patients With Resectable Liver Metastases From Colorectal Cancer,0.0006845508634625297,0.0007144689684592441
NCT02399943,A Trial of Trametinib and Panitumumab in RAS/RAF Wild Type Advanced Colorectal Cancer,0.0005249015205383847,0.0005736317533501812
NCT02301962,Phase IV Panitumumab Study in Indian Subjects With Metastatic Colorectal Cancer,0.0008343129195123025,0.000624586161835277
NCT02316028,Phase I:Decitabine by Hepatic Arterial Infusion(HAI) in Unresectable Liver Metastases Colorectal Cancer (CRC),0.0004672403852582453,0.0004932376261924199
NCT02316496,Rechallenge of Cetuximab Combined With Irinotecan as Third-line Chemotherapy in Patients With Metastatic Colorectal Cancer - Phase II Study,0.0008735855459735208,0.0007861043865685217
NCT02316340,Vorinostat Plus Hydroxychloroquine Versus Regorafenib in Colorectal Cancer,0.0005267756097079704,0.0005533532944339464
NCT02314819,A Phase III Trial Evaluating Fruquintinib Efficacy and Safety in 3+ Line Colorectal Cancer Patients ï¼FRESCO),0.0007592694025168647,0.000836280317898148
NCT02393755,Nintedanib and Capecitabine in Treating Patients With Refractory Metastatic Colorectal Cancer,0.0008299842499608939,0.0008916353602013312
NCT01304602,A Trial of Irinotecan and BKM120 in Previously Treated Advanced Colorectal Cancer,0.0007668436428339996,0.0008404918455187188
NCT01312857,"Study of Hepatic Arterial Infusion With Intravenous Irinotecan, 5FU and Leucovorin With or Without Panitumumab, in Patients With Wild Type RAS Who Have Resected Hepatic Metastases From Colorectal Cancer",0.0007127124247346632,0.0006919741113158871
NCT01312467,A Trial of Metformin for Colorectal Cancer Risk Reduction Among Patients With a History of Colorectal Adenomas and Elevated Body Mass Index,0.0005830526504740598,0.0004987513638928424
NCT01378832,Effect of Peritoneal Lavage With Clindamycin-gentamicin Solution on Postoperative Colorectal Cancer Infection in Elective Surgery,0.0004331547299304167,0.00032323407414191335
NCT01378143,Using OCZ103-OS in Patients With Unresectable and Locally Recurrent or Metastatic Colorectal Cancer Undergoing Standard Chemotherapy,0.000794798936982541,0.000982188764429438
NCT01326000,A Study of RO5083945 in Combination With FOLFIRI Versus FOLFIRI Plus Cetuximab or FOLFIRI Alone as Second Line Treatment in Patients With Metastatic Colorectal Cancer,0.0008452042765070136,0.0008754223893705797
NCT01387880,"Irinotecan, Cetuximab and Everolimus to Patients With Metastatic Colorectal Cancer",0.0008043923338399493,0.0007841540570536782
NCT01383707,A Study of Bevacizumab (Avastin) and Modified FOLFOX-6 (mFOLFOX-6) in Participants With Metastatic Colorectal Cancer,0.0007095143286161857,0.000696880896630118
NCT01383343,"Sorafenib Tosylate, Bevacizumab, Irinotecan Hydrochloride, Leucovorin Calcium, and Fluorouracil in Treating Patients With Metastatic Colorectal Cancer",0.0007574345240224722,0.0009054324307055727
NCT01328171,FOLFOXIRI With or Without Panitumumab in Metastatic Colorectal Cancer (VOLFI),0.0008966559069409695,0.0006623497685921908
NCT01303393,Information Needs After Surgery for Colorectal Cancer,0.0006717155530516731,0.0006362220173815717
NCT01358812,FOLFOXIRI Plus Panitumumab In Kras and Braf Wild-Type Metastatic Colorectal Cancer,0.0007228433092173806,0.0006767415568187848
NCT01320319,"Effect of EPA on Aerobic Performance, Muscle, and Quality of Life in Colorectal Cancer Surgery Patients",0.0006761887958769074,0.00043936612849553177
NCT01320683,Combination Chemotherapy and Bevacizumab Before Surgery and Radiolabeled Monoclonal Antibody Therapy in Treating Liver Metastases in Patients With Metastatic Colorectal Cancer,0.0007972867811962348,0.0009161387845349496
NCT01399684,A Study Evaluating the Efficacy and Safety of MEGF0444A Dosed to Progression in Combination With Bevacizumab and mFOLFOX-6 in Participants With Previously Untreated Metastatic Colorectal Cancer,0.0007008090334583163,0.0008190702078528573
NCT01399190,An Observational Study of Avastin (Bevacizumab) in Combination With Xeloda (Capecitabine) And Oxaliplatin in Patients With Colorectal Cancer,0.000758630976742181,0.0007987052809742778
NCT01321957,Efficacy of FOLFOX+Bevacizumab in Combination With Irinotecan in the Treatment of Metastatic Colorectal Cancer,0.0007170926929321691,0.0009386790650256129
NCT01325909,Exercise Training in Colorectal Cancer Patients,0.0007474702373557403,0.0007080251009390125
NCT01374425,Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer (mCRC),0.0007126429234307126,0.0007675626609509122
NCT01311050,"A Trial of Capecitabine (Xeloda), Oxaliplatin and Irinotecan in Combination With Bevacizumab in 1st Line Treatment of Metastatic Colorectal Cancer",0.000700281085038574,0.0007176598283870321
NCT01356706,Minimally Invasive Liver Surgery for Metastases From Colorectal Cancer: Oncologic Outcome and Prognostic Factors,0.0004741922261372652,0.0005778655752787443
NCT01386242,Recombinant Anti-tumor and Anti-virus Protein for Injection in Treatment of Metastatic Colorectal Cancer,0.0006031180896804694,0.0008131573229789697
NCT01367275,Irinotecan Plus Brivanib in Metastatic Colorectal Cancer (CRC) Enriched for Elevated Levels of Plasma FGF,0.0006003971887434919,0.0005987108589897243
NCT01310478,Recombinant Human Endostatin in Combination With mFOLFOX6 in Patients With Metastatic Colorectal Cancer,0.0008355987326279428,0.0008352929474418719
NCT01322152,Study of Irinotecan Plus Capecitabine to Treat Advanced Colorectal Cancer,0.0006636237997082416,0.0007735047970196772
NCT01344304,Study of Aprepitant / Fosaprepitant for the Prevention of Chemotherapy-induced Nausea and Vomiting (CINV) in Colorectal Cancer Patients - SENRI Trial,0.0006937352351088793,0.000735821551406164
NCT01315990,FOLFIRI in Combination With Cetuximab in the First-line Treatment of Metastatic Colorectal Cancer Including a Regular Dermal Prophylaxis to Prevent Acneiforme Follicular Exanthema,0.0006299077311621951,0.0006091824534278566
NCT01348412,Hepatic Arterial Chemotherapy With Raltitrexed and Oxaliplatin Versus Standard Chemotherapy in Unresectable Liver Metastases From Colorectal Cancer After Conventional Chemotherapy Failure,0.0004994646503860738,0.0008571790482152852
NCT01348256,Study With Dendritic Cell Immunotherapy in Resected Hepatic Metastasis of Colorectal Carcinoma,0.0005221495763124981,0.0006509120467894391
NCT01384994,Panitumumab After Resection of Liver Metastases From Colorectal Cancer in KRAS Wild-type Patients,0.0006937300451308387,0.0008708712271011604
NCT01338558,"A Study of Avastin (Bevacizumab) in Combination With mFOLFOX6 in Treatment-NaÃ¯ve Patients With Metastatic Colorectal Cancer With or Without K-RAS Mutations, and Comparison to Cetuximab",0.0009098628234078652,0.0008385148268985127
NCT01333475,MK-2206 and AZD6244 in Patients With Advanced Colorectal Carcinoma,0.0010200617645078722,0.0008188189108185698
NCT01319877,An Observational Study of Bevacizumab in Combination With 5-FU-Based Chemotherapy in Chinese Participants With Metastatic Colorectal Cancer,0.0007297989454812064,0.0008383668997509554
NCT01305980,Evaluating the Safety and Efficacy of SB Injection in Patients With Advanced or Metastatic Colorectal Cancer,0.0008614259522391853,0.0009937996338130063
NCT01317433,Pre-emptive Cycline Treatment on Cetuximab Induced Skin Toxicity in Colorectal Cancer,0.0005035375720494544,0.0006291955058553331
NCT01318447,CyberKnifeÂ® for Hepatic Metastases From Colorectal Cancer,0.0005365383803983891,0.0005538733035500751
NCT01318161,Epidural Versus Patient-controlled Analgesia for Reduction in Long-term Mortality Following Colorectal Cancer Surgery,0.0006064551519019264,0.0005966068033214089
NCT01343901,An Observational Study on Avastin (Bevacizumab) as First-Line Treatment in Colorectal Cancer Patients With Potentially Resectable Liver Metastases (PICASSO),0.0007343429752498246,0.0008030515895579598
NCT01307878,"New Adjuvant Chemotherapy of Non Resectable Liver Metastasis of Colorectal Cancer Without Bleeding, Obstruction",0.00048343221039430257,0.000526662246712023
NCT01362361,"TRICC-C (AIO-KRK-0111): BIBF 1120 Versus Placebo in Patients Receiving Oxaliplatin Plus Fluorouracil and Leucovorin (mFOLFOX6) for Advanced, Chemorefractory Metastatic Colorectal Cancer (mCRC)",0.0007969864622383278,0.0008269914791794628
NCT01309126,Study of Imprime PGGÂ® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer,0.0005807189986944888,0.000645521683159604
NCT01363739,Evaluation of VEGF Polymorphism as Predictive Factor in Metastatic Colorectal Cancer Treated With Folfiri Plus Bevacizumab,0.0007642529435601088,0.0009857894987023604
NCT01329809,Neoadjuvant Study of Recombinant Vaccinia Virus to Treat Metastatic Colorectal Carcinoma in Patients Undergoing Complete Resection of Liver Tumors,0.0008054858943164955,0.0007537425480319139
NCT01375816,"Liposome-encapsulated Irinotecan Hydrochloride PEP02 or Irinotecan Hydrochloride, Leucovorin Calcium, and Fluorouracil as Second-Line Therapy in Treating Patients With Metastatic Colorectal Cancer",0.0007269014472823405,0.0007539526647497841
NCT01365910,"Linifanib in Treating Patients With Advanced, Refractory Colorectal Cancer",0.0008081174015830303,0.0009058386103760654
NCT00827684,Temsirolimus and Irinotecan for Treatment Resistant Patients With Metastatic Colorectal Cancer and KRAS Mutations,0.0007844812954952824,0.0009554500740171681
NCT00868816,Oxaliplatine Based Adjuvant Chemotherapy for Stage II/III Colorectal Cancer: 8 Cycles Versus 12 Cycles,0.0005531497289119007,0.0007616480248472605
NCT00868569,Transhepatic Arterial Chemotherapy (TAC) Versus Transcatheter Arterial Chemoembolization (TACE) Plus Folfox4 as the Treatment of Unresectable Liver Metastasis of Colorectal Cancer,0.0005115499606912002,0.0006513668367026162
NCT00813137,FOLFOX4 Combined With Endostar in Patients With Advanced Colorectal Cancer,0.0008087173252600893,0.0005553380935563374
NCT00813605,QUILT-2.018: Safety & Efficacy of FOLFIRI With AMG 479 or AMG 655 vs FOLFIRI Alone in KRAS-mutant Metastatic Colorectal Carcinoma,0.000885724551583839,0.0006680966395816412
NCT00856375,"NKTR-102 Versus Irinotecan in Patients With Second-Line, Irinotecan-NaÃ¯ve, KRAS Mutant, Colorectal Cancer",0.0007960707380102893,0.0008471779376062286
NCT00856115,Differences in Timely Cancer Diagnosis in African American and Caucasian Patients With Newly Diagnosed Colorectal Cancer,0.0007499473431310091,0.0006861800357878836
NCT00825110,SS-GCC1- Screening Study of Genetic Changes in Colorectal Cancer,0.0005722172598298206,0.0005823343959553034
NCT00853203,Expressive Disclosure and Colorectal Cancer,0.0017174036041820706,0.0005874078217429759
NCT00853684,"Oxaliplatin, Capecitabine and Endostar as First Line Treatment for Patients With Advanced Colorectal Cancer",0.0006793926683377348,0.0006150518908833088
NCT00873756,"A Study of Dulanermin Administered in Combination With the FOLFOX Regimen and Bevacizumab in Patients With Previously Untreated, Locally Advanced, Recurrent, or Metastatic Colorectal Cancer",0.0008865061478981487,0.0008268373115434653
NCT00898378,Study of Biomarkers in Blood & Tissue Samples From Patients With Colorectal Cancer or Polyps & Patients Without Polyps,0.0006821945930671045,0.0006140702211118545
NCT00824161,Phase II Study of TAS-109 to Treat Advanced Colorectal Cancer,0.0008727381560976661,0.0007360063162788076
NCT00875771,"Irinotecan, Capecitabine and Bevacizumab in Metastatic Colorectal Cancer Patients",0.0008289737172274913,0.0010545522618414095
NCT00828984,Macrogol 3350-based Oral Osmotic Laxative in Preventing Cancer in Patients at Risk of Colorectal Cancer,0.0006588789856197452,0.0006802268059561598
NCT00828672,"Phase II Study of Neo Adjuvant Treatment With Avastin, Xeloda and/or Eloxatin in Colorectal Cancer",0.0005783224836804485,0.0006097005927162634
NCT00884767,Biomarkers in Predicting Neurotoxicity in Patients With Colorectal Cancer Receiving Oxaliplatin,0.0006872298394549998,0.0005782089188084494
NCT00807313,Non-interventional Observational Study of Helical Tomotherapy for Oligometastatic Colorectal Cancer,0.000568762194323268,0.0007604733261866826
NCT00816777,"Chemoembolization, Irinotecan Bead, Second Line Chemotherapy Treatment of Unresectable Metastatic Colorectal Cancer",0.0006547700457588711,0.000720894424247841
NCT00867334,New Individualized Therapy Trial for Metastatic Colorectal Cancer,0.0009483571664645194,0.0007297932614780035
NCT00860860,Study of Pretargeted Radioimmunotherapy of a Anti-CEA Bispecific Antibody and Lu177-labeled Peptide in Colorectal Cancer,0.0005606080401188672,0.0005524628792039726
NCT00842257,Panitumumab in Cetuximab Refractory KRAS Wild-Type Colorectal Cancer,0.000579635933988394,0.0005677547653052577
NCT00852228,Optimal Control of Liver Metastases From Colorectal Cancer With Cetuximab and Hepatic Artery Infusion of Chemotherapy,0.0005169182006823158,0.000685402475537069
NCT00862680,4D PET/CT Imaging in Lung and Colorectal Cancer With Liver Metastasis,0.0004867933756510948,0.0004805012403724085
NCT00862784,A Study of IMC-1121B (Ramucirumab) in Colorectal Cancer,0.0011299834464365364,0.0009700099236585997
NCT00862342,Post-First Progression Use of Bevacizumab in Metastatic Colorectal Cancer (mCRC),0.0007539587663142201,0.0006115189998979302
NCT00891332,Study of S-1 Plus LV for Untreated Metastatic Colorectal Cancer,0.0008281320352925987,0.0009422100378268106
NCT00835679,Cetuximab and/or Dasatinib in Patients With Colorectal Cancer and Liver Metastases That Can Be Removed by Surgery,0.0006550461548534602,0.0005744892939761357
NCT00835185,Study of IMC-11F8 in Participants With Colorectal Cancer,0.0011299834464365364,0.0012259175647021522
NCT00889343,Study to Evaluate the Effects of Sorafenib if Combined With Chemotherapy (FOLFOX6 or FOLFIRI) in the Second-Line Treatment of Colorectal Cancer,0.0005927251269764301,0.0007527780704149692
NCT00874406,Preoperative Transhepatic Arterial Chemotherapy (TAC) in the Treatment of Liver Metastasis of Resectable Colorectal Cancer,0.0005654180204404525,0.0007279726732103015
NCT00838578,Phase I/II Study of KRN330 Plus Irinotecan in Patients With Metastatic Colorectal Cancer,0.00093814058382122,0.0008898751059945158
NCT00838318,Colon Cancer Screening in First-Degree Relatives of Hispanic Colorectal Cancer (CRC) Patients,0.0006100666912365355,0.0004417290932926851
NCT00854971,Efficacy Study of TKcell in Advanced Colorectal Cancer,0.0008727381560976661,0.0012671969717913802
NCT00844233,Study of Chemoembolisation Using Irinotecan Bead Prior to Surgery in Metastatic Colorectal Cancer,0.0007081935781147195,0.0007205363211319265
NCT00895323,Bispecific Antibody in Finding Tumor Cells in Patients With Colorectal Cancer,0.0006232881447400874,0.000579864997976114
NCT00897819,Studying DNA and Outcome in Patients With Advanced Colorectal Cancer Treated With Fluorouracil and Oxaliplatin With or Without Bevacizumab on Clinial Trial E-3200,0.0007023640376004526,0.0006157303847857492
NCT00897754,Gene Expression in Patients With Advanced or Metastatic Colorectal Cancer Receiving Bevacizumab,0.0008316310829345392,0.0007137030934032321
NCT00826540,Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer,0.000852483256828675,0.0006901967602322425
NCT00865709,Study of Modified FOLFOX6 Plus or Minus Sorafenib in Stage IV Metastatic Colorectal Carcinoma (mCRC) Subjects,0.000718409567983183,0.0007791415256188088
NCT00820456,Metastatic Colorectal Cancer: Treatment Response With Dynamic Contrast MRI,0.0006655189957895589,0.0006991487969666179
NCT00806663,FOLFIRI and Sunitinib in Metastatic Colorectal Cancer,0.0008786742959021944,0.0007498224416336818
NCT00885885,Safety and Efficacy Study of FOLFOX4+Panitumumab vs.FOLFIRI+Panitumumab in Subjects WT KRAS Colorectal Cancer and Liver-only Metastases,0.000663237408900771,0.0007541695172439906
NCT00899210,Matrix Metalloproteinases After Surgery and/or Radiofrequency Ablation in Patients With Liver Metastases From Colorectal Cancer,0.0006461943501272018,0.0006033060879217653
NCT00839111,Sorafenib and FOLFIRI Regimen in 2nd Colorectal Cancer (CRC) After Failure of Oxaliplatin Treatment,0.0005318210367838028,0.0008368076396606949
NCT00803647,A Study With Neoadjuvant mFOLFOX7 Plus Cetuximab to Determine the Surgical Conversion Rate for Unresectable Colorectal Cancer With Metastases Confined to the Liver,0.0005719255772393899,0.0008319294138293453
NCT00851045,Ph II Trial of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Second-line Treatment of Metastatic Colorectal Cancer,0.0006458009556431824,0.0008243134251373503
NCT00851084,Study of Aflibercept And Modified FOLFOX6 As First-Line Treatment In Patients With Metastatic Colorectal Cancer,0.0008507375041875703,0.0007761451689942228
NCT00851136,"A Study of PRO95780 Administered in Combination With the FOLFOX Regimen and Bevacizumab in Patients With Previously Untreated, Locally Advanced, Recurrent, and Metastatic Colorectal Cancer (APM4566g)",0.0008888093159373691,0.0008888263145243483
NCT00801294,A Phase II Trial of Weekly Alternating Sequential Administration of BIBF 1120 and BIBW 2992 in Patients With Advanced Colorectal Cancer,0.0008087421358262792,0.0007815344726759464
NCT00819754,A Phase I/II Study of IXO With Bevacizumab in Patients With Metastatic Colorectal Cancer,0.000949579511856038,0.0008931325953205005
NCT00819780,PEAK: Panitumumab Plus mFOLFOX6 vs. Bevacizumab Plus mFOLFOX6 for First Line Treatment of Metastatic Colorectal Cancer (mCRC) Patients With Wild-Type Kirsten Rat Sarcoma-2 Virus (KRAS) Tumors,0.0007719759043925384,0.0008012070083342689
NCT00869271,Postoperative Folfox4 Only Versus Folfox4 Plus Transhepatic Arterial Chemotherapy (TAC) in the Treatment Unresectable Liver Metastasis of Colorectal Cancer,0.0005358040998275725,0.000714129805805422
NCT00890188,Thalidomide and Tegafur/Uracil(UFUR) in the Treatment of Advanced Colorectal Cancer,0.0005576244863065479,0.0008933868026523831
NCT00823810,Treatment Monitoring of Advanced Colorectal Cancer With 18F-FDG PET/CT,0.000523145357492363,0.0007277171094790779
NCT00879385,KRAS Wild-type Metastatic Colorectal Cancer Trial,0.0012584573285393244,0.0006076592008626263
NCT00846313,Can Malnutrition be Prevented in Patient With Colorectal Cancer Stage Dukes D?,0.000749934330227669,0.0006080368944370656
NCT01628211,Second Look Laparoscopy in Colorectal Cancer,0.0006400119613069921,0.0005057519537499068
NCT01673607,Study of Immune Response and Liver Damage Induced by Chemotherapy for Liver Metastases of Colorectal Cancer,0.0005704231915258372,0.0007451332910757312
NCT01697462,An Observational Study of Xeloda (Capecitabine) in Patients With Metastatic Colorectal Cancer (AXIOM),0.0008305046896263038,0.00089604092135418
NCT01697449,An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer (RELEVANT),0.0008528678296440198,0.0008761137924481834
NCT01676714,Study of Dovitinib and Biomarkers in Advanced Non-Small Cell Lung Cancer or Advanced Colorectal Cancer,0.0005793131103774262,0.000727487115311125
NCT01691391,Treatment Optimization of Cetuximab in Patients With Metastatic Colorectal Cancer Based on Tumor Uptake of 89Zr-labeled Cetuximab Assessed by PET,0.0007845417092089817,0.0008378739018082249
NCT01607957,Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies,0.000874234708374092,0.0010721971927297176
NCT01695772,A Study of Bevacizumab Plus 5-Flurouracil (5-FU) Based Doublet Chemotherapy as Neoadjuvant Therapy for Participants With Previously Untreated Unresectable Liver-Only Metastases From Colorectal Cancer,0.000602479651905907,0.0006337003959027967
NCT01606098,The Role of Surgery of the Primary Tumour in Patients With Synchronous Unresectable Metastases of Colorectal Cancer,0.0006256560076063598,0.0007618181684198238
NCT01606124,Polyphenon E in Treating Patients With High-Risk of Colorectal Cancer,0.000749717559331727,0.001014548317765885
NCT01675128,ISIS 183750 With Irinotecan for Advanced Solid Tumors or Colorectal Cancer,0.000629041778943403,0.000713030993236767
NCT01675505,Psychological Well-being Outcomes in Disease-free Survivors of Colorectal Cancer Following Curative Surgery,0.0005188189271221887,0.0005225176727843237
NCT01688232,The Immunoscore as a Prognostic Marker for Patients With a Colorectal Cancer,0.0007581168126946519,0.0009213378824257782
NCT01622543,Reolysin in Combination With FOLFOX6 and Bevacizumab or FOLFOX6 and Bevacizumab Alone in Metastatic Colorectal Cancer,0.000637728570859576,0.0007452269465335989
NCT01668498,Comparison of Two Preemptive Treatment Strategies of Panitumumab Mediated Skin Toxicity and Assessment of QoL in Patient With Ras-wt Colorectal Cancer,0.0006295577400971758,0.000541538685309959
NCT01668680,Maintenance Metronomic Chemotherapy for Metastatic Colorectal Carcinoma,0.0008779045306328955,0.0005847535295889639
NCT01664494,"An Observational Study of Xeloda (Capecitabine) in Patients With Metastatic Colorectal Cancer, Colon Cancer in the Adjuvant Setting, Advanced Gastric Cancer or Breast Cancer",0.0008539322339758612,0.0007684698172450949
NCT01604798,Serum Proteomic Profiling for the Early Diagnosis of Colorectal Cancer,0.000519782996588791,0.0004569544701616068
NCT01661972,Phase I/II Study of Capecitabine Plus Aflibercept to Treat Metastatic Colorectal Cancer,0.0007409735629351173,0.0007969903107837676
NCT01661270,A Study of Aflibercept Versus Placebo With FOLFIRI in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin Chemotherapy,0.0008469546975598535,0.0008561107649455198
NCT01669720,Adjuvant Aflibercept for Metastatic Colorectal Cancer,0.0008849923720089005,0.0007267335597625283
NCT01669109,Hatha Yoga for Patients With Colorectal Cancer,0.0009397699173793337,0.000571843535863917
NCT01629524,Influence of Tumor Associated Immunity on the Number of Lymph Node Retrieved After Colorectal Cancer Surgery (Preliminary Study),0.0005518290119771699,0.0005386097404522481
NCT01623206,Desmopressin (DDAVP) in Patients With Colorectal Cancer and Rectal Bleeding,0.0006534916970090185,0.0007202409173646415
NCT01632722,"Perioperative vs Postoperative Chemotherapy + Bevacizumab in Colorectal Cancer, Liver Mets",0.0006286622591175844,0.0008142123798534319
NCT01640405,Study of 5-Fluorouracil/Leucovorin/Oxaliplatin (FOLFOX) + Bevacizumab Versus 5-Fluorouracil/Leucovorin/Oxaliplatin/Irinotecan (FOLFOXIRI) + Bevacizumab as First Line Treatment of Patients With Metastatic Colorectal Cancer Not Previously Treated and With Three or More Circulating Tumoral Cells,0.0008913841929501288,0.0009245687729961308
NCT01640444,Influence of BRAF and PIK3K Status on the Efficacy of 5-Fluorouracil/Leucovorin/Oxaliplatin (FOLFIRI) Plus Bevacizumab or Cetuximab in Patients With RAS Wild-type Metastatic Colorectal Carcinoma and < 3 Circulating Tumor Cells (CTC),0.0008031400878866017,0.0008564578966284319
NCT01609075,An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer in Italy (BEWARE),0.0008528678296440198,0.0008985363834683743
NCT01670721,Colorectal Cancer Metastatic,0.0012584573285393244,0.0005738262875380262
NCT01605318,Dose Finding Study of Once or Twice Weekly IMMU-130 in Metastatic Colorectal Cancer,0.0007156555286967252,0.0007367138888784595
NCT01674907,An Observational Study of Avastin (Bevacizumab) in First Line in Patients With Metastatic Colorectal Cancer (AVANiS),0.000845987701416326,0.0008221104444941353
NCT01639326,Study to Evaluate the Efficacy and Safety of FOLFIRI-AD in Patients With Metastatic Colorectal Cancer UGT1A Genotype 1,0.000846562197886729,0.000851981347918966
NCT01651013,Observational Study on Treatment of Metastatic Colorectal Cancer and the Role of K-Ras,0.000707401341007805,0.0007236854045060344
NCT01696695,An Observational Study of First-Line Capecitabine Based Chemotherapy in Participants With Metastatic Colorectal Cancer,0.0006996140659962842,0.0008401992421623697
NCT01652482,Safety and Efficacy Study of MEHD7945A + FOLFIRI Versus Cetuximab + FOLFIRI as Second Line Therapy in Participants With KRAS Wild-Type Metastatic Colorectal Cancer (mCRC),0.0006987350360405585,0.000706999665505298
NCT01679327,Study of Bevacizumab Plus Chemotherapy in Patients With Metastatic Colorectal Cancer,0.0009061969998100325,0.0008805956318960453
NCT01619423,A Trial of PledOx + FOLFOX6 Compared to Placebo + FOLFOX6 in Patients With Metastatic Colorectal Cancer,0.0009343229146517634,0.0007537272315005327
NCT01052376,Endomicrocancer: Confocal Endomicroscopy in Patients With High Risk of Colorectal Cancer,0.0007485097906244489,0.0005955161236504068
NCT01082315,A Korean Post-marketing Surveillance Study on ErbituxÂ® in Patients With Metastatic Colorectal Cancer Refractory to Irinotecan-containing Treatment,0.0008553475710382093,0.0006886764799076336
NCT01082757,Prevalence of the Mutational Status of V-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) in Metastatic Colorectal Cancer (mCRC) in Argentine Patients,0.0008103703266239094,0.000911517553665331
NCT01080547,Study Comparing Conventional and Fast Track Multi-Discipline Treatment Interventions for Colorectal Cancer,0.0005369836695039196,0.0005244368559235204
NCT01032590,Internet-Based Weight-Loss Program for Colorectal Cancer Survivors,0.0006399499515837943,0.00048017858638351417
NCT01032291,A Study to Assess the Efficacy and Safety of Lenalidomide in Combination With Cetuximab in Pre-treated Patients With KRAS Mutant Colorectal Cancer,0.0007260100282149773,0.0008709759940975024
NCT01058655,"RAD001 and AV-951 in Patients With Refractory, Metastatic Colorectal Cancer",0.001179376051279735,0.000793041180151515
NCT01035385,Compare FOFLOX4 in Preoperative and Postoperative and Postoperative in Resectable Liver Metastasis Colorectal Cancer (MCC),0.0005421474715294705,0.000697682583726305
NCT01008475,EMD 525797 in Combination With Cetuximab and Irinotecan in K-ras Wild Type Metastatic Colorectal Cancer,0.0006338162366027003,0.0007053802199193537
NCT01086618,Chemotherapy With or Without Surgery in Treating Patients With Metastatic Colorectal Cancer That Cannot Be Removed by Surgery,0.0008036635810173907,0.000815725997773868
NCT01086267,Safety and Efficacy Study of BMS-908662 Alone or in Combination With Cetuximab in Subjects With K-RAS or B-RAF Mutation Positive Advanced or Metastatic Colorectal Cancer,0.0007264801329443624,0.0007826492932215195
NCT01003600,Colorectal Cancer Survivors' Needs and Preferences for Survivorship Information,0.0006383157124327663,0.0006345317666094528
NCT01057017,Panitumumab and Bevacizumab Maintenance After First-Line FOLFOX-Bevacizumab for Patients With Advanced Colorectal Cancer With Wild-Type Ras,0.0006908554556298511,0.0005897656111214574
NCT01057953,Oligogenic Determinism of Colorectal Cancer,0.0017174036041820706,0.0005848525960028185
NCT01040000,QUILT-3.019: Phase 2 Study of NPC-1C Chimeric Monoclonal Antibody to Treat Pancreatic and Colorectal Cancer,0.0005651551878845878,0.0006181745178803231
NCT01068132,Prognostic Factors for Patients With Advanced Colorectal Cancer Treated With Cetuximab.,0.0007395860904987911,0.0007630330506322066
NCT01006369,"Hydroxychloroquine, Capecitabine, Oxaliplatin, and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer",0.0007915058518104453,0.0007923412300293529
NCT01074333,An Observational Study of ErbituxÂ® in Patients With Metastatic Colorectal Cancer (mCRC) Refractory to Irinotecan-containing Treatment,0.0008579388250399736,0.0006642004952077474
NCT01064375,Safety Study of DNA Vaccine Delivered by Intradermal Electroporation to Treat Colorectal Cancer,0.0006362011557327132,0.0004922821636910325
NCT01056809,Treatment Strategies for Primarily Generalized Colorectal Cancer,0.0005732421375580851,0.0005745042631620011
NCT01051596,A Study of ABT-888 in Combination With Temozolomide for Colorectal Cancer,0.0006697485614075626,0.0006117106782148702
NCT01051167,Bi-weekly Cetuximab Combined With 5-fluorouracil/Leucovorin/Oxaliplatin (FOLFOX-6) in Metastatic Colorectal Cancer,0.0006469188633481616,0.0008267340118248007
NCT01085331,MEK Inhibitor MSC1936369B Plus FOLFIRI in Second Line K-Ras Mutated Metastatic Colorectal Cancer (mCRC),0.0007132226244033401,0.0007263335815361985
NCT01070355,Eicosapentaenoic Acid (EPA) for Treatment of Colorectal Cancer Liver Metastases,0.0005960808678973677,0.0005736548323118203
NCT01047475,A Phase II Trial of MB-6 Plus FOLFOX4 for Metastatic Colorectal Cancer (FDA IND 103675),0.0012584573285393244,0.0006724927602167773
NCT01047293,"RAD001, FOLFOX and Bevacizumab in Treatment of Colorectal Carcinoma",0.0007759113055005111,0.0006663984412640283
NCT01097018,Perifosine Plus Capecitabine Versus Placebo Plus Capecitabine in Patients With Refractory Advanced Colorectal Cancer,0.0006767323905653734,0.0008043884058865747
NCT01053013,Open-Label Phase 2 Efficacy Trial of Cancer Macrobeads in Patients With Treatment-Resistant Pancreatic or Colorectal Cancer,0.0006143002544932033,0.0007302431390643905
NCT01001377,ASPECCT: A Study of Panitumumab Efficacy and Safety Compared to Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer,0.0008478078054285677,0.0008389897093245721
NCT01022541,Capecitabine and Oxaliplatin Plus Bevacizumab as Neoadjuvant Treatment for Untreated Unresectable Liver-only Metastases From Colorectal Cancer,0.0005150629918872745,0.0005644638339994159
NCT01061515,Biweekly Intraperitoneal Oxaliplatin With Systemic Capecitabine and Bevacizumab for Patients With Peritoneal Carcinomatosis From Appendiceal or Colorectal Cancer,0.000684379203968691,0.000672182823631263
NCT01077739,A Study of Avastin (Bevacizumab) With XELOX or FOLFOX in Patients With Metastatic Colorectal Cancer and Disease Progression Under First-line FOLFIRI and Avastin,0.0008498351909985921,0.0008860337577518305
NCT01089413,Observational Study of Bevacizumab [Avastin] in Patients With Metastatic Colorectal Cancer (AVASTART),0.0008528678296440198,0.0008409852910740524
NCT01060423,TACE With Irinotecan Drug-eluting Beads and Intravenous (IV) Cetuximab in Refractory Colorectal Cancer,0.000493015506056971,0.0006584124571552034
NCT01079780,Irinotecan Hydrochloride and Cetuximab With or Without Ramucirumab in Treating Patients With Advanced Colorectal Cancer With Progressive Disease After Treatment With Bevacizumab-Containing Chemotherapy,0.0007458014970076796,0.0007560316344857037
NCT01075633,Colorectal Cancer Screening in Familiar-Risk Population: Immunochemical Fecal Occult Blood Testing Versus Colonoscopy,0.00047212567576668734,0.0005055438901794146
NCT01075893,Changes in Stem Cells of the Colon in Response to Increased Risk of Colorectal Cancer,0.00043407991024664876,0.00045458331742633174
NCT01075048,ARQ 197 in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer,0.0008734285848365439,0.0007126633694850063
NCT01004159,Cetuximab Plus Irinotecan in Colorectal Cancer Patients Who Progressed After Failure With Cetuximab Plus Irinotecan,0.0008237001416526064,0.0007453270246955672
NCT01071655,Selecting Treatment in Colorectal Cancer:Capecitabine or 5-fluorouracil Selection to be Combined With Oxaliplatin or Irinotecan as First-line Chemotherapy in Advanced Colorectal Cancer,0.0006002369798577722,0.0008883279181834378
NCT02401802,Low-fiber Diet for Colorectal Cancer Screening Colonoscopy,0.0004625438771275821,0.0004392305685386488
NCT02425683,Study of Colorectal Cancer Patients (Stage IIIC) With Either Regorafenib or Standard of Care (No Treatment) After Adjuvant FOLFOX,0.0007062285037210148,0.0007613230148285007
NCT02487992,The Study of CIK Plus S-1 and Bevacizumab as Maintenance Treatment for Patients With Advanced Colorectal Cancer,0.0008200510730265639,0.001196349224883834
NCT02442583,Reducing Sedentary Behaviors Among Colorectal Cancer Survivors,0.0008998547854466865,0.00028501862210659394
NCT02469480,Intravenous Ferric Carboxymaltose vs. Oral Iron Substitution in Patients With Metastatic Colorectal Cancer (CRC) and Iron Deficiency Anemia: a Randomized Multicenter Treatment Optimization Study.,0.0008254010954498985,0.0007601314442456748
NCT02457390,The Value of CE-LUS During Robot-assisted Surgery for Primary Colorectal Cancer,0.000672615603974373,0.0003240886251159927
NCT02419677,Radiofrquency Ablation Combined With Cytokine-induced Killer Cells for Colorectal Cancer Liver Metastases,0.00048712544260232554,0.0006102535244055194
NCT02488161,Factors Related to Adverse Events in Colorectal Cancer,0.0006395962064943694,0.0006106372708213631
NCT02437071,Assess the Efficacy of Pembrolizumab Plus Radiotherapy or Ablation in Metastatic Colorectal Cancer Patients,0.0007504602985501891,0.0006958427947241449
NCT02423785,Ocular Blood Flow in Colorectal Cancer Patients,0.0007465545508412451,0.0007289314510574504
NCT02423720,Mindfulness Meditation Intervention for Colorectal Cancer Patients and Caregivers,0.0006563683646515508,0.0007778951614008906
NCT02412683,Neurotoxic Symptoms in Adjuvant Chemotherapy in Patients With Colorectal Cancer,0.0006574002250748872,0.0005451964245942067
NCT02414009,"Study to Compare CAPTEM vs FOLFIRI as Second Line Treatment in Advanced, Colorectal Cancer Patients",0.0008074780677095887,0.0008906432441059015
NCT02402036,A Biomarker Study in Patients Getting Regorafenib for Metastatic Colorectal Cancer,0.0008503354993053152,0.0007344535154333459
NCT02455128,Therapeutic Listening in Patients With Colorectal Cancer,0.0008003921744242367,0.00048672788487532195
NCT02465502,Regorafenib in Subjects With Antiangiogenic-naive and Chemotherapy-refractory Advanced Colorectal Cancer,0.0005570298567384214,0.0006390356062757938
NCT02476045,"Panitumumab-based Maintenance in Patients With RAS Wild-type, Metastatic Colorectal Cancer (Valentino)",0.0009446790253543813,0.0008033077627962901
NCT02458664,BASE HSP110 : A New Therapeutic Target and a New Marker for Prognosis of Type MSI Colorectal Cancer,0.00052091587397827,0.0006067954106535453
NCT02489916,Donafenib Monotherapy for Previously Treated Metastatic Colorectal Cancer,0.000877483160805472,0.000746250286831815
NCT02484833,Erbitux MEtastatic Colorectal Cancer Strategy Study,0.0006408290450101745,0.0005866053472994443
NCT02495532,Clinical Trial Comparing Carnoy's and GEWF Solutions for Lymph Node Clearing Technique in Colorectal Cancer,0.0005206594919517383,0.0005697952220186901
NCT02413853,Combination Chemotherapy and Bevacizumab With or Without PRI-724 in Treating Patients With Newly Diagnosed Metastatic Colorectal Cancer,0.0008039660135287334,0.000928245092779832
NCT02456285,Colorectal Cancer With Liver-limited Synchronous Metastases: an Inception Cohort Study of Standardised Care Pathways,0.0005437514245986696,0.0007297211715702626
NCT02439580,Effect of Annona Muricata Leaves on Colorectal Cancer Patients and Colorectal Cancer Cells,0.0009465137809529106,0.0006504377240864935
NCT02439385,Avastin/FOLFIRI in Combination With Curcumin in Colorectal Cancer Patients With Unresectable Metastasis,0.0006376245215149328,0.0005993821488118294
NCT02450422,The Detection of Circulating Tumor Cells (CTCs) in Patients With Colorectal Cancer Undergoing Cryosurgery Combined With DC-CIK Treatment,0.000651511094075014,0.0004900029246680678
NCT02448810,Phase 2a Study of BAX69 and 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer,0.0006716639603541528,0.000807849250224298
NCT02403024,Feasibility and Efficacy of Interval Walking in Patients With Colorectal Cancer,0.0007468574356696248,0.0007319116609188593
NCT02460198,Study of Pembrolizumab (MK-3475) as Monotherapy in Participants With Previously-Treated Locally Advanced Unresectable or Metastatic Colorectal Cancer (MK-3475-164/KEYNOTE-164),0.0007204090733233377,0.0006362957456548507
NCT02453464,A Phase Ib Study of Humanized Anti-VEGF Monoclonal Antibody (Sevacizumab) Injection Plus FOLFIRI in Chinese Patients With Metastatic Colorectal Cancer,0.0008392684635393952,0.0007193688729887885
NCT02497157,Bevacizumab + Triplet Treatment for Untreated With Chemotherapy Metastatic Colorectal Cancer,0.0006880127951680793,0.0007345689900080911
NCT02409472,Intensive Versus Minimal Surveillance of Patients With Resected Dukes B2-C Colorectal Carcinoma,0.0007508256179843178,0.0005626946006840736
NCT00101894,Safety of AMG 706 Plus Panitumumab Plus Chemotherapy in the Treatment of Subjects With Metastatic Colorectal Cancer,0.0007100887384983344,0.0008736910753411517
NCT00165854,Study of E7070 Combined With Capecitabine to Determine Efficacy and Recommended Dose of Combination in Patients With Metastatic Colorectal Cancer,0.0008427092038705002,0.0007976250792225693
NCT00165568,Using Positron Emission Tomography to Evaluate the Effects of Bevacizumab on Intra-tumoral Pharmacokinetics of 5-fluorouracil in Metastatic Colorectal Cancer,0.0006148879529551106,0.0007002582277073268
NCT00165217,Capecitabine and Thalidomide in Previously Treated Metastatic Colorectal Carcinoma,0.0007275463543882807,0.0007945885324240241
NCT00165867,An Open Label Phase II Study of Indisulam in Combination With Irinotecan in Patients With Metastatic Colorectal Cancer Who Have Been Previously Treated With 5-Fluorouracil/Leucovorin and Oxaliplatin,0.0008661972111575968,0.0008813966476380564
NCT00102011,Colonoscopy or Fecal Occult Blood Test in Screening Healthy Participants for Colorectal Cancer,0.000530413483035285,0.0005914227839103545
NCT00154102,Cetuximab Combined With Irinotecan in First-line Therapy for Metastatic Colorectal Cancer (CRYSTAL),0.0006681260167532508,0.0010788155593402277
NCT00110721,GM-CT-01 Plus 5-Fluorouracil as Third- or Fourth-Line Therapy for Metastatic Colorectal Cancer,0.0007219615213083523,0.0008347862234064123
NCT00173472,"Association of MSI, TS, DPD, MVD and EGFR With Chemosensitivity in Stage IV in Colorectal Cancer",0.0005197538572936113,0.0005828227541652368
NCT00125034,Oxaliplatin and Cetuximab in First-line Treatment of Metastatic Colorectal Cancer (mCRC),0.0007168116527555053,0.0007973263896793851
NCT00109070,A Study to Evaluate Avastin in Combination With Standard Chemotherapy to Treat Colorectal Cancer,0.0005807553806455762,0.0007212490244725963
NCT00109226,A Study to Evaluate Avastin in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer,0.0008599497381130338,0.0009120618540375895
NCT00133913,Circulating Tumor Cells in Patients With Metastatic Colorectal Cancer,0.0009314316809906511,0.0007124595911846901
NCT00189683,Xeloda Vs Monitoring in Advanced Colorectal Cancer Responsive to Chemotherapy,0.000556781363114221,0.000642010094507837
NCT00111774,Evaluating ABX-EGF in Patients With Metastatic ColorectalCarcinoma,0.0009446790253543813,0.0011875569276831282
NCT00111761,Evaluating Panitumumab (ABX-EGF) in Patients With Metastatic Colorectal Cancer,0.0009446790253543813,0.0009551364293817588
NCT00176774,"Irinotecan, 5-Fluorouracil, and Leucovorin in Colorectal Carcinoma",0.0005884494972935279,0.0008049791824558771
NCT00192075,A Randomized Trial of Avastin + Gemcitabine + 5-Fluorouracil (5FU)/Folinic Acid Versus Avastin + Oxaliplatin + 5FU/Folinic Acid in Metastatic Colorectal Cancer,0.0005980341033450252,0.0007437576935387665
NCT00192114,Enzastaurin for Patients With Metastatic Colorectal Cancer,0.0009301056237364972,0.0007096090849918323
NCT00113763,Evaluating Panitumumab (ABX-EGF) Plus Best Supportive Care Versus Best Supportive Care in Patients With Metastatic Colorectal Cancer,0.0008218716714889271,0.0007784357445066802
NCT00199862,Safety Study of Radio-labeled huA33 Antibody in Colorectal Cancer,0.0006395164636957095,0.0008131911631327612
NCT00199654,Positron Emission Tomography (PET) Interest in the Follow Up of Colorectal Cancer Stage II and III,0.0005237577312260559,0.0005732153974826252
NCT00199173,Comparing Hepatic Intra-arterial Injection of Yttrium-90 Microspheres Versus Fluorouracil (5FU) in Colorectal Cancer Metastatic to the Liver Only,0.0005739540942912267,0.0005233747974758801
NCT00199797,Phase I Trial of huA33 Plus Chemotherapy in Patients With Metastatic Colorectal Cancer,0.0009762054289800861,0.0009393981313334232
NCT00193219,Bevacizumab and Cetuximab in Combination With FOLFOX6 in Patients With Metastatic Colorectal Cancer,0.0008365018357281381,0.0008084706404592553
NCT00193167,Weekly Topotecan in Patients Treated for Metastatic Colorectal Cancer,0.0009298078255548983,0.0009830096061231818
NCT00149396,Safety and Efficacy of a Genetically Engineered Herpes Simplex Virus NV1020 to Treat Colorectal Cancer Metastatic to Liver,0.0007144600742864526,0.0007635425344621081
NCT00106054,Neoadjuvant Colorectal Cancer With Unresectable Liver Metastases,0.0005582634740258075,0.0007665129192531016
NCT00103311,SB-715992 in Treating Patients With Advanced or Metastatic Colorectal Cancer,0.0009913799234917639,0.0008964093287717978
NCT00103142,Vaccine Therapy in Treating Patients With Liver or Lung Metastases From Colorectal Cancer,0.0006672946853069033,0.0005932359359667415
NCT00103298,Isolated Hepatic Perfusion With Melphalan Followed by Combination Chemotherapy in Treating Patients With Unresectable Liver Metastases From Colorectal Cancer,0.0006269609171145104,0.0006854304730752235
NCT00155727,Comparison of Laparoscopic Colectomy Versus Open Colectomy for Colorectal Cancer: â¦ A Prospective Randomized Trial,0.0004680705769502169,0.0006710832434008891
NCT00159484,Phase I/II Study of Celebrex and EPO906 in Patients With Metastatic Colorectal Cancer,0.0009077430749665649,0.0008721222455975142
NCT00159445,Capecitabine and Gemcitabine in Patients With Metastatic Colorectal Cancer,0.0008318788620518343,0.000873936336658736
NCT00159432,"Study of Oxaliplatin, Capecitabine and Bevacizumab as First Line Treatment for Patients With Advanced Colorectal Cancer",0.0007826859832168672,0.0008242420830413829
NCT00191984,A Study of the Combination of Pemetrexed and Irinotecan Every Two Weeks in Metastatic Colorectal Cancer,0.0007137847944636179,0.0009105792147322584
NCT00122720,The Effect of Darbepoetin Upon Rehabilitation for Colorectal Cancer Surgery,0.0005436736591426766,0.0007302966469812449
NCT00122187,Translation of Colorectal Cancer Screening Guidelines to Practice: A System Intervention,0.0004469914777407479,0.00039816377239361265
NCT00143403,Comparing Irinotecan and 5 FU/FA To 5-FU/FA After Resection Of Liver Metastases For Colorectal Cancer,0.0005361981683473511,0.000480259055173731
NCT00118365,Eflornithine and Sulindac in Preventing Colorectal Cancer in Patients With Colon Polyps,0.0006111828318960307,0.0005193160053263291
NCT00118755,A Study of Two Different Schedules of Xeloda (Capecitabine) as First Line Therapy in Patients With Metastatic Colorectal Cancer,0.0008215261445017899,0.0007807489507988161
NCT00118105,"S0408: Capecitabine, Oxaliplatin, and Bevacizumab in Pts Undergoing Surgery for Liver Mets From Colorectal Cancer",0.0005384008577399988,0.0006919876167896829
NCT00118989,Curcumin for the Chemoprevention of Colorectal Cancer,0.0006395406389364425,0.0003212279221411866
NCT00118261,"Erlotinib, Modified FOLFOX6, and Bevacizumab as First-Line Therapy Metastatic Colorectal Cancer",0.0006703645723382098,0.000746472837579114
NCT00123851,"Tarceva, Capecitabine and Oxaliplatin for Metastatic Colorectal Cancer",0.00066122405492754,0.0007104610026011004
NCT00147134,A Trial to Evaluate Laparoscopic Versus Open Surgery for Colorectal Cancer,0.0005329628751945463,0.0009106679971675576
NCT00182715,Combination Chemotherapy With or Without Cetuximab as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer,0.0008039451362314497,0.0007722723237849192
NCT00138177,"Suberoylanilide Hydroxamic Acid, Fluorouracil, Leucovorin, and Oxaliplatin in Treating Patients With Progressive Metastatic or Unresectable Colorectal Cancer or Other Solid Tumors",0.0007614363711048694,0.0007470259964784584
NCT00138060,Toxicity/Benefit Ratio Optimization of Chemotherapy in Colorectal Cancer (CRC) Patients by Determination of Individual Genotypic Determinants,0.0006420592560970558,0.0007085116802299946
NCT00188331,Cognitive Function and Fatigue in Colorectal Cancer (CRC) Patients After Chemotherapy,0.0006928944865392966,0.0006446369610359409
NCT00188305,A Randomized Trial of Cancer Risk and Health Education in Relatives of Colorectal Cancer Patients,0.000596704873683784,0.0005574710157423882
NCT00116506,"Study of Bevacizumab, Erlotinib, FOLFOX for Patients With Untreated Metastatic Colorectal Cancer",0.0008455535950245385,0.0008682455631001566
NCT00172757,"Association of Colorectal Cancer With Nutrition, Diet, Obesity, Diabetes Mellitus, and Genetic Alterations in Taiwan",0.00042347905490061003,0.0005816007987966689
NCT00115765,PACCE: Panitumumab Advanced Colorectal Cancer Evaluation Study,0.0006349585803544415,0.0007467124056413252
NCT00100841,"Phase II Trial of FOLFOX6, Bevacizumab and Cetuximab in Patients With Colorectal Cancer",0.0008376804444028868,0.0006838611081304853
NCT00134069,"Sorafenib, Cetuximab, and Irinotecan in Treating Patients With Advanced or Metastatic Colorectal Cancer",0.0008213196063465949,0.0008114970211374483
NCT00107250,"AZD2171 and Chemotherapy in Treating Patients With Advanced Non-Small Cell Lung Cancer, Colorectal Cancer, or Other Cancer Suitable for Treatment With Capecitabine (Non-Small Lung Cancer Patients Closed to Enrollment as 8/9/07)",0.0007056958218826158,0.0007282791760903925
NCT00177307,"Safety and Efficacy Study Using Bevacizumab, Capecitabine and Oxaliplatin for Colorectal Cancer",0.0006471364217829593,0.0007594252112768775
NCT00145860,Do Patients With Colorectal Cancer Understand That Their Family is at Risk?,0.000747479566659924,0.0005553295844340236
NCT00145314,FLOX in Combination With Cetuximab in First-line Treatment of Colorectal Cancer,0.0006446901195847014,0.0006281781421667057
NCT00126256,Trial Comparing Two Strategies of Chemotherapy for Metastatic Colorectal Cancer,0.0007490419088734383,0.0007639554621237571
NCT00129870,CONCEPT: Comparison of Oxaliplatin vs Conventional Methods With Calcium/Magnesium in First-Line Metastatic Colorectal Cancer,0.0005750956807987241,0.0007257696512927798
NCT00114946,A Study to Compare Two Avastin-Based Treatment Regimens for the Treatment of Metastatic Colorectal Cancer,0.000715671822447638,0.0007901706852790286
NCT00197405,Comparison of Fecal Ribonucleic Acid (RNA) Test With Fecal Occult Blood Test (FOBT) for Detecting Colorectal Cancer and Adenoma,0.00042592668417313614,0.00031866619885426476
NCT02139215,Study to Evaluate Real-world Pharmacoeconomics of Panitumumab in Metastatic Colorectal Cancer Patients,0.0008567898311594696,0.0008440066288948202
NCT02139475,Factors Influencing Quality of Bowel Cleansing for Colonoscopy in Patients With Colorectal Cancer Surgery; Prospective Observational Study,0.0006963647676662877,0.0004955820953203255
NCT02128425,FOLFOXIRI Compared to FOLFOX in First Line Treatment of Metastatic Colorectal Cancer,0.0008954661012072505,0.0008421449193352893
NCT02110082,Combination Study of Urelumab and Cetuximab in Patients With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Head and Neck Cancer,0.0008786343193690826,0.000766618514472387
NCT02162563,Treatment Strategies in Colorectal Cancer Patients With Initially Unresectable Liver-only Metastases,0.0006538757586539265,0.0007070667175047736
NCT02169388,Intestinal Microflora in Colorectal Cancer (CRC) After Chemotherapy,0.0006993449307309523,0.0003831352894711065
NCT02116894,Safety Study of Regorafenib With PF-03446962 to Treat Colorectal Cancer,0.0008024555843148686,0.0007056064709683224
NCT02122523,Sentinel Lymph Node (SLN) in Colorectal Carcinoma (CRC) With a Near-infrared (NIR)-Dye,0.0009004663468788987,0.0005422259775692462
NCT02164916,S1406 Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer,0.0007180858424241551,0.0007146758063132055
NCT02188342,Assessing The Effectiveness of a Preoperative High Intensity Interval Training Programme In Older Colorectal Cancer Patients,0.0006576116598062945,0.0006722469307604625
NCT02188264,Selumetinib and Cyclosporine in Treating Patients With Advanced Solid Tumors or Advanced or Metastatic Colorectal Cancer,0.0007757370723513125,0.0007984981149265752
NCT02176746,A Phase I/II Study of Active Immunotherapy With Cancer Stem Cells Vaccine for Colorectal Cancer,0.0005154771536336661,0.0004493250309951316
NCT02195011,Safety Study of Regorafenib and SIR-SpheresÂ® Microspheres Radioembolization in Patients With Refractory Metastatic Colorectal Cancer With Liver Metastases,0.0008115498987265052,0.0007873247302927896
NCT02135757,Study to Evaluate Real-world Pharmacoeconomics and Resistance Mechanisms of Panitumumab in Metastatic Colorectal Cancer Patients,0.0008242302868567982,0.0009063385699012765
NCT02106806,Zinc Supplementation on Markers of Oxidative Stress in Post Operative Colorectal Cancer During Chemotherapy Cycles,0.000475360593065691,0.0007217308131861775
NCT02129946,The Effect of Resistant Starch Bagels on Risk Factors of Type 2 Diabetes and Colorectal Cancer,0.00046315593764073196,0.0005202157648866786
NCT02129257,ï»¿Clinical Trial of Combination Chemotherapy With Aflibercept in Patients With Advanced Colorectal Cancer,0.0006791362051756999,0.0008568773923485545
NCT02138422,A Phase 3 Study to Evaluate Xilonix as an Anticancer Therapy in Patients With Symptomatic Colorectal Cancer,0.0007173279856253729,0.0007346437261844515
NCT02138370,Comprehensive Immune-landscape in Localized Colorectal Cancer,0.0009042293869980402,0.0006091851077897421
NCT02138617,Genotype-Directed Study Of Irinotecan Dosing In FOLFIRI + BevacizumabTreated Metastatic Colorectal Cancer,0.0006898514461417642,0.0008249110595847156
NCT02192034,Optimizing Navigation to Successful Colorectal Cancer Screening,0.0009178208135712787,0.00046941697417346575
NCT02117557,Safety Study of Transumbilical Single Incision Versus Conventional Laparoscopic Surgery for Colorectal Cancer,0.0005262437207449913,0.00047571178405488224
NCT02117466,Image Guided Treatment Optimization With Cetuximab for Patients With Metastatic Colorectal Cancer,0.0007856313707926982,0.0007483452044972128
NCT02103062,Phase 2 Study With Abraxane (NabÂ®Paclitaxel) in Metastatic Colorectal Cancer,0.000714679744170899,0.0007731395019155307
NCT02149108,Nintedanib (BIBF 1120) vs Placebo in Refractory Metastatic Colorectal Cancer (LUME-Colon 1),0.0006210506239017269,0.0008369213732094592
NCT02119026,Efficacy And Safety Of Xeliri + Avastin Followed By Xelox + Avastin Or Reverse Sequence In Metastatic Colorectal Cancer,0.0006291611210374515,0.0011364747866534105
NCT02119676,Study of Ruxolitinib in Colorectal Cancer Patients,0.0008654964145816015,0.0009980655295092323
NCT02186236,Detection of Oncogenic Tumor Mutations in the Urine and Blood of Lung and Colorectal Cancer Patients,0.0005937430356669624,0.0006334538654148241
NCT02173990,Aflibercept and Chemotherapy as First Line Treatment for Metastatic Colorectal Cancer Assessable With DCE-US (PULSAR).,0.0006206198600376597,0.0007606546432832574
NCT02181556,Efficacy and Safety of Aflibercept in Combination With FOLFIRI Chemotherapy as 1st Line Treatment for Patients With Metastatic Colorectal Cancer,0.0008079778662122796,0.0008429188039503983
NCT02175654,Regorafenib as Single Agent in Patients With Metastatic Colorectal Cancer (mCRC) With Any RAS or BRAF Mutation Previously Treated With FOLFOXIRI Plus Bevacizumab,0.0007296436896229878,0.0008126577035768973
NCT02100254,Narrative or Fact-Based Videos in Increasing Colorectal Cancer Screenings in African American Communities,0.0006494538976251327,0.0005184450696972056
NCT02118064,Phase II Study to Evaluate G17DT in Combination With Irinotecan in Patients With Colorectal Carcinoma,0.0007559641172858588,0.0008228920422533586
NCT02198274,Intravenous BIBH 1 in Patients With Metastatic Colorectal Cancer,0.0009322246796856227,0.0008745299200753629
NCT02141295,A Study Comparing the Efficacy and Safety of Vanucizumab and FOLFOX With Bevacizumab and FOLFOX in Participants With Untreated Metastatic Colorectal Cancer,0.0007044446336500412,0.0007973188967034772
NCT01198743,Presence of Circulating Tumor DNA in Colorectal Cancer,0.0006540706905506726,0.0005458534819179589
NCT01198535,Phase I Study of Cetuximab With RO4929097 in Metastatic Colorectal Cancer,0.0008595013957043586,0.0006891642526282003
NCT01198548,High-Dose Cholecalciferol in Treating Patients Receiving Combination Chemotherapy and Bevacizumab as First-Line Therapy For Metastatic Colorectal Cancer,0.0007710034586294857,0.0008624894274526602
NCT01190462,Cetuximab and Simvastatin in Treating Patients With Advanced or Metastatic Colorectal Cancer,0.0008253128506714577,0.0006936784699917207
NCT01175291,FOLFOX/Bevacizumab +/- MK-0646 in Metastatic Colorectal Cancer,0.0009446688086336126,0.0007191420375143256
NCT01126450,Lenalidomide and Cetuximab in Treating Patients With Metastatic Colorectal Cancer,0.0008418697173513256,0.0006820519816386349
NCT01126866,Curative Resectability of Not Optimally Resectable Liver and/or Lung Metastases From Colorectal Carcinoma (CRC) Under Intensified Chemotherapy,0.0005782045952890458,0.000748022332207378
NCT01103323,Patients With Metastatic Colorectal Cancer Treated With Regorafenib or Placebo After Failure of Standard Therapy,0.0007703087502452225,0.0008699726608622101
NCT01106261,A Randomised Trial of Pulmonary Metastasectomy in Colorectal Cancer,0.0006379244596703247,0.000597677567033334
NCT01161316,Safety and Efficacy Study of mFOLFOX-6 Plus Cetuximab for 8 Cycles Followed by mFOLFOX-6 Plus Cetuximab or Single Agent Cetuximab as Maintenance Therapy in Patients With Metastatic Colorectal Cancer and WT KRAS Tumours,0.0008270439597738416,0.0008759288887975487
NCT01159171,A Study of Avastin (Bevacizumab) and Oxaliplatin Plus Xeloda (Capecitabine) in Patients With Advanced Colorectal Cancer.,0.000781587118491366,0.0007988796763108843
NCT01154335,Everolimus and OSI-906 for Patients With Refractory Metastatic Colorectal Cancer,0.0009312968436288803,0.0011157792035045447
NCT01189903,Clinical Evaluation - A Phase IIA Proof of Concept Study of Regorafenib (Bayer 73-4506) in Biopsy-amenable Asian Colorectal Cancer Patients,0.0006769477933556571,0.0006013201814368069
NCT01189227,Combination Chemotherapy Before or After Surgery in Treating Patients With Colorectal Cancer With Liver Metastases That Could Be Removed By Surgery,0.0006667115997039665,0.0006932862887403663
NCT01189942,A Study of FOLFIRI Plus OMP-21M18 as 1st or 2nd-line Treatment in Subjects With Metastatic Colorectal Cancer,0.000873288201326541,0.0007451301001296064
NCT01116687,RO4929097 in Treating Patients With Metastatic Colorectal Cancer,0.001179376051279735,0.0010576544266134346
NCT01135498,A Study of Avastin (Bevacizumab) in Combination With Xelox and Tarceva in Patients With Metastatic Colorectal Cancer.,0.0008545836423254198,0.0007936553888491044
NCT01183780,A Study in Second Line Metastatic Colorectal Cancer,0.0008318719920620414,0.0009899821549964774
NCT01183494,A Genotype-guided Study of Irinotecan Administered in Combination With 5-fluorouracil/Leucovorin (FOLFIRI) and Bevacizumab in Advanced Colorectal Cancer Patients,0.0007967288300496733,0.0008299581507382752
NCT01172860,Endoscopic Treatment of Inoperable Colorectal Cancer With the EndoVe System,0.0007091839711560707,0.0006971018283147723
NCT01196260,Combination Chemotherapy Treatments in Patients With Colorectal Cancer Stage II and III,0.0007197455029362475,0.0007476950970291413
NCT01196130,Colorectal Cancer Umbrella Protocol - Assessment of Targeted Therapies Against Colorectal Cancer (ATTACC Program) Screening Protocol,0.00048712914140598956,0.000709543742851475
NCT01164215,Biomarker-Guided Fluorouracil in Treating Patients With Colorectal Cancer Receiving Combination Chemotherapy,0.0006483984884413984,0.0007784883344599754
NCT01133990,FOLFIRI Alone Versus FOLFIRI Plus Bevacizumab Versus FOLFIRI Plus E7820 as Second-Line Therapy in Patients With Locally Advanced or Metastatic Colorectal Cancer,0.0008067187041144718,0.0008298020688763489
NCT01109615,Pemetrexed and Gemcitabine for Treatment Resistant Patients With Metastatic Colorectal Cancer and KRAS Mutations,0.0007627634534293129,0.0009497033372819501
NCT01151007,KRAS Mutation and Incidence of the Colorectal Carcinoma in Martinique Between 2007 and 2009,0.0017174036041820706,0.00047214458853080647
NCT01139138,"Safety Study of the Combination of Panitumumab, Irinotecan and Everolimus in the Treatment of Advanced Colorectal Cancer",0.0006357109073367172,0.0007877412459009074
NCT01134640,A Post-Marketing Surveillance Study On ErbituxÂ® (Cetuximab) In Patients With Metastatic Colorectal Cancer Refractory To Irinotecan Containing Treatment,0.0008764727381464769,0.0007733548203570605
NCT01134666,An Observational Study to Evaluate the Safety and Efficacy of FOLFIRI / FOLFOX Plus Cetuximab as First-line Therapy in Patients With KRAS Wild-type Metastatic Colorectal Cancer,0.0008407506592348384,0.0008557105331668111
NCT01163305,PET-CT and Circulating Tumor Cells in Colorectal Cancer,0.0006428272955436859,0.0007112133807743804
NCT01163396,First-line FOLFOXIRI In Combination With Bevacizumab For Metastatic Colorectal Cancer,0.0007851310072769409,0.0008426225149165418
NCT01111292,Inositol in Preventing Colorectal Cancer in Patients With Colitis-Associated Dysplasia,0.0006534916970090185,0.0006200297095586856
NCT01111604,A Study of IMC-1121B or IMC-18F1 in Colorectal Cancer,0.0011299834464365364,0.0009500371244959305
NCT01152437,A Study of BIBW 2992 (Afatinib) in Patients With Metastatic Colorectal Cancer,0.0009079856431844001,0.0008505240418392223
NCT01144195,A Clinical Trial of Panitumumab in Combination With FOLFIRI Chemotherapy as Second Line Treatment in Subjects With Metastatic Colorectal Cancer Expressing Wild-type KRAS and Who Had Progressed â¥ 6 Months After the Last Dose of the First Line Chemotherapy,0.0006201727703783414,0.0007706572103659138
NCT01157052,Oxaliplatin Pharmacokinetics With and Without Ca2+/MG2+ Infusion in Colorectal Cancer Patients,0.0006802203666810874,0.0008285534391971402
NCT01186705,"Clinical And Translational Study Of MK-2206 In Patients With Metastatic KRAS-Wild-Type, PIK3CA-Mutated, Colorectal Cancer",0.0008139223031173893,0.0008179477051130654
NCT01110785,Simvastatin and Panitumumab in Treating Patients With Advanced or Metastatic Colorectal Cancer,0.0008072613455618786,0.0006938598664205368
NCT01110941,"Feasibility Study of SOL (S-1,Oral Leucovorin,and Oxaliplatin) for Colorectal Cancer in China",0.0004954810502845002,0.0005201408548995511
NCT01105377,Azacitidine and Entinostat in Treating Patients With Metastatic Colorectal Cancer,0.0008088429258425673,0.0008034719711947368
NCT01193517,Azacitidine and CAPOX in Metastatic Colorectal Cancer,0.0008778878906262513,0.0007353780391002726
NCT01143285,Impact of Early and Active Nutritional and Dietary Management grade3 or More Toxicities Induced by Chemotherapy and Targeted Therapies Administered to Patients as First Intention for Non Surgical Metastatic Colorectal Cancer,0.0007872700083237203,0.0007408942912884078
NCT02043821,Maintenance Chemotherapy for Metastatic Colorectal Carcinoma and Biological Marker,0.0007114404516477001,0.0006597432132886934
NCT02071069,Efficacy and Tolerance of Maintenance Therapy in Patients With Incurable Advanced Colorectal Cancer,0.0007079315742365922,0.0007477312510945417
NCT02057991,Mindfulness-Based Exercise Video in Educating Hispanic/Latino Patients With Colorectal Cancer and Their Caregivers,0.0006548875104918241,0.0006449485835774974
NCT02039635,Korean Red Ginseng in Treating Patients With Fatigue Caused by Chemotherapy for Colorectal Cancer,0.0006925964267354893,0.0008599804850866652
NCT02086656,"PERIOPERATIVE TREATMENT WITH COI-B (CAPECITABINE, OXALIPLATIN, IRINOTECAN AND BEVACIZUMAB) OF HIGH RISK OR BORDERLINE RESECTABLE COLORECTAL CANCER LIVER METASTASES",0.0005668557700959457,0.0005776379988557386
NCT02070146,Prospective Data Collection Initiative on Colorectal Cancer,0.0006379374900061901,0.0007414959319991064
NCT02022995,Investigation of Methylation of EGFR in the Response of the Cetuximab in Metastatic Colorectal Cancer Patients,0.0007902413887403686,0.0006913764248201866
NCT02068131,Recombinant Anti-tumor and Anti-virus Protein for Injection Plus Xeloda in Treatment of Metastatic Colorectal Cancer,0.000598694702217256,0.0007555967225631066
NCT02046174,"Nonrandomized, Open-Label Phase IIb Efficacy Trial of Cancer Macrobeads Compared With Best Supportive Care in Patients With Treatment-Resistant Colorectal Cancer",0.0006144373740699499,0.0007290567603004038
NCT02046538,Phase II Study of Zaltrap and Chemotherapy for Advanced Resectable Colorectal Cancer,0.0006500218965645356,0.0008437080915488629
NCT02012244,Effects of Postoperative Pain Management on Immune Function After Laparoscopic Resection of Colorectal Cancer,0.0004328259134481741,0.0004180625773882893
NCT02015923,Resection vs no Resection of the Primary in Colorectal Cancer With Unresectable Metastases,0.0005524578030419754,0.0006963355958993959
NCT02015754,Irinotecan -Eluting LC Bead-M1 (DEBIRI-M1) for Patients With Liver Metastases From Colorectal Cancer,0.0008082292209443635,0.0007514013452186593
NCT02041481,"MEK Inhibitor MEK162 in Combination With Leucovorin Calcium, Fluorouracil, and Oxaliplatin in Treating Patients With Advanced Metastatic Colorectal Cancer",0.0008027545077476302,0.0009195247246552723
NCT02053324,AvidinOX + [177Lu]DOTA-biotin (or 177Lu-ST2210) Complex in Patients With Liver Metastases From Colorectal Cancer,0.0006262233854112013,0.0006533472427693416
NCT02060669,Xeloda Maintenance Versus BSC in Metastatic Colorectal Cancer,0.0007076684300653797,0.0005979016551789615
NCT02083653,Sym004 vs Standard of Care in Subjects With Metastatic Colorectal Cancer,0.000701416005353674,0.0004944875995786352
NCT02045030,Study to Identify Biomarkers of Clinical Response to Aflibercept in Patients With Metastatic Colorectal Cancer,0.0008166788358627144,0.0008318989414142267
NCT02056691,EDICT - Exercise inDuced Changes In Colorectal Cancer Tissues,0.0005215742722594234,0.00046031842866461556
NCT02079220,A Phase II Study of Ziv-aflibercept in Combination With Capecitabine/Oxaliplatin (XELOX) Chemotherapy in the Front-Line Treatment of Patients With Metastatic Colorectal Cancer,0.000880889906223619,0.0008920323717236637
NCT02075086,Angiogenic Switch in Patients With Colorectal Cancer,0.0009393504733814734,0.0005094250982565187
NCT02008383,Cabozantinib and Panitumumab to Treat KRAS Wild-Type Metastatic Colorectal Cancer,0.0006337150943766589,0.0007839119199939106
NCT02085005,Capecitabine Plus Aflibercept as Maintenance Therapy Following Capecitabine Plus Oxaliplatin Plus Aflibercept in Patients With Metastatic Colorectal Cancer,0.0007627802474186392,0.000637835264329751
NCT02005913,A Novel Patent Platform of Detection of Circulating Tumor Cells to Early Detect Colorectal Cancer Recurrence,0.00044047070847781845,0.0006891068737738416
NCT02027363,Maintenance Treatment With Capecitabine in Colorectal Cancer Patients,0.0008265273583731242,0.000939266097373473
NCT02029326,Biomarker Analysis in Metastatic Colorectal Cancer Treated With Cetuximab,0.00075149163381127,0.0006718307394111739
NCT02096354,"A Phase 2 Randomized, Open-Label Study of RRx-001 vs Regorafenib in Subjects With Metastatic Colorectal Cancer",0.0006485174944190234,0.0007582111379246569
NCT02038283,Quality of Life of Patients With Colorectal Neoplasm and Cost-Effectiveness Analysis of Colorectal Cancer Screening,0.0006196174483330791,0.000660282153322994
NCT02077777,"Chemopreventive Action of Mesalazine on Colorectal Cancer: a Pilot Study for an ""in Vivo"" Evaluation of the Molecular Effects on Î²-catenin Signaling Pathway.",0.0005337099833862222,0.0005465729820132732
NCT02052050,Core Stability Program in Colorectal Cancer Survivors,0.0006399499515837943,0.0005921226707399841
NCT02052908,Naproxen in Preventing DNA Mismatch Repair Deficient Colorectal Cancer in Patients With Lynch Syndrome,0.0006542400319405015,0.0006437523431796991
NCT02032485,Near-Infrared Imaging of Peritoneal Carcinomatosis From Colorectal Cancer,0.0006407756943770469,0.0005480843404063719
NCT02090101,Study Evaluating the Influence of LV5FU2 Bevacizumab Plus Anakinra Association on Metastatic Colorectal Cancer,0.000699220557023141,0.000823165803333038
NCT02069561,Effects of Eicosapentaenoic Acid on Subjects at High Risk for Colorectal Cancer,0.0006399724800609827,0.0005918416411949838
NCT02063529,FOLFOXIRI With or Without Cetuximab as First-line Treatment of Patients With Non-resectable Liver - Only Metastatic Colorectal Cancer,0.0008037522016585382,0.0008569672593174729
NCT02026583,"A Single Arm, Phase II Study of Simvastatin Plus XELOX and Bevacizumab as First-line Chemotherapy in Metastatic Colorectal Cancer Patients",0.0008516619085855381,0.0008573063552060968
NCT02002299,Does Surface Tell us About the Invasive Front in Colorectal Cancer,0.000901723643023144,0.0006467146709521647
NCT00983580,Acetylsalicylic Acid and Eflornithine in Treating Patients at High Risk for Colorectal Cancer,0.0006586334098416316,0.0005988048735571625
NCT00955344,Increasing Primary Care Physician Colorectal Cancer Screening Rates,0.0005281457599111165,0.0004984566485520172
NCT00989469,Sorafenib With Irinotecan in Metastatic Colorectal Cancer (mCRC) and K-RAS Mutation,0.0007403943189209273,0.0010021192529231563
NCT00942266,"Vorinostat, Fluorouracil, and Leucovorin Calcium in Treating Patients With Metastatic Colorectal Cancer That Has Not Responded to Previous Treatment",0.0007729112824604831,0.0008380320962759955
NCT00936572,Probiotics In Colorectal Cancer Patients,0.0013521402111330778,0.0005934157916277448
NCT00950820,Study to Evaluate the Effects of Panitumumab if Combined With Chemotherapy for 2nd Treatment of Colorectal Cancer,0.0006152829724802307,0.0007549165244443557
NCT00910819,Tumour Registry Colorectal Cancer,0.0006550673167586357,0.00097491429737496
NCT00927680,Familial Colorectal Cancer Registry in Hispanics,0.0009010749998998108,0.0004784902444580388
NCT00958386,Safety and Efficacy Study of Panitumumab+Irinotecan in Patients Wild-Type (WT) KRAS Metastatic Colorectal Cancer Refractory to Irinotecan Based Chemotherapy (SPECTRA),0.0008657247456248862,0.0009579020060494536
NCT00967616,Study of CS-7017 in Combination With FOLFIRI in Subjects With Metastatic Colorectal Cancer Who Failed First-Line Therapy,0.0007531785432903141,0.000639026026650289
NCT00904839,BIBF 1120 Versus Bevacizumab in Metastatic Colorectal Cancer,0.0009446688086336126,0.0009581112949707193
NCT00920803,"A Clinical Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of SRT501 in Subjects With Colorectal Cancer and Hepatic Metastases",0.0005411187152143345,0.0005655926480491489
NCT00973609,Optimal Maintenance Therapy With Bevacizumab After Induction in Metastatic Colorectal Cancer (CRC),0.0006598584413897043,0.0006549674630461075
NCT00973869,Curcumin in Preventing Colorectal Cancer in Patients Undergoing Colorectal Endoscopy or Colorectal Surgery,0.00062862786367956,0.0005525748759579735
NCT00972465,Study of Nimotuzumab to Treat Colorectal Cancer,0.0007924314406727854,0.0005753984262633861
NCT00972036,Selective Internal Radiation Therapy (SIRT) in Patients With Unresectable Colorectal Cancer Liver Metastases Who Failed Prior Intraarterial Pump Chemotherapy,0.000645419733599451,0.0006637294316255987
NCT00929097,Implementation of Guidelines on Hereditary or Familial Colorectal Cancer,0.000901130191488761,0.00043714158808149143
NCT00982059,Colorectal Cancer Screening for Cancer Survivors,0.0006577673715530404,0.0005107592671181446
NCT00969033,CS-1008 Used With Irinotecan Versus Irinotecan Alone in Subjects With Metastatic Colorectal Carcinoma Who Failed First-line Treatment With Oxaliplatin,0.0006647665170926712,0.0008900937268358332
NCT00940303,OPAL Study: A Study of Avastin (Bevacizumab) in Combination With FOLFOXIRI in Patients With Previously Untreated Metastatic Colorectal Cancer,0.0008591640629916304,0.0009038421528534736
NCT00940316,Dual Epidermal Growth Factor Receptor Inhibition With Erlotinib and Panitumumab With or Without Chemotherapy for Advanced Colorectal Cancer,0.0005053958529696932,0.0006528750114638084
NCT00997685,Evaluate Efficacy and Safety of XELOX in Potentially Resectable Liver Metastasis From Colorectal Cancer(CRC),0.000686084584481703,0.0007503057719965423
NCT00905918,Vitamin E Supplements in Treating Patients Undergoing Surgery for Colorectal Cancer,0.000675171722589344,0.0005309875639985927
NCT00905047,Xeloda or UFT (Tegafur-uracil) With Folinic Acid in Advanced or Metastatic Colorectal Cancer,0.0006342638618116262,0.000691755363217908
NCT00977613,Adherence to a Recommended Exercise Regimen in Colorectal Cancer Patients,0.0007520671803769448,0.0005413181326378397
NCT00974389,S-1 and Bevacizumab in Treating Patients With Colorectal Cancer That is Recurrent or Cannot Be Removed by Surgery,0.0007212955805603159,0.0006702510145344193
NCT00974610,"Study of Blood Samples From Patients With Malignant Melanoma, Metastatic Breast Cancer, Advanced Lung Cancer, Pancreatic Cancer, or Colorectal Cancer. ICORG 07-12",0.0007067400465581771,0.0005593635273559062
NCT00921661,Study of Intravenous Aflibercept in Combination With FOLFIRI in Japanese Patients With Metastatic Colorectal Cancer,0.0008316288782941333,0.000756974888728257
NCT00932724,CY-503 for the Treatment of Chemotherapy-refractory Metastatic Colorectal Cancer,0.0008007324615704676,0.0006948071191372474
NCT00931840,A Study of EZN-2208 Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma,0.0009409267243253163,0.000727153045636914
NCT00954876,Study of Capecitabine and Cetuximab as First-Line Therapy in Patients With Metastatic Wild Type Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Colorectal Cancer,0.0008442864828589873,0.0007167206238722447
NCT00912743,"Efficacy and Safety of Olaparib in Pretreated Patients With Measurable Colorectal Cancer, Stratified by Microsatellite Instability (MSI) Status",0.0006551838829747833,0.0006453819367093476
NCT00912327,Efficacy and Safety Study of Imprime PGG With Cetuximab in Subjects With Stage IV KRAS-Mutated Colorectal Cancer,0.0005949078754232728,0.000563399125861204
NCT00981110,Standard Versus Advanced Antimicrobial Dressing Containing Ionic Silver Following Colorectal Cancer Surgery,0.0004895677976376451,0.0006678686665273745
NCT00961129,The Continuing Care Needs in Colorectal Cancer Patients in Different Stages,0.000749934330227669,0.000739127312895978
NCT00984048,Study to Identify Mechanisms of Resistance to Standard Therapy in Patients With Metastatic Colorectal Cancer,0.0008460150706601093,0.0008054718146562659
NCT00986440,Study of CS-7017 in Colorectal Cancer Patients Who Have Achieved Disease Control Following First-Line Chemotherapy,0.0007118387092484509,0.0007500993453678517
NCT00988897,Colorectal Cancer RECHALLENGE,0.0009004408312705923,0.0005547803237957675
NCT00925015,Phase I Study of Dalotuzumab (MK0646) in Combination With Cetuximab and Irinotecan in Colorectal Cancer Patients (0646-016),0.0007454208910525467,0.0008110275435669066
NCT00991003,A New Method for Colorectal Cancer Screening: Colon Capsule Endoscopy Compared to Conventional Endoscopy,0.0004341947411052418,0.0004954378987260606
NCT00952016,Methotrexate in Metastatic Colorectal Cancer With MSH2 Deficiency,0.0007005062836891147,0.0006592777676711469
NCT00952029,Combination Chemotherapy and Bevacizumab With or Without Bevacizumab Maintenance Therapy in Treating Patients With Metastatic Colorectal Cancer,0.0008030495248785282,0.0007814488924895592
NCT00975897,Study of Tumor Tissue Testing in Selecting Treatment for Patients With Metastatic or Locally Advanced Colorectal Cancer,0.0008827945728081323,0.000825200076190107
NCT00022477,BMS-247550 in Treating Patients With Recurrent or Metastatic Colorectal Cancer,0.000930099450333375,0.0010023666891354978
NCT00022698,"Capecitabine and Irinotecan in Treating Patients With Locally Advanced, Recurrent, or Metastatic Colorectal Cancer",0.0008400254701931292,0.0009848767968002562
NCT00064181,Combination Chemotherapy With or Without Celecoxib in Treating Patients With Metastatic Colorectal Cancer,0.0008294716926345987,0.0008070995787862507
NCT00028626,Portal Vein Embolization in Treating Patients With Liver Metastases From Primary Colorectal Cancer,0.0006740062882601334,0.0006570689426108848
NCT00028015,SarCNU in Treating Patients With Recurrent or Metastatic Colorectal Cancer,0.0009298078255548983,0.001002239404486785
NCT00017082,Oxaliplatin in Treating Patients With Recurrent Metastatic Colorectal Cancer,0.0009593123986885952,0.0010361038868594043
NCT00006037,Chemotherapy Plus IM-862 in Treating Patients With Metastatic Colorectal Cancer,0.0009762054289800861,0.0009250209519777803
NCT00006468,Comparing Two Combination Chemotherapy Regimens in Treating Patients With Metastatic Colorectal Cancer,0.0008309437539637537,0.0008217449156856786
NCT00006015,"Combination Chemotherapy Plus Trastuzumab in Treating Patients With Advanced, Recurrent, or Metastatic Colorectal Cancer",0.0008124626952952578,0.0007614897174127413
NCT00006786,Combination Chemotherapy Plus Bevacizumab in Treating Patients With Advanced Colorectal Cancer,0.0007661642470633722,0.000857062186981541
NCT00006115,Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer,0.0009520505645878211,0.001016473862925747
NCT00006479,Surgery With or Without Combination Chemotherapy in Treating Patients With Liver Metastases From Colorectal Cancer,0.0007140443008750686,0.0007675927236784596
NCT00006050,Combination Chemotherapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver,0.0007827468496716843,0.000827527849592052
NCT00006046,Monoclonal Antibody Therapy in Treating Patients With Advanced Colorectal Cancer,0.0008114631888700678,0.0007383208525384232
NCT00006103,Combination Chemotherapy in Treating Patients With Colorectal Cancer,0.0009686145371210766,0.0009789329518798805
NCT00006387,Vaccine Therapy Plus QS21 in Treating Patients With Advanced Pancreatic or Colorectal Cancer,0.0007081353442494248,0.0007207694962178613
NCT00084721,Irinotecan and Celecoxib in Treating Patients With Unresectable or Metastatic Colorectal Cancer,0.00078565088760161,0.0008114665378112059
NCT00084643,"GTI-2040, Oxaliplatin, and Capecitabine in Treating Patients With Locally Advanced or Metastatic Colorectal Cancer or Other Solid Tumors",0.0007999688802921047,0.0008070368045084749
NCT00066274,Comparison of Combination Chemotherapy Regimens in Treating Patients With Metastatic Colorectal Cancer,0.0007706502210539039,0.0008285893288541922
NCT00041691,Safety Study of 90Y-hMN14 to Treat Colorectal Cancer Patients With Limited Residual Disease After Surgery,0.0006898257414327727,0.0008849191193917588
NCT00087334,"Capecitabine, Oxaliplatin, and Gefitinib in Treating Patients With Metastatic Colorectal Cancer",0.0007871865710286953,0.0008060782130120472
NCT00083616,"Evaluating Panitumumab (ABX-EGF) Monotherapy in Patients With Metastatic Colorectal Cancer Following Treatment With Fluoropyrimidine, Irinotecan, and Oxaliplatin Chemotherapy",0.0008242832299180889,0.0008933225272665713
NCT00033306,BMS-247550 in Treating Patients With Metastatic Colorectal Cancer,0.000930099450333375,0.0010023666891354978
NCT00033371,Celecoxib With or Without Eflornithine in Preventing Colorectal Cancer in Patients With Familial Adenomatous Polyposis,0.0006568719605796565,0.0007198982474074427
NCT00033748,Vaccine Therapy in Treating Patients With Colorectal Cancer Metastatic to the Liver,0.0008214741299946039,0.0008071475355224658
NCT00060411,"A Phase I, Pharmacological, and Biological Study of OSI-774 in Combination With FOLFOX 4 (5-FU, Leucovorin, and Oxaliplatin) and Bevacizumab (Avastin) in Patients With Advanced Colorectal Cancer",0.0007978324142042966,0.0009281701681555927
NCT00016250,Ro 31-7453 in Treating Patients With Recurrent or Refractory Metastatic Colorectal Cancer,0.0009298078255548983,0.0008271223753051209
NCT00016042,Fluorouracil and Biological Therapy in Treating Patients With Metastatic Kidney or Colorectal Cancer,0.0007628671487293633,0.0009279921859948473
NCT00016952,Irinotecan or Fluorouracil Plus Leucovorin in Treating Patients With Previously Treated Metastatic Colorectal Cancer,0.0007977225699610089,0.0008905730750831053
NCT00016978,Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer Previously Treated With Irinotecan,0.0008574556518876511,0.0009745538841738381
NCT00016198,Fluorouracil and Leucovorin With or Without Oxaliplatin in Treating Patients With Recurrent Metastatic Colorectal Cancer,0.0007920316858669444,0.0009707197668646296
NCT00063141,"Study of Irinotecan and Cetuximab Versus Irinotecan as Second-Line Treatment in Patients With Metastatic, EGFR-Positive Colorectal Cancer",0.0008814048646501877,0.000787489944410625
NCT00063960,Hepatic Arterial Infusion With Floxuridine and Systemic Irinotecan After Surgery in Treating Patients With Hepatic (Liver) Metastases From Colorectal Cancer,0.0006421257309335466,0.0007772015047244119
NCT00063427,Study Evaluating MAC-321 in Colorectal Cancer,0.0011299834464365364,0.0006253429207296801
NCT00078468,Study of the GARFT Inhibitor AG2037 in Patients With Metastatic Colorectal Cancer Who Failed Treatment,0.0008760208176108648,0.0008609732456693006
NCT00012389,Irinotecan With or Without Oxaliplatin in Treating Patients With Metastatic Colorectal Cancer,0.0008626839923578596,0.0008847426454415081
NCT00014079,Genetic Markers in Patients With Colorectal Cancer,0.0007590001703267725,0.0005221566812932352
NCT00030797,Combination Chemotherapy in Treating Patients With Advanced or Metastatic Colorectal Cancer,0.000879066763441987,0.000968334391952271
NCT00030563,Surgery With or Without Radiofrequency Ablation Followed by Irinotecan in Treating Patients With Colorectal Cancer That is Metastatic to the Liver,0.0007741006893196892,0.0007951617326631752
NCT00030524,ZD 1839 in Treating Patients With Locally Advanced or Metastatic Colorectal Cancer,0.0008604501521372469,0.0009809803148691065
NCT00030342,Biological Therapy and Chemotherapy in Treating Patients With Metastatic Kidney Cancer or Colorectal Cancer,0.0007810351984350979,0.0009053950312478796
NCT00049101,Erlotinib and Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer,0.0008290961362333209,0.0009371942904663198
NCT00047762,"Safety, Efficacy, and Pharmacokinetics Study of Tarceva to Treat Advanced Colorectal Cancer",0.0006141315106383746,0.0006767991134944145
NCT00081237,OSI-7904L and Oxaliplatin in Treating Patients With Refractory or Recurrent Advanced Colorectal Cancer,0.000837617445404935,0.0007908310659643922
NCT00081627,Clinical Trial in Patients With Metastatic Colorectal Cancer,0.0009325695037008227,0.0008009824781954442
NCT00081536,Aroplatin and Capecitabine in Patients With Advanced Colorectal Cancer Resistant to Standard Therapies,0.0006823447302910575,0.0007713818985769192
NCT00025142,Gefitinib and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors or Colorectal Cancer,0.0006828971797596667,0.0008885413999845827
NCT00025337,Combination Chemotherapy With or Without Bevacizumab Compared With Bevacizumab Alone in Treating Patients With Advanced or Metastatic Colorectal Cancer That Has Been Previously Treated,0.0008216633759991959,0.0007912290261059385
NCT00025350,Gefitinib in Treating Patients With Recurrent Metastatic Colorectal Cancer,0.0009304052546494644,0.0008290340147827682
NCT00019760,Isolated Hepatic Perfusion With Melphalan Followed By Chemotherapy in Treating Patients With Unresectable Colorectal Cancer That is Metastatic to the Liver,0.0007576097077546882,0.000830203404563879
NCT00019591,Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Locally Advanced or Metastatic Colorectal Cancer,0.0007963598369022289,0.000801282718016733
NCT00019747,Surgery With or Without Thalidomide in Treating Patients With Recurrent or Metastatic Colorectal Cancer,0.0008301983247294684,0.0007459588837346178
NCT00003834,Combination Chemotherapy in Treating Patients With Liver Metastases From Colorectal Cancer,0.0007933722686505917,0.0009327722588870385
NCT00003543,Monoclonal Antibody Therapy Plus Combination Chemotherapy in Treating Patients With Advanced Colorectal Cancer,0.0007273790057220143,0.0007852739812110503
NCT00003431,Flt3L in Treating Patients With Metastatic Colorectal Cancer,0.001179376051279735,0.0008562345349921959
NCT00003260,Combination Chemotherapy in Treating Patients With Recurrent Metastatic Colorectal Cancer,0.0009520505645878211,0.0008691088323159979
NCT00003225,Amifostine Plus Irinotecan in Treating Patients With Metastatic Colorectal Cancer,0.0008388417450959552,0.000987832068235392
NCT00003186,Diagnostic Procedure for Identifying Patients With Metastatic Colorectal Cancer,0.0009298078255548983,0.0007419043853607431
NCT00003254,SWOG-S9635 Fluorouracil Plus Ethynyluracil in Advanced Colorectal Cancer Not Responded to Fluorouracil,0.0006011699002453413,0.0007824301373660792
NCT00003354,Conventional Surgery Compared With Laparoscopic-Assisted Surgery in Treating Patients With Colorectal Cancer,0.000676820582300611,0.0005760129535473176
NCT00003001,Combination Chemotherapy in Treating Patients With Recurrent or Metastatic Colorectal Cancer,0.0009520505645878211,0.0009485987821644324
NCT00003995,Monoclonal Antibody Plus Chemotherapy in Treating Patients With Advanced Colorectal Cancer That Overexpresses HER2,0.0006922938203753543,0.0007784935709188174
NCT00003594,Combination Chemotherapy in Treating Patients With Advanced Colorectal Cancer,0.0008303556113041607,0.0007369232779910192
NCT00003063,Biological Therapy With Combination Chemotherapy in Patients With Colorectal Cancer,0.0007693826624904989,0.0006676079566170077
NCT00003360,Radiolabeled Monoclonal Antibody in Treating Patients With Advanced Colorectal Cancer,0.0007097158952992908,0.0006846911042243099
NCT00003873,Fluorouracil With or Without Eniluracil in Treating Patients With Advanced Colorectal Cancer,0.0007238782623938133,0.0007830541443637971
NCT00003753,"Floxuridine, Dexamethasone, and Irinotecan After Surgery in Treating Patients With Liver Metastases From Colorectal Cancer",0.0006502512868115572,0.0007665465949449919
NCT00003648,Genetic Study of Patients and Families With a History of Colorectal Cancer,0.000754585662727391,0.0006450091121070713
NCT00003544,Irinotecan in Treating Patients With Metastatic Colorectal Cancer,0.000966907516881593,0.0010344152679721253
NCT00003220,Bryostatin 1 in Treating Patients With Metastatic Colorectal Cancer,0.0009298078255548983,0.001002239404486785
NCT00003441,Irofulven in Treating Patients With Metastatic Colorectal Cancer,0.0009298078255548983,0.001002239404486785
NCT00003843,Irinotecan in Treating Patients With Colorectal Cancer,0.0009884193112879767,0.000998454597116671
NCT00003287,Combination Chemotherapy in Treating Patients With Recurrent or Metastatic Colorectal Cancer,0.0009520505645878211,0.0009477254879457837
NCT00003446,Chemotherapy in Treating Patients With Recurrent or Metastatic Colorectal Cancer,0.0009762054289800861,0.0009549470139119956
NCT00003057,Octreotide Compared With Loperamide Hydrochloride for Chemotherapy-Related Diarrhea in Patients With Colorectal Cancer,0.0006204831974723422,0.0006994742725150048
NCT00065117,"Safety, Tolerability and Efficacy of ZD6126 in Combination With Oxaliplatin, 5-Fluorouracil and Leucovorin in Subjects With Metastatic Colorectal Cancer.",0.0006171369640331692,0.0008878024044534615
NCT00096330,Folate-Depleted Diet Compared With Folate-Supplemented Diet in Preventing Colorectal Cancer in Patients at High Risk for Colorectal Cancer,0.000610375780635947,0.000556631264016097
NCT00088933,Vaccine Therapy and Sargramostim With or Without Docetaxel in Treating Patients With Metastatic Lung Cancer or Metastatic Colorectal Cancer,0.0007225553083415325,0.0008204473097099047
NCT00062023,"Comparison of Sulindac, Aspirin, and Ursodiol in Preventing Colorectal Cancer",0.0004668880747449942,0.0005157163844212346
NCT00062426,Oxaliplatin and Bevacizumab (Avastinâ¢) With Either Fluorouracil and Leucovorin or Capecitabine in Treating Patients With Advanced Colorectal Cancer,0.00071511469811844,0.0008415384255096109
NCT00008281,Comparison of Three Chemotherapy Regimens in Treating Patients With Metastatic Colorectal Cancer,0.0007866030178696558,0.0008530991086407922
NCT00008060,Combination Chemotherapy in Treating Patients With Unresectable Metastatic Colorectal Cancer,0.0008381960278508368,0.0008419394592388063
NCT00008294,Combination Chemotherapy in Treating Patients With Unresectable Liver Metastases From Colorectal Cancer,0.0007039819109366955,0.0008566079927777238
NCT00069108,A Study of Xeloda (Capecitabine) in Patients With Metastatic Colorectal Cancer,0.0008596486152507919,0.0007570230180318974
NCT00069095,A Study of Capecitabine (Xeloda) and Bevacizumab as a First-line Therapy in Patients With Metastatic Colorectal Cancer,0.0008807757848570953,0.0008446011216630058
NCT00055822,Combination Chemotherapy and Oblimersen in Treating Patients With Advanced Colorectal Cancer,0.0007243336983556389,0.0008866152130011822
NCT00040599,Safety Study of 90Y-hMN14 to Treat Colorectal Cancer,0.0007924350793546488,0.0011043481167888846
NCT00040391,A Trial of an Investigational Drug for the Prevention of Diarrhea Associated With Irinotecan/5FU/Leucovorin Chemotherapy in Previously Untreated Metastatic Colorectal Cancer,0.0005930399499755512,0.0008322679382364199
NCT00040820,Oxaliplatin in Treating Patients With Previously Treated Locally Advanced or Metastatic Colorectal Cancer,0.0008842951039121957,0.0009604934801408136
NCT00034619,"A Phase 2 Trial of ALIMTA (LY231514, Pemetrexed) Plus Oxaliplatin Administered Every 21 Days for First-Line Treatment of Patients With Advanced Colorectal Cancer.",0.0006636514888696237,0.000722100735466646
NCT00034502,A Trial of ALIMTA (Pemetrexed) Plus Irinotecan in Patients Who Have Been Previously Treated For Metastatic Colorectal Cancer.,0.0007758754650192096,0.0008823325746096731
NCT00034034,Acupuncture to Reduce Symptoms of Advanced Colorectal Cancer,0.000580756492068275,0.0006789406823728822
NCT00077337,FR901228 in Treating Patients With Previously Treated Unresectable Locally Advanced or Metastatic Colorectal Cancer,0.000871350674281146,0.0009288614808623547
NCT00077987,Assessment Of Safety And Efficacy Of SU11248 In Patients With Metastatic Colorectal Cancer Who Have Failed Selected Previous Treatments.,0.000790077848034102,0.0010413743669012545
NCT00077259,Epothilone D as Second-Line Treatment for Patients With Advanced or Metastatic Refractory Colorectal Cancer,0.0008115139659353373,0.000854577308909092
NCT00077298,Bevacizumab and Cetuximab With or Without Irinotecan in Treating Patients With Irinotecan-Refractory Metastatic Colorectal Cancer,0.0008397948491890969,0.0008000452697667902
NCT00043199,A Safety and Effectiveness Study of Aroplatin in Patients With Advanced Colorectal Cancer Resistant to Standard Therapies,0.000744920451358346,0.0007462131160539963
NCT00043004,Chemotherapy and Bevacizumab With or Without Radiofrequency Ablation in Treating Unresectable Liver Metastases in Patients With Colorectal Cancer,0.000680235233587467,0.0006584707448314088
NCT00099346,MK0457 (an Aurora Kinase Inhibitor) Study in Patients With Advanced Colorectal Cancer and Other Advanced Solid Tumors (0457-001),0.0007275121017453006,0.0006560017409087832
NCT00023933,Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Recurrent or Persistent Metastatic Colorectal Cancer,0.0009331581421537284,0.0008238070680483304
NCT00023868,Combination Chemotherapy With or Without Chemoembolization in Treating Patients With Colorectal Cancer Metastatic to the Liver,0.0007754922440487759,0.0007917878820696192
NCT00079066,Cetuximab and Best Supportive Care Compared With Best Supportive Care Alone in Treating Patients With Metastatic Epidermal Growth Factor Receptor-Positive Colorectal Cancer,0.0007432073890642538,0.0007018367432910627
NCT00079872,Pemetrexed Plus a Comparator Versus a Combination of 2 Comparators in First-Line Treatment of Colorectal Cancer,0.0005009053650396694,0.0006244247380719642
NCT00039611,Combination Chemotherapy in Treating Patients With Advanced Colorectal Cancer,0.0008303556113041607,0.0008839790088432251
NCT00039273,Monoclonal Antibody Therapy in Treating Patients With Metastatic Colorectal Cancer,0.0009331581421537284,0.0008000857315972315
NCT00039208,Combination Chemotherapy in Treating Patients With Colorectal Cancer,0.0009686145371210766,0.0007207206151031016
NCT00048126,A Study of Xeloda (Capecitabine) in Patients With Advanced and/or Metastatic Colorectal Cancer,0.0008716383269363455,0.0008113920008936117
NCT00048139,A Study of Xeloda (Capecitabine) in Patients With Advanced and/or Metastatic Colorectal Cancer,0.0008716383269363455,0.000808423212288853
NCT00059930,Adjuvant Hepatic Arterial Infusion and Combination Chemotherapy in Treating Patients With Resectable Hepatic Metastases From Colorectal Cancer,0.0006410386515060268,0.000678018111652409
NCT00027833,Vaccine Therapy and Chemotherapy With or Without Tetanus Toxoid Compared With Chemotherapy Alone in Treating Patients With Metastatic Colorectal Cancer,0.0007576669013978783,0.0008672403319010638
NCT00027729,Monoclonal Antibody Therapy in Treating Patients With Advanced Colorectal Cancer,0.0008114631888700678,0.0007412529680327908
NCT00072553,"Celecoxib, Leucovorin, Fluorouracil, and Oxaliplatin in Treating Patients With Metastatic Colorectal Cancer",0.0007636784846635013,0.000924682590010679
NCT00072098,Interleukin-12 Gene in Treating Patients With Liver Metastases Secondary to Colorectal Cancer,0.0006849877403710202,0.0006609112246999631
NCT00072748,Study Evaluating EKB-569 in Advanced Colorectal Cancer,0.0008727381560976661,0.0007774233326420268
NCT00021268,Tocladesine in Treating Patients With Recurrent or Progressive Metastatic Colorectal Cancer,0.0009298078255548983,0.0009580005621601511
NCT00021281,Combination Chemotherapy With or Without SU5416 in Treating Patients With Metastatic Colorectal Cancer,0.0008275366141649985,0.0007875414936101681
NCT00020501,Chemotherapy With or Without Isolated Hepatic Perfusion With Melphalan in Treating Patients With Colorectal Cancer That Has Spread to the Liver,0.0006329750811830292,0.0006590824580433023
NCT00051688,Tezacitabine and Oxaliplatin for the Treatment of Patients With Metastatic Colorectal Cancer,0.000807543435386195,0.001003859817720135
NCT00036517,Safety Study of the Chemotherapy Modulator PHY906 in Patients With Advanced Colorectal Cancer,0.0007774922112144728,0.0008024720613249189
NCT00002893,Palliative Chemotherapy in Treating Patients With Advanced Colorectal Cancer,0.0008545104756964258,0.0007358769129662145
NCT00002793,Chemotherapy Via an Implantable Pump Compared With a Subcutaneous Port for Unresectable Liver Metastases in Patients With Resected Colorectal Cancer,0.000636713455532899,0.0006613467965953954
NCT00002664,Monoclonal Antibody Therapy and Colony- Stimulating Factor in Treating Patients With Metastatic Colorectal Cancer,0.0009331581421537284,0.000829055069577918
NCT00002997,Cryosurgery in Treating Patients With Unresectable Liver Metastases From Colorectal Cancer,0.0006856251570949559,0.0007538732593343012
NCT00002650,High-Dose Folic Acid in Preventing Colorectal Cancer in Patients Who Have Had Polyps Surgically Removed,0.0006123471806393,0.0007049474560592325
NCT00002716,Combination Chemotherapy in Treating Patients With Liver Metastases From Colorectal Cancer,0.0007933722686505917,0.0007423210454197244
NCT00002692,Intravenous Compared With Intrahepatic Chemotherapy in Treating Patients With Colorectal Cancer Metastatic to the Liver,0.0007926822707518813,0.0007470050298553356
NCT00002842,Liver Resection and Floxuridine Plus Fluorouracil and Leucovorin in Treating Patients With Liver Metastases From Colorectal Cancer,0.0006347333793425961,0.0008304061204373055
NCT00002570,Immediate Compared With Delayed Chemotherapy in Treating Patients With Advanced Colorectal Cancer Without Signs or Symptoms of Disease,0.0006558980771731136,0.0007476766748271985
NCT00002527,Aspirin in Treating Patients With Colorectal Cancer That Has Been Surgically Removed,0.0006821766877601346,0.0007292949273861158
NCT00002828,Chemotherapy With Raltitrexed and Fluorouracil in Treating Patients With Advanced Colorectal Cancer,0.0007054061071974303,0.0009350279322174888
NCT00002796,Phase I-II Study of Fluorouracil in Combination With Phenylbutyrate in Advanced Colorectal Cancer,0.0006083725094734529,0.0007133474766550538
NCT00002801,Combination Chemotherapy and Radiation Therapy in Treating Patients With Colorectal Cancer,0.0007705996549853731,0.0008184977876060942
NCT00005030,SCH 66336 Before Surgery in Treating Patients With Colorectal Cancer That Has Metastasized to the Liver,0.0006972482240718617,0.0007706283705206109
NCT00005050,"Eniluracil, Fluorouracil, and Oxaliplatin in Treating Patients With Advanced Colorectal Cancer",0.0006920744929923649,0.0008880115879230543
NCT00005882,Eflornithine Plus Sulindac in Preventing Colorectal Cancer in Patients With Benign Colorectal Polyps,0.0006103488532480499,0.0005951883422883192
NCT00005036,Irinotecan Compared With Combination Chemotherapy in Treating Patients With Advanced Colorectal Cancer,0.0007547253190285545,0.0008326940473172746
NCT00005616,Monoclonal Antibody Therapy in Treating Patients With Colorectal Cancer,0.0009436870243248128,0.0007407893617618574
NCT00005833,S9923 R115777 in Treating Patients With Advanced Colorectal Cancer,0.0008081174015830303,0.0009318721050231342
NCT00005094,Celecoxib to Prevent Colorectal Cancer in Patients Who Have Undergone Surgery to Remove Polyps,0.0006127357307549787,0.0005584174643703088
NCT00005076,Cetuximab and Irinotecan in Treating Patients With Advanced Colorectal Cancer,0.0007690549944086236,0.0008729375324478384
NCT00005586,Leucovorin and Fluorouracil Compared With Observation in Treating Patients With Colorectal Cancer That Has Been Surgically Removed,0.000631186684339124,0.0007382962877687768
NCT00005981,Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer,0.0009520505645878211,0.001016473862925747
NCT00005818,SU5416 and Irinotecan in Treating Patients With Advanced Colorectal Cancer,0.0007363498161818745,0.0008457832668669201
NCT00005640,Lymphatic Mapping and Sentinel Lymph Node Biopsy in the Treatment of Colorectal Cancer,0.0005714106609348639,0.0005867057269333771
NCT00004142,Radiofrequency Ablation Followed By Hepatic Artery Chemotherapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver,0.000652091723692275,0.0008330141091165128
NCT00004195,Eniluracil and Surgery in Treating Patients With Primary or Metastatic Colorectal Cancer,0.0008301947573049842,0.0008223756070761477
NCT00004102,Combination Chemotherapy in Treating Patients With Advanced Colorectal Cancer,0.0008303556113041607,0.0008715032304438608
NCT00004252,Leucovorin and Fluorouracil With or Without SU5416 in Treating Patients With Metastatic Colorectal Cancer,0.0007714730230603046,0.0007989146498495156
NCT00004885,Fluorouracil and Leucovorin With or Without Irinotecan in Treating Patients With Metastatic Colorectal Cancer,0.0007977225699610089,0.000848464700524838
NCT00004005,"Irinotecan Followed By Fluorouracil and Leucovorin in Treating Patients With Stage III or Stage IV Colorectal Carcinoma (Cancer), Other Refractory Carcinoma, or Metastatic Adenoma (Cancer) of Unknown Primary Origin",0.000754157210891435,0.0006979608704000394
NCT00004187,Capecitabine and Oxaliplatin in Treating Patients With Advanced or Metastatic Colorectal Cancer,0.0008343345860990643,0.0009895605675799778
NCT00080951,"Irinotecan, Fluorouracil, Leucovorin, and Oxaliplatin as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer",0.0007826701459289558,0.0009628187290469906
NCT00024401,DHA-Paclitaxel in Treating Patients With Metastatic Colorectal Cancer,0.0009298078255548983,0.001002239404486785
NCT00001428,A Phase II Study of 5-Fluorouracil Administered as a One Hour Infusion in Combination With Calcium Leucovorin and Interferon Alpha-2A in Advanced Colorectal Cancer,0.0005789200628550589,0.0006043605422402534
NCT00001693,Phase I-II Multiple-Dose Safety and Efficacy Study of a Selective Inhibitor of Cyclooxygenase - 2 (SC-58635) in Hereditary Non-Polyposis Colorectal Cancer (HNPCC) Patients and Carriers,0.000672393163969329,0.0006200157347397857
NCT00035919,Safety and Efficacy of Targeted Gene Transfer in Colorectal Cancer Metastatic to Liver,0.0007144600742864526,0.00060870037608996
NCT00035087,EPO906 Therapy in Patients With Advanced Colorectal Cancer,0.0008619593538849597,0.000772033522266356
NCT00037180,For Prevention of Diarrhea in Patients Diagnosed With Metastatic Colorectal Cancer Treated With Chemotherapy,0.0007573778473430689,0.0008244522353815913
NCT00044967,Genetic Study of Young Patients With Colorectal Cancer,0.0008670099322198615,0.0007357828472581785
NCT00044863,Study of Erbitux (Cetuximab) in Patients With Metastatic Colorectal Carcinoma,0.0008674501409402329,0.0008722956137550491
NCT00044343,"GW572016, An Oral Drug For Colorectal Cancer Patients Having Prior Therapy With 5-FU Plus CPT-11 And/Or Oxaliplatin",0.0006227019641093572,0.0008369349199998542
NCT00007826,Monoclonal Antibody Therapy and/or Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Colorectal Cancer,0.000799249253807503,0.0007981773967455491
NCT00007943,Gemcitabine in Treating Patients With Advanced Colorectal Cancer,0.0008109207353871843,0.0009334504964281445
NCT00007618,"The Identification of Prognostic Factors of Late Stage Disease, Particularly Those That Are Modifiable, That Might Explain the Worsened Prognosis With Colorectal Cancer Among Veterans.",0.0004280608560962636,0.0004414194904527614
NCT00075595,"Fluorouracil, Leucovorin, and Irinotecan in Treating Patients With Recurrent or Refractory Metastatic Unresectable Colorectal Cancer",0.0007763422614308641,0.0008668733405153868
NCT00026364,"ZD 1839 Plus Combination Chemotherapy in Treating Patients With Locally Advanced, Locally Recurrent, or Metastatic Colorectal Cancer",0.00081246138055938,0.0009876862417638529
NCT00026234,Hepatic Arterial Infusion Plus Chemotherapy in Treating Patients With Colorectal Cancer Metastatic to the Liver,0.0007931106841929025,0.0009331690767364006
NCT00056030,Combination Chemotherapy Plus Cetuximab in Treating Patients With Liver Metastases From Colorectal Cancer,0.0007260276754776063,0.0006704174678947574
NCT00056459,Study of Oxaliplatin/5-FU/Leucovorin Plus Vatalanib Versus Oxaliplatin/5-FU/Leucovorin in Patients With Metastatic Colorectal Cancer.,0.0008450951754426935,0.000977730791403977
NCT00056446,Study of Oxaliplatin/5-FU/Leucovorin Plus Vatalanib Versus Oxaliplatin/5-FU/Leucovorin in Patients With Previously Treated Metastatic Colorectal Cancer,0.0008450951754426935,0.0008322263098253091
NCT00098982,"Bortezomib, Fluorouracil, Leucovorin, and Oxaliplatin in Treating Patients With Advanced or Metastatic Colorectal Cancer",0.0007944024739142435,0.0008199365019385961
NCT00089635,ABX-EGF (Panitumumab) Monotherapy in Subjects With Metastatic Colorectal Cancer,0.0008966559069409695,0.0007587806082711324
NCT00089401,Isolated Hepatic Perfusion With Melphalan in Treating Patients With Unresectable Colorectal Cancer That Has Metastasized to the Liver,0.0006108312368562897,0.0006740924595205614
NCT00073138,A Study of ABT-751 in Patients With Colorectal Cancer,0.0010943138245516437,0.0009927471515642622
NCT00061815,"Study of Cetuximab, Oxaliplatin, 5-FU/LV Versus Oxaliplatin, 5-FU/LV in Patients With Previously Treated Metastatic, EGFR-Positive Colorectal Cancer",0.0008510176699641894,0.0007781083349068496
NCT00032110,Erlotinib in Treating Patients With Recurrent or Metastatic Colorectal Cancer,0.0009322076821866116,0.0009709120563628943
NCT00070265,Neoadjuvant and Adjuvant Capecitabine and Oxaliplatin in Treating Patients With Resectable Liver Metastases Secondary to Colorectal Cancer,0.0006529474009342116,0.0007381889758967434
NCT00070213,Leucovorin and Fluorouracil With or Without Oxaliplatin Compared to Capecitabine With or Without Oxaliplatin in Treating Patients With Metastatic Colorectal Cancer,0.000778653129624823,0.0008931890154757893
NCT01456923,Chemotherapy With DNA Damaging Agents In Colorectal Cancer,0.0007013771950236593,0.0006518172543555612
NCT01418222,FOLFOX/Bevacizumab With Onartuzumab (MetMAb) Versus Placebo as First-Line Treatment in Patients With Metastatic Colorectal Cancer,0.0007667962099573064,0.000764677507263804
NCT01483027,Efficacy Evaluation of TheraSphere Following Failed First Line Chemotherapy in Metastatic Colorectal Cancer,0.0006244828724522106,0.0005836110541818923
NCT01403103,Cholecalciferol(25-[OH]-Vitamin D) in Treating Patients With Colorectal Cancer,0.0013521402111330778,0.0009758929291950236
NCT01471353,Sorafenib Plus Capecitabine (SorCape) in Previously Treated Metastatic Colorectal Cancer,0.0007294347300192631,0.0006276037546458595
NCT01427647,Inflammatory Response After Colorectal Cancer Surgery,0.0006709242108775686,0.00044698736037353975
NCT01460745,A Retrospective Review of Liver Resection Rate in Metastatic Colorectal Cancer Patients Following Downsizing Treatment With Chemotherapy Plus Cetuximab in Normal UK National Health Service Clinical Practice,0.0008139867718227978,0.0008459297490157207
NCT01465451,Intra-operative Chemotherapy With 5-FU for Colorectal Cancer Patients Receiving Curative Resection: Efficacy and Safety,0.0007164261132357184,0.0006572526942330326
NCT01450319,Cetuximab in Refractory Colorectal Cancer With K-RAS Mutated and Favorable FcÎ³RIIa (CD32) Genotype,0.000691478801733052,0.0006819919143824918
NCT01437618,First-line FOLFOXIRI Plus Bevacizumab in BRAF Mutant Metastatic Colorectal Cancer,0.0008774891600530274,0.0010319624777265527
NCT01409005,Gemcitabine-UFTE Chemotherapy in Refractory Colorectal Cancer,0.0007021322413753149,0.0008238765508063889
NCT01470586,Surgical Resection Lowers Oxidative Stress Markers in Patients With Colorectal Cancer,0.0006200872325354517,0.000609947464728997
NCT01433146,"Effect of Temperament, Anxiety and Depression on Immuninity in Colorectal Cancer Patients. Effetti Del Temperamento, Dell'Ansia e Della Depressione Sulla Sopravvivenza Globale e Sulla Risposta Immunitaria Del Paziente Affetto da Adenocarcinoma Colo-Rettale.",0.0005799077110053121,0.0006183352039852194
NCT01426490,"The Effects of Vitamin B-6 Status on Homocysteine, Oxidative Stress, One-carbon Metabolism and Methylation: Cross-section, Case-control, Intervention and Follow-up Studies in Colorectal Cancer",0.00041857966128291697,0.0005724417521207508
NCT01472770,"A Phase II Study of Gemcitabine and Capecitabine for Treatment Resistant, Metastatic Colorectal Cancer",0.0006961672862102987,0.0008440112955735293
NCT01486251,Assessment of Tumor Vascular Effects of Axitinib With Dynamic Ultrasonography in Patients With Metastatic Colorectal Cancer,0.0007225803369333745,0.0008089100790566333
NCT01486745,Urine Metabolomics and Colorectal Cancer Screening,0.0006498631102770239,0.0004483609159068886
NCT01492049,R-21 Colorectal Cancer Screening (CRCS) Pilot Trial,0.0009178208135712787,0.0006087990543543612
NCT01493713,"Correlation Between RECIST, Morphologic Response by CT- Histopathologic Response in Hepatic Metastasis Secondary to Colorectal Cancer",0.0004514936313544967,0.0006096204487977537
NCT01405391,Study of PM01183 in Non-Colorectal Cancer Patients as a Days 1 and 8 Intravenous Short Infusion Every 3 Weeks,0.0007562612773994482,0.0010575308039951579
NCT01457287,A Longitudinal Investigation of Cognitive Function in Colorectal Cancer Patients,0.0007595327907432543,0.0007017476127814537
NCT01448655,"Iscador Qu as Supportive Treatment in Colorectal Cancer (Union International Cancer Control, UICC Stages II-IV)",0.0005077911506496333,0.0005425735700098651
NCT01462513,L-BLP25 in Patients With Colorectal Carcinoma After Curative Resection of Hepatic Metastases,0.0006764904851929793,0.0005627613350936365
NCT01440127,Impact of Pretreatment With Metformin on Colorectal Cancer Stem Cells (CCSC) and Related Pharmacodynamic Markers,0.00043730600266502314,0.0006267688513869776
NCT01478594,A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy,0.0008479721071165912,0.0007387059043310754
NCT01464151,Risk Factors for Colorectal Cancer in Patients With Inflammatory Bowel Disease Undergoing Surveillance: a Prospective Cohort Study,0.0006999055363496465,0.0006198574227991673
NCT01464593,Phase 2 Study of Thermodox as Adjuvant Therapy With Thermal Ablation (RFA) in Treatment of Metastatic Colorectal Cancer(mCRC),0.000702163171835134,0.0006989733036862305
NCT01416714,"Tissue Procurement for Gastric Cancer, Gastrointestinal Stromal Tumors (GIST), Esophageal Cancer, Pancreas Cancer, Hepatocellular Cancer, Biliary Cancer, Neuroendocrine, Peritoneal Mesothelioma, Anal Cancer and Colorectal Cancer in Patients Undergoing Surgery or Biopsy",0.0005964917961006338,0.0005797599865762644
NCT01416688,"S1013: Validation of Cancer Questionnaire for Skin Toxicities in Patients With Colorectal Cancer or Lung Cancer Receiving Cetuximab, Panitumumab, or Erlotinib Hydrochloride",0.0006183646776899561,0.0005539667601890784
NCT01442649,"Efficacy of Chemotherapy, Associated to Either Cetuximab or Bevacizumab, in KRAS Wild-type Metastatic Colorectal Cancer Patients With Progressive Disease After Receiving First-line Treatment With Bevacizumab",0.0008303030643586956,0.000825279592319707
NCT01428752,Study of Prevalence of Colorectal Adenoma in 30- to 49-year-old Subjects With a Family History of Colorectal Cancer,0.0006371274665309817,0.0004459137296424669
NCT01490866,A Trial of Single Agent Axitinib as Maintenance Therapy for Patients With First Line Metastatic Colorectal Cancer (mCRC),0.0007226012500904481,0.0006719552067133283
NCT01490996,Combining Curcumin With FOLFOX Chemotherapy in Patients With Inoperable Colorectal Cancer,0.0007939596052322329,0.0006168140161703216
NCT01461148,Vaccination Against MSI Colorectal Cancer,0.0009016785714431631,0.0004546744990499639
NCT01412957,Comparison of Survival Benefit of Panitumumab With Supportive Care to Best Supportive Care Alone in Patients With Metastatic Colorectal Cancer,0.000739168719855622,0.0007701754228393848
NCT01413295,Randomized Trial With Dendritic Cells in Patients With Metastatic Colorectal Cancer,0.0008177314792854126,0.0009532621948759577
NCT01468623,Study Comparing Optimized 5-FU Dosing and Standard Dosing in Metastatic Colorectal Cancer Patients Treated With mFOLFOX6,0.0008560662239516083,0.0007547314462495182
NCT01479608,Liver Transplantation and Colorectal Cancer,0.0009004972952398827,0.00048233707105290754
NCT01455831,Extended Peri-operative Tinzaparin to Improve Disease-free Survival in Patients With Resectable Colorectal Cancer,0.0006090240360117321,0.0005853004344601328
NCT01249521,Dual Targeting of Vascular Endothelial Growth Factor-A Together With Angiopoietins in Chemotherapy-naÃ¯ve Metastatic Colorectal Cancer,0.0006071611819964971,0.0008316190603096366
NCT01228734,"A Trial to Compare Oxaliplatin, Folinic Acid (FA) and 5-Fluorouracil (5FU) Combination Chemotherapy (FOLFOX-4) With or Without Cetuximab in the 1st Line Treatment of Metastatic Colorectal Cancer (mCRC) in Chinese Rat Sarcoma Viral Oncogene Homolog (RAS) Wild-type Patients",0.000828630696786908,0.0008472409895016605
NCT01243372,Biomarkers in Predicting Response to Cetuximab in Patients With Advanced Colorectal Cancer,0.0006970344784866947,0.0007850048905050508
NCT01221324,Diagnostic Value of C-reactive Protein and White Blood Cell Counts for Early Detection of Inflammatory Complications After Open Resection of Colorectal Cancer,0.00042207007853668917,0.0005063152656237813
NCT01212718,Response Prediction in Metastasized Colorectal Cancer Using Intratumoral Thymidylate Synthase,0.0006621944200743055,0.0006747054379421445
NCT01212510,Study of Circulating Markers in Serum of Patients Treated for Metastatic Colorectal Cancer,0.0008450301558768928,0.000877151228995085
NCT01287130,AZD6244 With Cetuximab for Solid Tumors and Colorectal Cancer,0.0007068727965995437,0.0007255454796645329
NCT01289821,First Line Treatment of Metastatic Colorectal Cancer With mFOLFOX6 in Combination With Regorafenib,0.0006601808760134476,0.0008352701755665399
NCT01270698,Study of IMMU-130 in Patients With Relapsed/Refractory Colorectal Cancer,0.000866087652050393,0.0008056941237376866
NCT01270438,Combination Chemotherapy and Bevacizumab With or Without RO4929097 in Treating Patients With Metastatic Colorectal Cancer,0.000868894579922469,0.0007731616087434829
NCT01266564,An Observational Study of Avastin (Bevacizumab) in Patients With Colorectal Cancer,0.000749329357047112,0.0008066508948116408
NCT01254617,Lenalidomide and Cetuximab in Treating Patients With Advanced Colorectal Cancer or Head and Neck Cancer,0.0006854079950850947,0.0007430067126555557
NCT01254591,"Positron Emission Tomography/Computed Tomography Scanning Before Surgery in Patients With Non-Small Cell Lung Cancer, Colorectal Cancer, Breast Cancer, Esophageal Cancer, or Head and Neck Cancer",0.0006004057734019209,0.00043426426056968986
NCT01210313,Physical Activity for Reduction of Recurrence Rate After Adjuvant Chemotherapy for Localised Colorectal Carcinoma,0.00044321467470832273,0.0003700274198555825
NCT01260415,A Study of Perioperative Chemotherapy Plus Panitumumab in Patients With Colorectal Cancer Liver Metastases,0.0007598339136773464,0.0009414842862019373
NCT01288339,Study Assessing Potential Predictive Tumor Markers in Metastatic Colorectal Cancer,0.0007349944942655192,0.0007678869700806748
NCT01220063,RSHF in Colorectal Cancer,0.0017174036041820706,0.0006488032399771493
NCT01220999,An Imaging and Pharmacodynamic Trial of CS-1008 in Patients With Metastatic Colorectal Cancer,0.0009317760114015643,0.0007820547949287796
NCT01219920,FOLFOXIRI Compared With FOLFIRI for Metastatic Colorectal Cancer,0.0012584573285393244,0.0008221612002194408
NCT01238094,Trial of XELIRI/FOLFIRI + Simvastatin Followed by Simvastatin Maintenance in Metastatic Colorectal Cancer,0.000878676962860389,0.0011300783947776685
NCT01238939,Study of NK012 and 5-FU/LV in Solid Tumors Followed by Dose Expansion in Colorectal Cancer,0.0006707885076094396,0.0008286963869770137
NCT01286064,Colorectal Cancer Detection by Means of Optical Fluoroscopy,0.0006413797011287906,0.00046867860087698254
NCT01277406,4SC-201 (Resminostat) in Advanced Colorectal Carcinoma,0.0007177868340453019,0.000812588785758515
NCT01277120,An Observational Study on The Correlation Between Time of Initiation of Avastin (Bevacizumab) Treatment And Progression-Free Survival in Patients With Colorectal Cancer (CRONOS 1),0.0007397532285780233,0.0007610715899819293
NCT01280643,Combination Chemotherapy and Cetuximab or Bevacizumab in Treating Patients With Metastatic Colorectal Cancer,0.0008304518041888504,0.0007894614667256854
NCT01215539,Study of Panitumumab-Capecitabine-Oxaliplatin In Wild-Type K-Ras Metastatic Colorectal Cancer Patients,0.0008418029623905937,0.0008810680389055313
NCT01281761,Simvastatin + Cetuximab/Irinotecan in K-ras Mutant Colorectal Cancer (CRC),0.0006386691648524584,0.0006352892305992053
NCT01239095,Oral Green Tea Extract and Milk Thistle Extract to Colorectal Cancer Patients Undergoing Resection,0.0006610107278508876,0.0006484452503033783
NCT01226719,FOLFOXIRI Plus Panitumumab Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only,0.000782580011331161,0.0008557656749346313
NCT01205022,"Radiolabeled Monoclonal Antibody Therapy, Combination Chemotherapy, and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer",0.0008040645863613671,0.0008758428316711434
NCT01205711,"Irinotecan Hydrochloride, Fluorouracil, and Leucovorin Calcium With or Without Zibotentan in Treating Patients With Metastatic Colorectal Cancer",0.0007361586530669607,0.0007887457838202359
NCT01294826,Study of AUY922 and Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer,0.0008709423577385369,0.0008754543742111516
NCT01214681,Chemoprevention of Colorectal Cancer: the Role of Non-digestible Carbohydrates,0.0005195200061414711,0.00047124253920115635
NCT01274624,Study of REOLYSINÂ® in Combination With FOLFIRI and Bevacizumab in FOLFIRI Naive Patients With KRAS Mutant Metastatic Colorectal Cancer,0.0008596326853426814,0.0010195340867915038
NCT01274143,Family Colorectal Cancer Awareness and Risk Education Project (Family CARE Project),0.0004623053999292611,0.0003261497890182656
NCT01244022,Cytokine Changes After Colorectal Cancer Resection,0.000527881953936264,0.0005758066259309443
NCT01276379,Study Evaluating Biomarkers in Patients With Colorectal Cancer and Native KRAS Treated With Chemotherapy + Cetuximab,0.0007673282965813441,0.0007151930470578937
NCT01276405,An Observational Study of Xeloda (Capecitabine) Monotherapy in Patients With Colorectal Cancer (AXEL),0.0007250767991049087,0.0006910018912856268
NCT01229813,Avastin and Chemotherapy Followed by a KRAS Stratified Randomization to Maintenance Treatment for First Line Treatment of Metastatic Colorectal Cancer.,0.0006665759897562302,0.0007263144784463813
NCT01273402,Study of TF2 Carcinoembryonic Antigen (CEA) Antibody in Patients With Metastatic Colorectal Cancer,0.0008390484859487807,0.0006912208064580208
NCT01251536,Cetuximab Standard or Dose Escalation in First Line Colorectal Cancer,0.000576379838341445,0.000635700095669633
NCT01292681,Multi-modality Imaging in the Prediction of Response to Systemic Treatment in Colorectal Cancer,0.00047983026140271983,0.0006430918431265531
NCT01208194,Efficacy Study of a Maintenance Therapy With Immunomodulator MGN1703 in Patients With Advanced Colorectal Carcinoma,0.0007467031230657334,0.0006656948869468871
NCT01271166,GlivecÂ® Plus m-FOLFOX AvastinÂ® in Advanced Colorectal Cancer,0.000594950923514809,0.0006655363571678066
NCT01206530,FOLFOX/Bevacizumab/Hydroxychloroquine (HCQ) in Colorectal Cancer,0.0007054687612126599,0.0006217991541834343
NCT01234246,Sexual Dysfunction and the Quality of Sexual Life in Patients With Colorectal Cancer and Their Partners.,0.0009393504733814732,0.0006268454587393052
NCT01299493,Systems Intervention to Promote Colorectal Cancer (CRC) Screening,0.0006529693170791803,0.0005972181732416431
NCT01290926,Sorafenib Plus Capecitabine Efficacy Assessment in Patients With Advanced Pre-treated Colorectal Cancer,0.0006610407601315691,0.0007180287034372559
NCT01298570,Regorafenib+FOLFIRI Versus Placebo+FOLFIRI as 2nd Line Tx in Metastatic Colorectal Cancer,0.0008935316451070537,0.0006756121764759167
NCT02934529,Metastatic Colorectal Cancer (RAS-wildtype) After Response to First-line Treatment With FOLFIR Plus Cetuximab,0.000697695623057554,0.0007698035953878625
NCT02969681,IV Ascorbic Acid in Advanced Colorectal Cancer,0.0007177868340453019,0.0006497845653672102
NCT02907086,Circulating Tumor Material in Colorectal Cancer and Melanoma,0.0006544706921004325,0.0006314799955147078
NCT02997228,"Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Microsatellite Instability-High Metastatic Colorectal Cancer",0.0007625951520284415,0.0008632235830799197
NCT02954913,Simultaneous Resection of Colorectal Cancer With Synchronous Liver Metastases,0.0005521501700773593,0.0005657440232491444
NCT02980146,Impact of HLA-E Overexpression by Tumor Cells on the Biology of TIL in Colorectal Cancer,0.0005362100000031098,0.0005917415066909534
NCT02980510,Study Comparing FOLFIRINOX + Panitumumab Versus mFOLFOX6 + Panitumumab in Metastatic Colorectal Cancer Patients Selected by RAS and B-RAF Status From Circulating DNA Analysis,0.000816093040732309,0.0009337994583965699
NCT02981524,Phase 2 Study of GVAX (With CY) and Pembrolizumab in MMR-p Advanced Colorectal Cancer,0.0006134041544782198,0.000679559215837452
NCT02906059,"Study of Irinotecan and AZD1775, a Selective Wee 1 Inhibitor, in RAS or BRAF Mutated, Second-line Metastatic Colorectal Cancer",0.0007450701381362452,0.000921442175559652
NCT02970916,Phase II Trial to Assess FOLFIRI+Aflibercept Efficacy in Patients With Oxaliplatin-pretreated Metastatic Colorectal Cancer With or Without ACE Polymorphisms,0.0009593123986885952,0.0012872080647866047
NCT02987296,Perioperative Immunonutrition in Colorectal Cancer Patients Undergoing Abdominal Surgery,0.0007723656355934129,0.000530531377606017
NCT02909478,Aprepitant Without Steroid in Preventing Chemotherapy-induced Nausea and Vomiting in Patients With Colorectal Cancer,0.0006416980947631676,0.0006750452387712949
NCT02909114,Stereotactic Body Radiotherapy for Oligometastases From Colorectal Cancer,0.0006375033527082742,0.000785231913503532
NCT02994888,PROSPECT-C: A Study of Biomarkers of Response or Resistance to Anti-EGFR Therapies in Metastatic Colorectal Cancer,0.0006881226612050624,0.0007943443117891478
NCT02923622,Efficacy and Safety Evaluation of Traditional Chinese Medicine in the Treatment of Advanced Colorectal Cancer,0.000569208765908125,0.0008505900465536897
NCT02940223,Effects of Fish Oil and Physical Activity on Fatigue in Colorectal Cancer Patients Receiving Regorafenib,0.0005995124621112649,0.0006338873055018541
NCT02965794,Care Pathways for Colorectal Cancer Surgery,0.0009496827605953155,0.0005421567820720232
NCT02965521,Survivor Choices for Eating and Drinking - Colorectal Cancer,0.0006370993815903943,0.00043709557000233334
NCT02965417,Sym004 in Metastatic Colorectal Cancer and ECD-EGFR Patients,0.001179376051279735,0.000573023553153516
NCT02965703,Aspirin in Preventing Colorectal Cancer in Patients With Colorectal Adenoma,0.0007498195796709021,0.0008352583198223374
NCT02965248,Adjuvant Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Versus no HIPEC in Locally Advanced Colorectal Cancer (APEC Study),0.0006980659783529243,0.000693146202645092
NCT02901600,Expression of DMBT1 in Colorectal Cancer Patients,0.000939769895653452,0.0005719157526594637
NCT02982694,"Study With Atezolizumab Plus Bevacizumab in Patients With Chemotherapy Resistant, MSI-like, Colorectal Cancer",0.0007255406416471522,0.0007740216581250772
NCT02991196,Antibody DS-8273a Administered in Combination With Nivolumab in Subjects With Advanced Colorectal Cancer,0.0005066927807750551,0.0005360889648461119
NCT02928120,Diagnostic Potential of Hypermethylated DNA in Colorectal Cancer,0.0009060590157021434,0.0004268565634373409
NCT02928224,Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer,0.000848119889696569,0.0006695009542374091
NCT02983578,"AZD9150 With MEDI4736 in Patients With Advanced Pancreatic, Non-Small Lung and Colorectal Cancer",0.000707933323830636,0.0006931918627021346
NCT02935764,FOLFIRI Versus Irinotecan as Second-line Treatment in Metastatic Colorectal Cancer Patients,0.0008830185672469076,0.001091483047472774
NCT02953782,Trial of Hu5F9-G4 in Combination With Cetuximab in Patients With Solid Tumors and Advanced Colorectal Cancer,0.0006912760295906329,0.0008743936808773467
NCT02542436,Avastin (Bevacizumab) in the Treatment of Metastatic Colorectal Cancer in Normal Clinical Use in the UK Population,0.000639188577964094,0.0007644574127428187
NCT02519582,Drug Trial to Investigate the Safety and Efficacy of Niclosamide Tablets in Patients With Metastases of a Colorectal Cancer Progressing After Therapy,0.0006582993947835353,0.0007269745924258067
NCT02573220,Irinotecan Hydrochloride With FOLFIRI and Cetuximab as First-Line Therapy in Treating Patients With RAS Wild-Type Colorectal Cancer,0.0006531975889693476,0.0008993320612322325
NCT02512172,A Pilot Study of Enhancing Response to MK-3475 in Advanced Colorectal Cancer,0.0007036996291009337,0.0006630136827718735
NCT02556281,Prognostic Value of Circulating Tumoral Free DNA Versus Circulating Tumoral Cells in Patients With Colorectal Cancer Stage II-III,0.0006170387498079128,0.0006798122647887395
NCT02563002,Study of Pembrolizumab (MK-3475) vs Standard Therapy in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (MK-3475-177/KEYNOTE-177),0.0005409815914496389,0.0006082409430674381
NCT02508077,FOLFIRI and Panitumumab in Treating Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer,0.0008267807408060031,0.0009036400023578848
NCT02502630,Microwave Ablation for Pulmonary Metastases From Colorectal Cancer,0.0005313897873747847,0.0006549070362101217
NCT02502656,RAS Mutation Testing in the Circulating Blood of Patients With Metastatic Colorectal Cancer,0.0009313385338380994,0.000880219150620271
NCT02502760,Using Multimodal Prehabilitation to Improve Outcomes for Frail Patients Undergoing Resection of Colorectal Cancer,0.0005949952564676123,0.000554143408168225
NCT02588781,Pemetrexed Alone as Salvage Treatment in Metastatic Colorectal Cancer Patients Who Were Failed After Standard Chemotherapy: A Phase II Single Arm Prospective Study,0.0008257902934842376,0.0007439552315012404
NCT02543762,Usefulness of Chromoendoscopy for the Early Detection of Colorectal Cancer Associated With Inflammatory Bowel Disease,0.0005198938624690839,0.0005246392674437105
NCT02518373,Effect of G17DT in Patients With Stage II/III Colorectal Cancer,0.0009438975840234212,0.0006578973549220884
NCT02577588,Trial of Adoptive T Cell Therapy With Activated P53 Specific T Cells for Treatment of Advanced Colorectal Cancer,0.0005250262017398492,0.0007112301522947162
NCT02553031,Application of MR-PET in Colorectal Cancer,0.0006412380841889453,0.0007040961603736132
NCT02510001,MErCuRIC1: MEK and MET Inhibition in Colorectal Cancer,0.0009004862559740549,0.0005675158592819943
NCT02535988,Abscopal Effect for Metastatic Colorectal Cancer,0.0008770913495305137,0.0008067609443190015
NCT02549456,Natural Orifice Transluminal Endoscopic Surgery for Colorectal Cancer,0.0008998547854466865,0.0006677735322869531
NCT02522520,Pedometer Intervention and Health Effects for Sedentary Colorectal Cancer Patients During Adjuvant Chemotherapy,0.0006127632191064574,0.0006782085682203725
NCT02515344,Impact of the Distribution to Attending Physicians of a Nominative List of Their Patients Not Participating in the Organised Screening of Colorectal Cancer,0.0006168830905529199,0.0005224529988260008
NCT02568046,Sym004 in Combination With FOLFIRI in Metastatic Colorectal Cancer Patients,0.0009633704622233065,0.0007977399455138148
NCT02564835,Effects of Yoga on Cognitive and Immune Function in Colorectal Cancer,0.0005204670056218884,0.0005955566857987262
NCT02564224,Study Comparing Pursestring Wound Closure vs Conventional Closure to Reverse Stoma of Colorectal Cancer Patients,0.0006728543533800928,0.0005489086472774136
NCT02567045,Uptake to Colorectal Cancer Screening in Familial-risk Population,0.0006498489857783889,0.00044714607710112355
NCT02567331,A Study of Capecitabine (Xeloda) in Patients With Metastatic Colorectal Cancer,0.0008596486152507919,0.0008115329558145158
NCT02559024,Anti-OX40 Antibody (MEDI6469) in Patients With Metastatic Colorectal Cancer,0.0009331365730083497,0.0008395468390945661
NCT02571374,Symbiotics to Prevent Postoperative Infection in Colorectal Cancer,0.0006387440133422949,0.0006315974780313722
NCT02527967,ERAS in Laparoscopic Surgery for Colorectal Cancer: Risk Factors for Delayed Recovery,0.0004630440424590813,0.00036588833965469134
NCT02575378,Maintenance Treatment With Capecitabine Metronomic Chemotherapy and Chinese Traditional Medicine in Metastatic Colorectal Cancer,0.0006329494615793436,0.0008045794754782055
NCT02597075,Physical Activity in Patients With Metastatic Colorectal Cancer Who Receive Palliative First-line Chemotherapy,0.0007862629917553806,0.0008449332311818008
NCT02529774,Alternating Systemic and Hepatic Artery Infusion Therapy As Adjuvant Treatment After Resection of Liver Metastases From Colorectal Cancer,0.0005352906785444889,0.0005866547189656284
NCT02591667,Histopathological Response to FOLFOXIRI + Bevacizumab in Peritoneal Metastasis From Colorectal Cancer,0.0005187480113250602,0.0006271949498745468
NCT02503150,Trial of Antigen Pulsed Dendritic Cells (APDC) in Metastatic Colorectal Cancer,0.0007063155911961272,0.0006669789854967354
NCT02503631,Stool Sample Collection Protocol for Development of Screening Test for Colorectal Cancer and Other Digestive Tract Cancers,0.000429422913276427,0.0005071133119226507
NCT02523495,The Clinical Outcome and the Exploration of Related Biomarkers of Target Therapy in Metastasis Colorectal Cancer,0.00048074304590277323,0.0004999769176535307
NCT02523911,Efficacy and Tolerability of Suprep With and Without Simethicone for Routine Colonoscopy for Colorectal Cancer Screening,0.00044391630326181506,0.0005029257531700197
NCT02557490,Oxaliplatin and Raltitrexed Treatment of Colorectal Cancer With Liver Metastases,0.0005513595059152425,0.0006576527264215338
NCT00685568,Celecoxib in Preventing Colorectal Cancer in Young Patients With a Genetic Predisposition for Familial Adenomatous Polyposis,0.00061111725859285,0.000549696639826248
NCT00695201,Hepatic Arterial Infusion With Floxuridine and Dexamethasone in Combination With Intravenous Oxaliplatin Plus Irinotecan in Patients With Unresectable Hepatic Metastases From Colorectal Cancer,0.000661293899436183,0.0007319300894453461
NCT00623805,A Study of Avastin (Bevacizumab) and Xeloda (Capecitabine) as Maintenance Treatment in Patients With Metastatic Colorectal Cancer,0.0008838200134692998,0.0008130098082186908
NCT00642603,A Study of Xeloda (Capecitabine) in Combination With Avastin + Short Course Chemotherapy in Patients With Metastatic Colorectal Cancer,0.000865671355045773,0.0008241352655411538
NCT00642746,Erlotinib and Chemotherapy for 2nd Line Treatment (Tx) of Metastatic Colorectal Cancer (mCRC),0.000656364709715664,0.0008953731845643665
NCT00642577,A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Chinese Patients With Metastatic Colorectal Cancer.,0.0008839480144135001,0.000858799461388194
NCT00614393,Study of Dalotuzumab (MK-0646) in Combination With Cetuximab and Irinotecan in Metastatic Colorectal Cancer (MK-0646-004),0.0007128590707214955,0.0006866440147314329
NCT00631410,Study Of Sunitinib In Combination With Folfox In Patients With Colorectal Cancer,0.0007814202432130651,0.0009073056524024466
NCT00636610,"A Study of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) With Concurrent Chemotherapy and Bevacizumab As First-Line Therapy for Metastatic Colorectal Cancer",0.0007010353512395359,0.0009256061989273175
NCT00673322,Trial of Second Generation Designer T Cells in Colorectal Carcinoma,0.0009103002211678446,0.0005212995662916578
NCT00625625,"Lymphatic Mapping, Sentinel Lymph Node Analysis, and Blood Tests in Detecting and Predicting Early Micrometastases in Patients With Colorectal Cancer",0.0006083733004731603,0.0004704133567074547
NCT00625651,Phase 1b/2 Study of AMG 655 With mFOLFOX6 and Bevacizumab for First-Line Metastatic Colorectal Cancer,0.0007668261380668062,0.0007446306517382826
NCT00643877,Trial of Preoperative Hepatic and Regional Arterial Chemotherapy (PHRAC) to Prevent Postoperative Liver Metastasis of Colorectal Cancer,0.0004919578017870577,0.0005977655772780477
NCT00696345,Detection of Colorectal Cancer in Peripheral Blood by Septin 9 DNA Methylation Assay,0.0005213784142367022,0.00042901875277613513
NCT00681876,Phase II Study of Avastin + Erbitux + Irinotecan as 2nd Line Treatment of Colorectal Cancer,0.0005873076145140678,0.0007381820648904823
NCT00684801,"Disease Management Program or Usual Care in Patients With Stage III or Stage IV Lung Cancer, Pancreatic Cancer, Ovarian Cancer, or Colorectal Cancer, and Their Caregivers",0.0005822904561928416,0.00039993190428037054
NCT00668863,Study Of Sunitinib With FOLFIRI In Colorectal Cancer,0.0007936120691741029,0.0008452496139682083
NCT00609622,Randomized Study Of Sunitinib Plus FOLFOX Versus Bevacizumab Plus FOLFOX In Metastatic Colorectal Cancer,0.0007035206538982266,0.0009231635629937538
NCT00660153,Study of Tivozanib (AV-951) Plus FOLFOX6 in Subjects With Advanced Colorectal Cancer and Other Gastrointestinal Cancers,0.0005716499587699772,0.0006844834222936365
NCT00660582,FLOX + Cetuximab (ErbituxÂ®) for Patients With Metastatic Colorectal Cancer and Wild Type K-RAS Tumor,0.0007642859791602108,0.0008950265555928871
NCT00635596,"Phase I Study of MT110 in Lung Cancer (Adenocarcinoma and Small Cell), Gastric Cancer or Adenocarcinoma of the Gastro-Esophageal Junction, Colorectal Cancer, Breast Cancer, Hormone-Refractory Prostate Cancer, and Ovarian Cancer",0.0004982678595614205,0.00044169237651236527
NCT00656123,Vaccine Therapy and Cyclophosphamide in Treating Patients Who Have Undergone Surgery for Liver Metastases Due to Colorectal Cancer,0.0006471029089521649,0.000729288011407831
NCT00655499,Panitumumab and Irinotecan as Third-Line Therapy in Treating Patients With Metastatic Colorectal Cancer,0.0007851545413132332,0.0007362156987769974
NCT00689364,Comprehensive Therapy to Relieving the Risk of Recurrence and Metastasis for Colorectal Cancer,0.0005860529200508385,0.0005601641612379141
NCT00689624,Irinotecan/Oxaliplatin/5-Fluorouracil/Leucovorin/Cetuximab As First Line Treatment In Colorectal Cancer,0.0005077816200918542,0.0007052100923794727
NCT00647153,Immunoscintigraphy Using Radiolabeled Monoclonal Antibody in Finding Tumor Cells in Patients With Colorectal Cancer,0.0005973301282018922,0.0005119450924978954
NCT00675012,NGR-hTNF Administered in Combination With a Standard Oxaliplatin Based Regimen in Patients With Metastatic Colorectal Cancer,0.0007562107111826368,0.0007468217300228708
NCT00675636,Collecting Information From Patients and Family Members With Hereditary Colorectal Cancer Syndromes or Who Are at High Risk of Developing Colorectal Cancer,0.0006114769074101337,0.0005436464410086817
NCT00690677,Phase II Trial of LBH589 in Refractory Colorectal Cancer,0.0017174036041820706,0.000969394405991142
NCT00601198,A Study of Amifostine (Ethyol) in Patients With Colorectal Cancer,0.0007532488773708199,0.0005940511749208821
NCT00630045,Phase 3 Study of Surgery Combined With Neoadjuvant Chemotherapy(XELOX) in Colorectal Cancer With Resectable Liver Metastasis,0.0006039844547092157,0.0007707580736284155
NCT00630786,Conatumumab/Panitumumab Combination Metastatic Colorectal Cancer Study,0.0006965439647403713,0.0007798660821081927
NCT00645710,"Hepatic Arterial Infusion of Floxuridine, Gemcitabine Hydrochloride, and Radiolabeled Monoclonal Antibody Therapy in Treating Liver Metastases in Patients With Metastatic Colorectal Cancer Previously Treated With Surgery",0.0007466582674464846,0.0007564420128567578
NCT00641615,Peptide Vaccine and S-1/CPT-11 Therapy for Patients With Unresectable Advanced Colorectal Cancer,0.0007044341197742518,0.0008518623891077084
NCT00602329,MRI in Predicting Response in Patients Receiving Combination Chemotherapy and Bevacizumab For Advanced or Metastatic Colorectal Cancer,0.0008214994827049774,0.000917802099746567
NCT00628810,Combination Chemotherapy and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer,0.000868894579922469,0.0007783783427909599
NCT00615056,A Study Combining FOLFOX or FOLFIRI With AG-013736 or Bevacizumab (Avastin) in Patients With Metastatic Colorectal Cancer After Failure Of One First Line Regimen,0.0008448098027326678,0.0009058873542844871
NCT00677924,Zalutumumab With or Without Irinotecan Chemotherapy in Cetuximab-Refractory Colorectal Cancer,0.0005620606810443456,0.0006940832529978323
NCT00677144,Oxaliplatin and S-1 (OS) Versus Oxaliplatin and Capecitabine (XELOX) for Advanced Colorectal Cancer,0.0006344380988066247,0.00082955537607604
NCT00677287,Histocompatibility Leukocyte Antigen (HLA)-A*2402 Restricted Peptide Vaccine Therapy in Patients With Colorectal Cancer,0.0006477774818644562,0.0007392488821827004
NCT00677443,Study of S-1 and Oxaliplatin (SOX) Versus Capecitabine and Oxaliplatin (COX) in Patients With Advanced Colorectal Cancer,0.0007532680070227105,0.0008722382270319488
NCT00677612,Histocompatibility Leukocyte Antigen (HLA)-A*0201 Restricted Peptide Vaccine Therapy in Patients With Colorectal Cancer,0.0006477774818644562,0.0007392488821827004
NCT00677586,I Phase Surgery Versus Staged Surgery for Synchronous Liver Metastasis of Colorectal Cancer,0.0005066396996247397,0.00069879122559179
NCT00632515,Screening for Familial Colorectal Cancer (CRC) Patients,0.0009517236934731948,0.0005152950906240383
NCT00671372,A Study of Dulanermin Administered in Combination With CamptosarÂ®/ErbituxÂ® Chemotherapy or FOLFIRI (With or Without Bevacizumab) in Subjects With Previously Treated Metastatic Colorectal Cancer,0.0007090435989446193,0.0006574921553462884
NCT00640081,Combination Chemotherapy and Cetuximab as First-Line Therapy in Treating Patients With Advanced and/or Metastatic Colorectal Cancer,0.0008203967522175115,0.000787178258844838
NCT00640471,Cetuximab With or Without Brivanib in Treating Patients With K-Ras Wild Type Tumours and Metastatic Colorectal Cancer,0.0007627325533912164,0.0006787235883715408
NCT00380874,Prevention And Treatment Of Chemotherapy-Induced Peripheral Neuropathy In Subjects With Advanced Colorectal Cancer,0.0005559614478567754,0.0006938148377484474
NCT00335595,Study of Bevacizumab Alone or Combined With Capecitabine and Oxaliplatin as Support Therapy in Metastatic Colorectal Cancer Patients,0.0008902028315855848,0.0008381501981303592
NCT00311272,Dendritic Cell Vaccination in Patients With Advanced Colorectal Cancer,0.0007090311305498504,0.0004537443792707037
NCT00311610,Liposomal SN-38 in Treating Patients With Metastatic Colorectal Cancer,0.0009298078255548983,0.0008658818017094666
NCT00349336,A Study of Avastin (Bevacizumab) in Combination With XELOX or FOLFOX-4 in Patients With Metastatic Colorectal Cancer.,0.0008695419539586385,0.000702569987153345
NCT00303914,"Study of Symptoms Caused by Cancer and Cancer Therapy in Patients With Invasive Breast, Lung, Prostate, or Colorectal Cancer",0.0006634196710693111,0.0005619922787676179
NCT00353262,A Study of Xeloda (Capecitabine) in Combination With Oxaliplatin in Patients With Metastatic Colorectal Cancer.,0.0008509976423738562,0.0007043965240978973
NCT00343408,AZD2171 and Standard Combination Chemotherapy in Treating Patients With Advanced Non-Small Cell Lung Cancer or Colorectal Cancer,0.000678432431637027,0.0006775428969965028
NCT00326495,BAY 43-9006 Plus Cetuximab to Treat Colorectal Cancer,0.0009787854368510055,0.000962036613218961
NCT00337389,"Phase III Randomized Study of 5-FU, CoFactor, and Avastin vs. 5-FU, LV and Avastin for First-Line Colorectal Cancer.",0.0005409380187880569,0.000701583442904129
NCT00337545,Phase II Trial of RAD001 in Refractory Colorectal Cancer,0.0017174036041820706,0.0008501539067175383
NCT00314353,Study of Bevacizumab Combined With Capecitabine and Either Oxaliplatin or Irinotecan as First Course of Treatment for Patients With Colorectal Cancer That Has Spread Beyond the Colon,0.0007822276402131036,0.0008254697683585195
NCT00399035,"Cediranib (AZD2171, RECENTINâ¢) in Addition to Chemotherapy in Patients With Untreated Metastatic Colorectal Cancer",0.0007574877863753063,0.0008349184814434163
NCT00399750,TREE-2: Three Regimens of Eloxatin in Advanced Colorectal Cancer,0.0005846449112052089,0.0006214680398761945
NCT00345761,"Clinical Study of Capecitabine, Oxaliplatin and Bevacizumab in Colorectal Cancer",0.0006019624094674289,0.0007258873639222952
NCT00362102,A Phase II Study of Cetuximab Plus Irinotecan in Patients With EGFR-detectable Metastatic Colorectal Carcinoma,0.0008572312195764467,0.000771827310289062
NCT00384176,First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX,0.0006970171797326719,0.0008215697064586974
NCT00397384,"Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer",0.0006535972904422323,0.0005704043667070013
NCT00372840,"Printed Education Materials in Patients Who Are Finishing Treatment for Stage I, Stage II, or Stage IIIA Breast Cancer, Colorectal Cancer, Prostate Cancer, or Chest Cancer",0.0006202306473121088,0.00045956174984305043
NCT00310076,Thalidomide in Treating Patients Who Have Undergone Surgery and Chemotherapy for Cancer That Has Spread Throughout the Abdomen Due to Colorectal Cancer or Appendix Cancer,0.0006319633654466537,0.0006302896048555542
NCT00316745,IRIS Followed by mFOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer,0.0005138993270407352,0.0006011151251865837
NCT00394992,Adjuvant Xeloda Plus Eloxatin +/- Avastin After Radical Resection of Liver Metastasis of Colorectal Cancer,0.00047543834515825615,0.0006027236568144214
NCT00309179,"A Phase II Study of the Safety and Efficacy of E7820 Plus Cetuximab in Colorectal Cancer, Preceded by a Run-in Study in Advanced Solid Tumors",0.0006089859189071165,0.0007460173929964728
NCT00313794,Study of Ticilimumab in Patients With Metastatic Colorectal Cancer Whose Disease Had Progressed After Treatment,0.0008431915732671974,0.0006974790330976224
NCT00313755,Magnification Narrow Band Imaging Colonoscopy for Hereditary Non-Polyposis Colorectal Cancer Surveillance,0.00046510751439171025,0.0004500763551449971
NCT00332163,Skin Toxicity Treatment in Metastatic Colorectal Cancer (mCRC) Patients Receiving Panitumumab + Irinotecan-based Therapy,0.0007821465291173499,0.0007913470833446092
NCT00336141,Vorinostat and IV Fluorouracil/Leucovorin (5FU/LV) in Patients With Metastatic Colorectal Cancer,0.0007717081955393649,0.0007520653313113292
NCT00336856,Irinotecan and Cetuximab for Colorectal Cancer as Second Line Therapy,0.0005973857482362832,0.0006522062770849362
NCT00320320,Irinotecan Discontinuation and Reintroduction for Advanced Colorectal Cancer,0.0005430877114782576,0.000801872061800535
NCT00361842,Multicenter Study Of CPX-1 (Irinotecan HCl: Floxuridine) Liposome Injection In Patients With Advanced Colorectal Cancer,0.0007201253408890782,0.0007488295282657455
NCT00364013,PRIME: Panitumumab Randomized Trial In Combination With Chemotherapy for Metastatic Colorectal Cancer to Determine Efficacy,0.0006446302744134806,0.0008209926926162533
NCT00325871,Chemoradiation and Endothelial Progenitor Cells in Colorectal Cancer,0.0006442442629426635,0.0006177394468523767
NCT00389870,Irinotecan With or Without Panitumumab or Cyclosporine in Treating Patients With Advanced or Metastatic Colorectal Cancer That Did Not Respond to Fluorouracil,0.0008030638062352179,0.0008070332503285451
NCT00312000,Sequential Versus Combination Chemotherapy in Advanced Colorectal Carcinoma,0.0007470388686670997,0.0007643244818291053
NCT00354978,Study of FOLFIRI Plus Bevacizumab in Colorectal Cancer Patients,0.0009165741115926094,0.0007753944737757994
NCT00390364,Everolimus in Treating Patients With Advanced or Metastatic Colorectal Cancer That Did Not Respond to Previous Therapy,0.0008353369008772913,0.0008454647482690397
NCT00327093,Elaboration of a Model for Predicting Efficacy of Monoclonal Antibodies (Cetuximab and Bevacizumab) in Patients With Colorectal Cancer and Liver Metastases,0.000660366826191112,0.0007498825177813328
NCT00385021,ChronoFOLFOX Plus Avastin for Patients With Metastatic Colorectal Cancer,0.0009459488244748567,0.000949869788691411
NCT00385970,"A Phase III Trial Comparing UFT+PSK to UFT+LV in Stage IIB, III Colorectal Cancer",0.0009060330171586522,0.0005192165153867793
NCT00305643,Celecoxib in Preventing Hand/Foot Syndrome Caused By Capecitabine With Metastatic Breast or Colorectal Cancer,0.000567552293608289,0.0005664388574554459
NCT00339469,Effect of High-Legume Diet on Colorectal Cancer Risk,0.0006424420976391688,0.0005298636331367664
NCT00388700,"A New Agent GM-CT-01 in Combination With 5-FU, Avastin and Leucovorin in Subjects With Colorectal Cancer",0.000492947500697625,0.0005283740073693302
NCT00388206,A Study of Avastin in Combination With Chemotherapy for Treatment of Colorectal Cancer and Non-Small Cell Lung Cancer (ARIES),0.0005953496047929884,0.0007568481311968038
NCT00352638,Educational Intervention With or Without Telephone Counseling in Increasing Colorectal Cancer Screening Compliance in Brothers and Sisters of Patients With Colorectal Cancer,0.0005967214082676549,0.0004559484049497659
NCT00323011,FOLFIRI + Bevacizumab With or Without Dalteparin in First Line Treatment of Advanced Colorectal Cancer,0.0005656106731460897,0.0006666645483929478
NCT00766142,Combination Chemotherapy and Cetuximab in Treating Patients Undergoing Surgery for Peritoneal Carcinomatosis From Colorectal Cancer,0.0006739309294535351,0.000708771429882662
NCT00766220,Yttrium Microspheres With Cetuximab Plus Irinotecan for Patients With Advanced Colorectal Cancer Mets to Liver,0.000696607427722982,0.000720379549331812
NCT00720512,Second-Line Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Metastatic Colorectal Cancer Who Have Received First-Line Chemotherapy and Bevacizumab,0.0007972541700362808,0.0008530703449855325
NCT00793455,Outreach for Patients With Uncompleted Colorectal Cancer Screening Orders,0.0007568268319962605,0.0006046666673920943
NCT00780169,Phase I Trial of Sorafenib + FOLFIRI In Metastatic Colorectal Cancer,0.000880699456858131,0.0010102573884636157
NCT00780988,Feasibility of Autologous Tumor Cell-TLR9 Agonist Vaccination for Metastatic Colorectal Cancer,0.0005670244867494133,0.0009483098715709494
NCT00785122,IMA910 Plus GM-CSF With Low-dose Cyclophosphamide Pre-treatment in Advanced Colorectal Carcinoma Patients Following a Successful 12 Week First-line Treatment With Oxaliplatin-based Chemotherapy (IMA910-101),0.0007100173695235066,0.000839862534270845
NCT00711672,Study of the Therapeutic Use of Language in Patients With Metastatic Colorectal Cancer,0.0008755768267561657,0.0007352440946395987
NCT00725400,Comparative Study of Cetuximab and Radiation Vs Surgery Before or After Radiation in Patients With Colorectal Carcinoma,0.0006570465358359087,0.0006556086860315613
NCT00778830,Study Evaluating the Safety and Efficacy of FOLFIRI Plus Cetuximab or FOLFOX Plus Cetuximab as First-line Therapy in Subjects With KRAS Wild-type Metastatic Colorectal Cancer (APEC-Study),0.0007306640207556239,0.0007519020466747119
NCT00778102,A Study of Avastin (Bevacizumab) in Combination With mFOLFOX-6 or FOLFOXIRI in Patients With Metastatic Colorectal Cancer.,0.0008541257102930404,0.0009267657039867103
NCT00700570,A Study of Avastin (Bevacizumab) in Combination With XELOX in Patients With Metastatic Colorectal Cancer,0.0008695419539586385,0.0007601698351114946
NCT00700102,A Study of Avastin (Bevacizumab) Plus Crossover Fluoropyrimidine-Based Chemotherapy in Patients With Metastatic Colorectal Cancer.,0.0008646136959748169,0.0008796928563297431
NCT00769405,Systemic Chemotherapy With or Without Intraperitoneal Chemohyperthermia in Treating Patients Undergoing Surgery for Peritoneal Carcinomatosis From Colorectal Cancer,0.0006755711763086809,0.0006893642690406449
NCT00724503,FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer,0.0006720962542234481,0.0007219312162321194
NCT00735241,FOLFOX6 Plus Sir-Spheres Microspheres Plus Avastin in Patients With Nonresectable Liver Metastases From Colorectal Carcinoma,0.00064813553628596,0.0007590158693803612
NCT00777192,Longitudinal Study of Symptoms in Colorectal Cancer,0.0007932530515043575,0.0005141572087326872
NCT00786643,Study of Gamma Interfereon in Metastatic Colorectal Carcinoma,0.0008194454688279984,0.0007224899386904451
NCT00757965,Study of Genes and the Environment in Patients With Colorectal Cancer in the East Anglia Region of the United Kingdom,0.0010943138245516437,0.0006714112218906114
NCT00707889,Phase 2 Study of ABT-869 in Combination With mFOLFOX6 Versus Bevacizumab in Combination With mFOLFOX6 to Treat Advanced Colorectal Cancer,0.0006809233046822026,0.0008224280208988991
NCT00719199,Study of FOLFIRI Plus Cetuximab Plus IMO-2055 in Patients With Colorectal Cancer,0.0009055537935071734,0.0008124400433177447
NCT00719797,Combination Chemotherapy and Bevacizumab as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer,0.0008112575327568847,0.0008640109768289132
NCT00788957,Panitumumab Combination Study With Rilotumumab or Ganitumab in Wild-type Kirsten Rat Sarcoma Virus Oncogene Homolog (KRAS) Metastatic Colorectal Cancer (mCRC),0.00067129460304784,0.0007550266348295077
NCT00788281,A Multi-Center Randomised Controlled Study to Evaluate Laparoscopic Versus Open Surgery for Colorectal Cancer,0.0005119112621007814,0.0005195276605798809
NCT00797485,Bevacizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Metastatic Colorectal Cancer That Cannot Be Removed By Surgery,0.0007856908659623972,0.0007989929932022092
NCT00754494,Erlotinib Hydrochloride in Treating Patients With Stage I-III Colorectal Cancer or Adenoma,0.0006581604817410008,0.000565933772274603
NCT00718055,Magnetic Resonance Imaging (MRI) Using Liverspecific Oral Contrast Agent in Metastatic Colorectal Cancer Patients,0.0008092137900785178,0.0008646006982626459
NCT00713128,Evaluation of the Incidence of Nausea and Vomiting in Patients With Colorectal Cancer Receiving Irinotecan-based Therapy,0.0006831753629909056,0.0007747289871410532
NCT00752570,"A Phase 2, Randomized, Double Blind, Placebo Controlled Study of AMG 386 in Combination With FOLFIRI in Subjects With Previously Treated Metastatic Colorectal Carcinoma",0.0006565619274272091,0.0007690616323201743
NCT00717990,"Irinotecan, Capecitabine and Avastin for Metastatic Colorectal Cancer as Salvage Treatment",0.0006296336789986275,0.0007916756797613769
NCT00779311,A Phase I Trial Evaluating mFOLFOX6 and Avastin With Nexavar as First-Line Treatment for Metastatic Colorectal Cancer,0.0006395319680850064,0.0006408344184283785
NCT00730158,"A Phase II Multicenter, Randomized, Placebo Controlled, Double Blinded Clinical Study of KD018 as a Modulator of Irinotecan Chemotherapy in Patients With Metastatic Colorectal Cancer",0.0008482673612539077,0.0008042913397894419
NCT00748215,Calcium Aluminosilicate Anti-Diarrheal in Treating and Preventing Diarrhea in Patients With Metastatic Colorectal Cancer Receiving Irinotecan,0.0007747366499104794,0.000665419030763902
NCT00743678,Neoadjuvant FOLFOX6 + Cetuximab in Patients With Colorectal Cancer and Unresectable Liver Metastasis,0.0006671972935377904,0.0007311631968579958
NCT00721916,Randomized Phase II Study of SOL for Untreated Metastatic Colorectal Cancer,0.0006721734721169215,0.0008223573154215882
NCT00729677,Delayed Nausea and Vomiting in Patients With Colorectal Cancer Receiving Oxaliplatin,0.000776051082134348,0.0006251018928805363
NCT00407654,VEGF Trap in Treating Patients With Previously Treated Metastatic Colorectal Cancer,0.0009358337082731199,0.0007954292644415361
NCT00468910,Aspirin in Preventing Colorectal Cancer in Patients at Increased Risk of Colorectal Cancer,0.000750148317859117,0.0006009317743152276
NCT00466505,Cetuximab & Celecoxib for Metastatic Colorectal Cancer or Colorectal Cancer That Cannot Be Removed by Surgery,0.0006273045459656348,0.0006038629156018363
NCT00403052,A Study of 1018 Immunostimulatory Sequence (ISS) Administered With Irinotecan and Cetuximab to Treat Patients With Previously Treated Metastatic Colorectal Cancer,0.000857726738047483,0.0008488688766715526
NCT00442637,Maintenance Treatment Versus Observation After Induction in Advanced Colorectal Carcinoma,0.0005580481875242333,0.0006613946797439441
NCT00423696,Bevacizumab and Combination Chemotherapy as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer That Cannot Be Removed By Surgery,0.0007896310181939129,0.0007983549342709827
NCT00450424,Educational CD-ROM Compared With Standard Informed Consent for Patients With Colorectal Cancer or a Family History of Colorectal Cancer,0.0005927308235088959,0.0004040884737154886
NCT00467142,Bevacizumab and Combination Chemotherapy as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer That Cannot Be Removed by Surgery,0.0007896310181939129,0.0008331202777688597
NCT00467129,Genes That Affect Disease Outcome in Patients With Metastatic Colorectal Cancer,0.0008084550837038962,0.0006934886844555192
NCT00457691,Study Of FOLFIRI Chemotherapy With Or Without Sunitinib In Patients With Metastatic Colorectal Cancer,0.0008708319571665194,0.0009537372626793477
NCT00492999,Hepatic Arterial Infusion With Floxuridine and Dexamethasone Combined With Combination Chemotherapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver,0.0006178740421124368,0.0006224903204524853
NCT00437268,A Study of Irinotecan Plus Cetuximab With or Without Enzastaurin in Patients With Colorectal Cancer,0.0007528104924929018,0.000852566909209212
NCT00433576,Resveratrol in Treating Patients With Colorectal Cancer That Can Be Removed By Surgery,0.0006794669356130808,0.0006907124126181432
NCT00433927,"5-FU, Folinic Acid and Irinotecan (FOLFIRI) Plus Cetuximab Versus FOLFIRI Plus Bevacizumab in First Line Treatment Colorectal Cancer (CRC)",0.0005393004525232622,0.0007609379705547594
NCT00444041,Pre- and Postoperative Chemotherapy Including Bevacizumab in Potentially Curable Metastatic Colorectal Cancer,0.000797965974033721,0.0009089466543652281
NCT00444678,"Cetuximab, Capecitabine and Oxaliplatin in Patients With Epidermal Growth Factor Receptor (EGFr) Expressing Metastatic Colorectal Cancer",0.0007849310958118474,0.0008221985865974454
NCT00478946,A Study of Picoplatin in Colorectal Cancer,0.0007920339507145687,0.0006460546994610024
NCT00478634,"A Phase 1 Study Investigating the Combination of RAD001, Cetuximab and Irinotecan as Second-line Therapy After FOLFOX (or XELOX) Plus Bevacizumab in Patients With Metastatic Colorectal Cancer",0.0009249796038440389,0.0010052954586662424
NCT00440310,Phase 3 Trial of Litxâ¢ Plus Chemotherapy vs. Chemotherapy Only Treating Colorectal Cancer Patients With Recurrent Liver Metastases,0.0008175271330428569,0.0008007243062755942
NCT00405561,Study to Evaluate Progression Free Survival in Cancer Patients With Advanced Colorectal Carcinoma With AMT2003,0.0007315665167644192,0.0008806314362012022
NCT00459901,Study of the Antitumor Activity of Capecitabine in Combination With Erlotinib in Patients With Metastatic Colorectal Cancer,0.0008265661527002349,0.0007285915821790365
NCT00422773,Safety of Cetuximab and Oxaliplatin/5-FU/FA/Irinotecan in First-Line Treatment of Metastatic Colorectal Cancer,0.0006900713004618185,0.0009458686272636856
NCT00473980,Preoperative Non-steroidal Anti-inflammatory Drugs(NSAID) to Colorectal Cancer Patients,0.0007468582988936736,0.0007687301471434448
NCT00496704,"Gemcitabine, Capecitabine, and Oxaliplatin as Second-Line Therapy in Treating Patients With Advanced Colorectal Cancer Previously Treated With Irinotecan",0.0006874682721198291,0.000725480268659509
NCT00496509,Phase I Efficacy On Vascular Permeability In Patients With Advanced Colorectal Cancer,0.0008087258808528651,0.0008387775352509647
NCT00497497,A Study of PRO95780 in Combination With Cetuximab and Irinotecan Chemotherapy or the FOLFIRI Regimen With Bevacizumab in Patients With Previously Treated Metastatic Colorectal Cancer (APM4187g),0.0009167986115143865,0.00084235638961964
NCT00497107,Uracil and Tegafur/Leucovorin (UFT/LV) Versus UFT/LV+ Polysaccharide-K (PSK) for Stage IIIa/IIIb Colorectal Cancer,0.0004738156444968823,0.0005473120904301378
NCT00499369,Irinotecan and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic Colorectal Cancer That Progressed During First-Line Therapy,0.0008166600403957151,0.0008070563796452871
NCT00499395,Fludeoxyglucose F 18-PET Imaging for Early Detection of Residual Disease in Patients Undergoing Radiofrequency Ablation of Liver Metastases From Colorectal Cancer,0.0006016145680365383,0.0004579015123357957
NCT00436072,"ZD6474, Cetuximab, and Irinotecan in Patients With Metastatic Colorectal Cancer",0.0008036115209584497,0.0007616305633056737
NCT00436514,Colonoscopy by Videocapsuls Versus Standard Colonoscopy. Intra-individual Comparison for the Subject With a Medium or High Risk of Colorectal Cancer.,0.0004438008730387845,0.00032727247813369294
NCT00419159,Efficacy and Safety of Everolimus in Patients With Metastatic Colorectal Cancer Who Have Failed Prior Targeted Therapy and Chemotherapy,0.0007817258271830304,0.0007666111582525294
NCT00458809,Intraperitoneal Hyperthermic Perfusion With Oxaliplatin in Treating Patients With Stage IV Peritoneal Cancer Due to Appendix Cancer or Colorectal Cancer,0.0005998328808923254,0.0006835877982267471
NCT00479752,Safety and Efficacy of Folfox4 + Weekly Cetuximab vs Folfox 4+Biweekly Cetuximab by Metastatic Colorectal Cancer,0.000929907860473297,0.0011243130109030804
NCT00411450,Panitumumab Regimen Evaluation in Colorectal Cancer to Estimate Primary Response to Treatment,0.0005007921874055628,0.0007033280691807833
NCT00454116,"A Phase II, Double Blind Study of 2 Doses of ZACTIMAâ¢(ZD6474) in Combination With FOLFIRI vs FOLFIRI Alone for the Treatment of Colorectal Cancer in Patients",0.0007220241404053699,0.000791052219190751
NCT00493857,Study of Nimotuzumab and Irinotecan in Metastatic Colorectal Cancer,0.0007454667801679771,0.0007628934020269571
NCT00438737,"Cetuximab, Leucovorin, Oxaliplatin, and Fluorouracil With or Without Bevacizumab in Treating Patients With Resectable Liver Metastases From Colorectal Cancer",0.0006959785262613078,0.0008133142700727323
NCT00408772,"Oxaliplatin, Capecitabine, and Bevacizumab Followed By Surgery and/or Radiofrequency Ablation in Patients With Colorectal Cancer",0.0006763390844816578,0.000692056479252424
NCT00408551,Chemotherapy and Internal Radiation in Treating Patients With Colorectal Cancer That Has Spread to the Liver,0.000703139818798795,0.0007134367333084909
NCT00498407,A Phase II Study of CP-4055 as Second Line Therapy in Patients With Advanced Colorectal Cancer,0.0008074780677095887,0.0006732967785669071
NCT00485316,Laparoscopic Assisted Versus Open Resection for Colorectal Carcinoma,0.0006404477054259805,0.0007357464904307442
NCT00460603,Study With AG-013736 Combined With Chemotherapy And Bevacizumab In Patients With Metastatic Colorectal Cancer,0.0009061969998100325,0.0009683537105221529
NCT00489697,Evaluation of Contrast-enhanced Ultrasound Imaging for the Early Estimate of Bevacizumab Effect on Colorectal Cancer Liver Metastases,0.0004988679101931335,0.0007701653962699828
NCT00483834,"A Phase II Study of Bevacizumab, Irinotecan and Capecitabine in Patients With Previously Untreated Metastatic Colorectal Cancer",0.0008702073435932653,0.0008124596116187533
NCT00483080,Study of NGR-hTNF as Single Agent in Patients Affected by Colorectal Cancer (CRC),0.0007001397573527513,0.0006764256004676612
NCT00494221,A Phase I/II Study of Cediranib (AZD2171) in Japanese Metastatic Colorectal Cancer Patients in Combination With FOLFOX,0.0008600991618280886,0.0007611906792445118
NCT00482222,Combination Chemotherapy With or Without Cetuximab Before and After Surgery in Treating Patients With Resectable Liver Metastases Caused By Colorectal Cancer,0.0006918353741205985,0.0008055861943603634
NCT01863303,Epidemiological Study of Colorectal Cancer in WuHan,0.0011299834464365364,0.0005092904741714121
NCT01860144,An Observational Study of Bevacizumab in Chinese Patients With Metastatic Colorectal Cancer,0.0008780479056124122,0.0009647306546148197
NCT01856322,Surgery Plus Sulindac or Surgery Alone for Advanced Colorectal Cancer,0.0005399342244215456,0.0006504966360051336
NCT01830621,BBI608 and Best Supportive Care vs Placebo and Best Supportive Care in Patients With Pretreated Advanced Colorectal Carcinoma,0.0007103433069235399,0.000775835959169597
NCT01815879,Metastatic Colorectal Cancer Liver Metastases Outcomes After Resin 90Y Microsphere Radioembolization in the USA Evaluation Project,0.0005831640751069756,0.00044338462062117507
NCT01853813,"First-line Irinotecan, Lederfolin and 5FU (FOLFIRI) and Bevacizumab in Patients With Advanced Colorectal Cancer",0.0007184041821981234,0.0006434570679179383
NCT01853319,Regorafenib in Subjects With Metastatic Colorectal Cancer (mCRC) Who Have Progressed After Standard Therapy,0.0006714834001673039,0.0007990557129832879
NCT01811108,Assessment of Clinical Practice Administration of Chemotherapy and Anti-angiogenic Agent (Bevacizumab) in Colorectal Cancer,0.0004861665414295463,0.0005658516024873469
NCT01814501,Panitumumab and Chemotherapy in Patients With Advanced Colorectal Cancer After Prior Therapy With Bevacizumab,0.0007088983593061142,0.0008730304942948433
NCT01880658,Phase II Study of Maintenance Capecitabine to Treat Resectable Colorectal Cancer,0.0008267479548956501,0.0005481823413266261
NCT01832948,Endostar Combined With mFOLFOX6 for First-line Treatment of Metastatic Colorectal Cancer,0.0007549393111341313,0.0010176844067749
NCT01895257,Comparing HAI-90Y (SIR-spheres)+Chemotx LV5FU2 Versus Chemotx LV5FU2 Alone to Treat Colorectal Cancer,0.0009125085816778097,0.00042242294440579536
NCT01882868,A Study of Aflibercept in Combination With FOLFIRI in Patients With Second-Line Metastatic Colorectal Cancer in Japan,0.0008381278756443496,0.0007545395447812555
NCT01889680,Safety and Effectiveness Study of Chemotherapy and Ziv-aflibercept to Treat Metastatic Colorectal Cancer,0.0007015079235777827,0.0007453581285614912
NCT01878422,Sequential Treatment Strategy for Metastatic Colorectal Cancer,0.0007026531772973002,0.0009923841931929879
NCT01896856,Phase I Study of SGI-110 With Irinotecan Followed by Randomized Phase II Study of SGI-110 With Irinotecan Versus Regorafenib or TAS-102 in Previously Treated Metastatic Colorectal Cancer,0.000698293652508115,0.0007402526404173201
NCT01881932,Acupuncture to Prevent Chemotherapy Dose Reduction Due to Chemotherapy-induced Peripheral Neuropathy in Breast and Colorectal Cancer Patients (GCC1232),0.0006128071691778851,0.0005716653515618976
NCT01847495,Evaluation of Low-dose Irinotecan and CyberknifeÂ® SBRT to Treat Colorectal Cancer With Limited Liver Metastasis,0.0004749144250954484,0.0008226252327588163
NCT01875380,Regorafenib in Frail and/or Unfit for Chemotherapy Patients With Metastatic Colorectal Cancer,0.0007866048676615649,0.00092470670713702
NCT01885702,Dendritic Cell Vaccination in Patients With Lynch Syndrome or Colorectal Cancer With MSI,0.00065753012403499,0.0006284495222821577
NCT01839539,Study of DC-CIK to Treat Colorectal Cancer,0.0011299834464365364,0.0016189642445381535
NCT01839877,Intra-arterial Hepatic Beads Loaded With Irinotecan With Concomitant Chemotherapy With FOLFOX in Patients With Colorectal Cancer With Unresectable Liver Metastases: a Phase II Multicenter Study,0.0007394330844816474,0.0007111177784475717
NCT01858649,Study Comparing Pathological Responses Observed on Colorectal Cancer Metastases Resected After Preoperative Bevacizumab With FOLFOX or FOLFIRI.,0.0005743830388513925,0.0008075509553978891
NCT01858662,Study Comparing Pathological Responses Observed on Colorectal Cancer Metastases Resected After Preoperative Treatment Combining Cetuximab With FOLFOX or FOLFIRI in RAS and B-RAF WT Tumors,0.0005850080069251741,0.0007941383141511331
NCT01801904,A Phase 2 Study of Panitumumab in Patients With Cetuximab-refractory Metastatic Colorectal Cancer,0.0008767750781179766,0.0009772807126778669
NCT01801930,A Phase 1 Study of OCV-C02 in Patients With Advanced or Relapsed Colorectal Cancer,0.0008056051464725786,0.0008001302830300314
NCT01821105,2 Phase Comparison of Pre-operative CT and PET Images for Metastatic Colorectal Cancer,0.0006210020482287852,0.0006034557914002717
NCT01802684,OPTIMOX-aflibercept as First-line Therapy in Patients With Unresectable Metastatic Colorectal Cancer,0.0008005246900157921,0.0006831566156249467
NCT01969591,Fast Track Laparoscopic Surgery: A Better Option for Treating Colorectal Cancer Than Conventional Laparoscopic Surgery,0.0004635027949467655,0.0005541209495338836
NCT01923337,Irinotecan and Alisertib in Treating Patients With Advanced Solid Tumors or Colorectal Cancer,0.0006917509744448124,0.0007508184682602462
NCT01937715,A Study Of PF-05212384 Plus FOLFIRI Versus Bevacizumab Plus FOLFIRI In Metastatic Colorectal Cancer,0.0008705217137897944,0.0007020109540523802
NCT01950403,Linaclotide Acetate in Preventing Colorectal Cancer in Healthy Volunteers,0.0008998547854466865,0.0006129741718494143
NCT01952730,GVAX for Colorectal Cancer,0.0017174036041820706,0.0007237020667073253
NCT01911988,Study of Association Between Peripheral Immune Cells and Recurrence in Stage II/III Colorectal Cancer,0.000516830655305161,0.0005728809110953051
NCT01915472,A Phase II Study of IMMU 130 in Patients With Metastatic Colorectal Cancer,0.0010487611687361596,0.0008770463164793936
NCT01903395,Risk-adapted Screening in First-degree Relatives of Patients With Colorectal Cancer,0.0006640359070537499,0.0005546118308157363
NCT01909830,Gemcitabine in Combination With Pemetrexed Long Term Infusion in the Treatment of Pretreated Metastatic Colorectal Cancer Patients,0.0007657555351767368,0.0007583639966219718
NCT01909362,Biomarker Analysis for Patients With Metastatic Colorectal Cancer (MCC),0.0008176978890338892,0.0007413960866254518
NCT01919879,Dual Targeting of EGFR With Cetuximab and Afatinib to Treat Refractory wtKRAS Metastatic Colorectal Cancer,0.0006490613547220303,0.0006584107506984771
NCT01996969,Identification of Predictive Biomarker of Regorafenib in Refractory Colorectal Cancer,0.0005373371302477263,0.0006178737033768178
NCT01963182,Individualization of Dosage of Irinotecan in the FOLFIRI According to the Genetic Polymorphism of UGT1A1 in the First Line Treatment of Metastatic Colorectal Cancer,0.0006582184176772773,0.0008728380618737619
NCT01959269,Investigating the Use of Regorafenib (StivargaÂ®) in Patients With Metastatic Colorectal Cancer (mCRC) After Failure of Standard Therapy,0.0007673798454234383,0.0007870438499465583
NCT01959061,Efficacy and Safety of Raltitrexed-based Transarterial Chemoembolisation(TACE)for Colorectal Cancer Liver Metastases,0.0006723161975276092,0.0008557620247673658
NCT01926769,A Phase II Study to Determine the Safety and Efficacy of Second-line Treatment With Metformin and Chemotherapy (FOLFOX6 or FOFIRI) in the Second Line Threatment of Advanced Colorectal Cancer,0.0006287997560902637,0.0008572272213051438
NCT01930864,Metformin Plus Irinotecan for Refractory Colorectal Cancer,0.0006882105101036322,0.0007192780250153156
NCT01966289,SGI-110 in Combination With an Allogeneic Colon Cancer Cell Vaccine (GVAX) and Cyclophosphamide (CY) in Metastatic Colorectal Cancer (mCRC),0.0005709782496837143,0.0006445532069554344
NCT01998152,Individualized Nutritional Counselling During Chemotherapy for Colorectal Cancer (COLONUT),0.0005642600726397336,0.0005897439745105914
NCT01929421,A Phase II Trial of Salvage Treatment With Gemcitabine and S-1 Combination in Patients With Heavily Treated Advanced Colorectal Cancer.,0.0006813008730521197,0.0007136878318535896
NCT01991080,The Relationship Between Relaxation or Wheat Germ Juice to the Immune Indices and Quality of Life (QoL) in Colorectal Cancer Patients on Adjuvant Chemotherapy,0.0005847633174578137,0.0007134571460777556
NCT01991873,Maintenance Therapy With 5-FU/FA Plus Panitumumab vs. 5-FU/FA Alone After Prior Induction and Re-induction After Progress for 1st-line Treatment of Metastatic Colorectal Cancer,0.0006136925690681643,0.000737150973582543
NCT01960023,Safety and Efficacy Study of Neratinib and Cetuximab to Treat Patients With Quadruple Wild-Type Metastatic Colorectal Cancer,0.0008371535647190476,0.0007953731447927231
NCT01912443,Safety Study of Bevacizumab Plus Chemotherapy To Treat Metastatic Colorectal Cancer,0.0007945790630642269,0.001089331330855488
NCT01910610,Multi-Line Therapy Trial in Unresectable Metastatic Colorectal Cancer,0.0006320454792869061,0.0008577326437113329
NCT01902849,Anesthetic Technique on Immune Response in Colorectal Cancer,0.000525681707112662,0.0005517623459441365
NCT01972503,Intraoperative Intraportal Chemotherapy Combined With Adjuvant Chemotherapy for Stage II and III Colorectal Cancer,0.0005039683408694911,0.0005550001123900691
NCT01972490,Avastin in Combination With Chemotherapy for the Treatment of Metastatic Colorectal Cancer,0.0006799255159687741,0.0008965856434164597
NCT01975454,Study of TLBZT Based Herbal Therapy Plus Chemotherapy for Metastatic Colorectal Cancer,0.000752747379424323,0.000842962022977188
NCT01975077,Phase Ib Study of Fruquintinib in Patients With Metastatic Colorectal Carcinoma,0.0009080410805787783,0.0007261741423497759
NCT01955629,"Study of Aflibercept as Maintenance Therapy Following Induction With Aflibercept in Combination With XELOX, as First-Line Treatment for Metastatic Colorectal Cancer Patient",0.0008220734757593662,0.0008383900716410752
NCT01955837,Study of TAS-102 in Patients With Metastatic Colorectal Cancer in Asia,0.0010487611687361596,0.0010561324439385866
NCT01925274,A Study Of PF-05212384 Plus Irinotecan Vs Cetuximab Plus Irinotecan In Patients With KRAS And NRAS Wild Type Metastatic Colorectal Cancer,0.0008622585692962843,0.0008040561111423317
NCT01949194,Study to Determine the Efficacy of Regorafenib in Metastatic Colorectal Cancer Patients and to Discover Biomarkers,0.0008503354993053152,0.0009412855964773892
NCT01941173,Short-Infusion Ziv-aflibercept in Treating Patients With Metastatic Colorectal Cancer Receiving Combination Chemotherapy,0.0007700476563372792,0.0007648346197893607
NCT01941953,Metformin and 5-fluorouracil for Refractory Colorectal Cancer.,0.0006674304070330719,0.0007955457784650631
NCT01983098,Analysis of Circulating Tumor DNA to Monitor Metastatic Colorectal Cancer Treatment,0.0006707022163663558,0.0007114069202465736
NCT01983371,Diagnostic Accuracy of Ferumoxytol-Enhanced MRI for Detecting Lymph Node Metastases in Colorectal Cancer,0.00047494714393573283,0.0007926116451417624
NCT01904630,Sequencing to Identify Gene Variants in Familial Colorectal Cancer,0.0009004961112033125,0.00028596936624616215
NCT01904955,Should Colorectal Cancer Patients be Followed After Five Years? Study of Recurrence in a Population Cohort,0.0008673798265376302,0.0005996520992384817
NCT01985763,Genistein in Treatment of Metastatic Colorectal Cancer,0.0007543415464405599,0.0007803272739251156
NCT01978249,"A Randomized, Prospective, Multicenter Study for the Role of Primary Tumor Resection in Colorectal Cancer Patients With Asymptomatic, Synchronous Unresectable Metastasis",0.0006842522738354046,0.0005879230688138421
NCT01938300,Magnesium and Rotational Thromboelastometry (ROTEM) in Colorectal Cancer Surgery,0.0005430859507421769,0.0003626112246227135
NCT01916239,Pomegranate Extract Supplementation in Colorectal Cancer Patients,0.0007468738606332012,0.000468660045862245
NCT02652663,Liver MRI for Colorectal Cancer Liver Metastasis: Comparative Effectiveness Research for the Choice of Contrast Agents,0.0004955453748800141,0.0004899070681915904
NCT02652702,Study Comparing Circular Stapler-assisted Colostomy vs Hand-stitching Colostomy of Colorectal Cancer Patients,0.0006713483139277285,0.0005111599342933796
NCT02615574,"A Study of Type-1 Polarized Dendritic Cell (Î±DC1) Vaccine in Combination With Tumor-Selective Chemokine Modulation (Interferon-Î±2b, Rintatolimod, and Celecoxib) in Subjects With Chemo-Refractory Metastatic Colorectal Cancer",0.0006576174592537727,0.0006710264769762605
NCT02630420,Cetuximab and Savolitinib Treatment of Ras Wild-Type Colorectal Cancer,0.0005441149197122344,0.0005997263625772931
NCT02633098,A Safety and Effectiveness Study of Pre-operative Artesunate in Stage II/III Colorectal Cancer,0.0005652311352696762,0.0006479050248587327
NCT02641873,A Study of BBI608 Administrated With FOLFIRI + Bevacizumab in Adult Patients With Metastatic Colorectal Cancer,0.000949579511856038,0.000946020175698176
NCT02602938,Aspirin on CTCs of Advanced Breast and Colorectal Cancer,0.0005833216131496985,0.0007184620930300172
NCT02605044,Study to Compare the Efficacy and Safety of Masitinib in Combination With FOLFIRI to Placebo in Combination With FOLFIRI in Second Line Treatment of Patients With Metastatic Colorectal Cancer,0.0008166596611795118,0.0008502075598329206
NCT02619435,Regorafenib Monotherapy as Second-line Treatment of Patients With RAS-mutant Advanced Colorectal Cancer,0.0007564319641685406,0.0008626838690438517
NCT02623621,Soluble Vascular Endothelial Growth Factor Receptor 2 as Predictor of Benefit From Bevacizumab Beyond Progression in Metastatic Colorectal Cancer,0.0006594862383111529,0.0007146766474492485
NCT02654639,Ph 2 Study of TAS-102 / Bevacizumab Maintenance Therapy Post Induction Chemotherapy in Metastatic Colorectal Cancer,0.0007006481790012228,0.001011191688747639
NCT02665312,Cardiotoxicity and Risk Factors in Patients With Colorectal Cancer Receiving Fluoropyrimidine,0.0006554458464593256,0.0007332486349762896
NCT02612077,Observation of Patients With Metastatic Colorectal Cancer Starting Chemotherapy Combined With Bevacizumab (Avastin),0.0007959237038758305,0.000894336849283422
NCT02631564,"Safety of TACE With Oxaliplatin, Irinotecan and Raltitrexed for Refractory Colorectal Cancer Liver Metastasis",0.0005018277228361267,0.0006093095761857301
NCT02688023,Neoadjuvant Triplet Chemotherapy Regimen in Patients With Resectable Colorectal Cancer,0.0007499106436846634,0.0007756353985371072
NCT02624726,Trial in Metastatic Colorectal Cancer With FOLFIRI Plus Aflibercept as First Line Treatment,0.0007203953475697814,0.0007642460325381876
NCT02647099,Adjuvant Low Dose Aspirin in Colorectal Cancer,0.0006424286348447759,0.0005687462763676464
NCT02618356,Combined Use of Raltitrexed and S-1 as Treatment for Patients With Metastasizing Colorectal Cancer,0.0008026441861910119,0.000793029989113629
NCT02642978,Robot-assisted Procedure Versus Open Simultaneous Resection of Colorectal Cancer With Liver Metastases,0.0005531538003280039,0.000638114922043884
NCT02613728,Accelerated Enhanced RECOVERy Following Minimally Invasive Colorectal Cancer Surgery (RecoverMI),0.00054461525701883,0.0005224178923046278
NCT02613221,A Phase I/II Study for the Safety and Efficacy of Panitumumab in Combination With TAS-102 for Patients With Colorectal Cancer,0.0007926217457260213,0.0008880064073961056
NCT02607072,Aspirin for Prevention of Postsurgical Recurrence and Metastasis in Asian Colorectal Cancer Patients: a Multi-center Randomized Trial,0.000598911543579331,0.000744509287421539
NCT02614534,Clinical Trial to Evaluate Safety and Efficacy of Hyperthermic Intra-peritoneal Chemotherapy (HIPEC) With Mitomycin C Used During Surgery for Treatment of Locally Advanced Colorectal Carcinoma,0.0005524310191596173,0.0007147314457850864
NCT02677389,Survivorship Care Plan in Promoting Physical Activity in Breast or Colorectal Cancer Survivors in Wisconsin,0.00046823411689161747,0.0005101438168341982
NCT02699073,Evaluation of Treatment Response With CHOI and RECIST Criteria and CT Texture Analysis in Patients With Metastatic Colorectal Cancer Treated With Regorafenib,0.0007762207159742702,0.000876638534764299
NCT02645084,Identifying Patients With Hereditary and Familial Colorectal Cancer by Using an Online Risk Tool,0.0013521402111330778,0.0005059921979967865
NCT02673710,A Study to Assess the Impact of Sarcopenia on the Outcomes of Colorectal Cancer Survivors Treated With Chemotherapy Combined With Bevacizumab,0.0006398500669826454,0.0006840658397941399
